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ABSTRACT 
Introduction: Burn patients are currently monitored by, and their treatment based on, 
systemic parameters. Although much of their outcome depends upon wound healing, very 
little work has previously been done to examine the possibility of monitoring the local 
wound environment. Microdialysis is a technique established in other specialties to 
monitor local tissues. This thesis investigates the use of the microdialysis technique to 
provide a method of continuously monitoring the burn wound. Markers of ischaemia, and 
nitric oxide metabolism were investigated. 
Methods: Ten healthy volunteers and 10 patients with acute burns were recruited. 
Microdialysis of the dermis was undertaken to establish a normal range in the volunteers. 
Microdialysis probes were placed in the zones of coagulation, and stasis (as per Jackson’s 
burn wound model) and in the unburned skin of the burn patients, and samples taken half 
hourly until 36 hours following the burn. An additional 2 patients with major burns were 
recruited. Microdialysate was examined for glucose, lactate, pyruvate, glycerol and urea in 
both groups. Amino acids were also measured in the burn groups. Time-related trends 
were compared with LDI images taken at the start and completion of the study period. 
Results: From the volunteer studies, the technique was validated, and a normal range for 
healthy dermis was calculated. There was no significant change with increased ambient 
temperature. In the burn studies, there were several significant differences in metabolites 
between zones and with time. Glycerol in the zone of coagulation was significantly raised 
at 6-12 hours following burn compared to the remaining time periods. Glucose in the zone 
of stasis and in unburned skin was significantly lower at 6-12h, and increased with time to 
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30-36h post-burn. LPR was significantly higher in unburned skin at 6-12h post burn and 
declined with time. There were significant differences in glucose, lactate, pyruvate, LPR 
and glycerol between zones.  
Patients undergoing a theatre episode during their treatment showed a significant peak of 
glycerol in the zone of stasis during this time. Aspartate showed significant changes with 
time and probe location. There was an elevated level of arginine in the burn tissues 
compared with the literature on surgical wounds, and it was significantly higher in the 
unburned skin, and lowest in the zone of coagulation. Ornithine showed the reverse. 
Orn/Arg ratio was significantly affected by probe location, with highest levels in 
unburned skin. Burn wound progression was evident in only one wound at the site of the 
zone of stasis probe.  
Conclusion: This thesis has produced normal values for metabolites in the dermis of 
healthy volunteers. The Microdialysis technique was shown to be safe, well tolerated and 
effective as a method of monitoring the burn wound environment in patients. It was 
possible to monitor changes in biochemistry in the burn wound over time and between 
zones. Correlating biochemical changes with burn wound progression was not possible 
since all but one burn wound in this series showed no progression in the area monitored. 
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1 INTRODUCTION 
1.1 Burns – the historical perspective 
1.1.1 The history of burn treatment 
Documentation of the treatment of burns can be traced as early as 1500BC. Treatments 
constituted various topical agents from honey and resin, to rendered pig fat and vinegar 
soaks. Cold water was noted to relieve the pain from burns at an early stage  (1) 
However there was a persistently high mortality from major burns until the latter part of 
the 20th Century. In 1954, Bull and Fisher, in Birmingham, published the mortality rate 
of patients in the burns unit between the years of 1942 and 1952. The Lethal Dose 
causing 50% mortality (LD50) was 49% Total Body Surface Area (TBSA) burn in 
children aged 0-14 years  (2). Following refinements in fluid resuscitation, and 
introduction of topical antimicrobials in the 1950s, the LD50 had increased to 64% 
TBSA by 1971  (3). A move to early excision of large burn wounds gave further 
improvements in survival which led to an LD50 of 95% TBSA for children, reported in 
1987 by Herndon et al, in Galveston  (4). 
 
1.1.2 The current challenge 
As a consequence of the increased survival rates, burn wound management and 
subsequent functional and aesthetic outcome has become the next major challenge in 
burn care.  
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Burn wound healing occurs by migration of new epidermal cells from undamaged skin 
edges, or from adnexal skin structures. The deeper the burn wound, the fewer adnexal 
structures remain, and the longer it takes to heal. In superficial partial-thickness burns, 
most adnexal structures are undamaged, and re-epithelialisation can occur within 2 
weeks, with little or no scarring. In full-thickness injury, no adnexal structures remain, 
and the natural history of the wound is to heal by contraction and epithelialisation from 
the edges, leading to thickened, shortened scars with a disfiguring and often functionally 
disabling outcome  (5). Early excision and skin grafting shortens wound healing time, 
which has been shown to decrease hypertrophic scar formation  (6) with its associated 
contractures and poor aesthetic outcomes. Mid-dermal burns present a challenge. They 
may heal with little scarring, if conditions are optimal, but the depth of the burn may 
increase (wound progression) for reasons which are discussed below. Treatment of these 
burns would ideally centre upon preventing wound progression. Monitoring the cellular 
activity in the wound would allow adjustment of management to improve conditions in 
the wound, and would also allow surgical decisions to be made early in those patients 
for whom wound progression may be inevitable. 
 
1.2 The Burn Wound 
1.2.1 Burn wound descriptions 
1.2.1.1 Percentage Total Body Surface Area 
Percentage of total body surface area (TBSA) is a measurement of the size of the 
burn as a proportion of the total surface area of the skin. This classification of the 
severity of a burn allows the systemic effects of the burn to be predicted. Burns 
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under 15% TBSA in an adult can usually be adequately treated with oral 
rehydration, and wound care. Burns over 15% TBSA routinely require additional 
intravenous fluid and thermal supportive care. Burn wounds over 30% TBSA 
result in burn shock. This is due to a combination of hypovolaemia and the release 
of inflammatory mediators from the burn wound. It is not entirely corrected by 
fluid resuscitation alone, as systemic effects on the microcirculation cause 
capillary leak and oedema. 
 
1.2.1.2 Mechanism of injury 
Description of the mechanism of injury is important, giving an idea of the severity 
of the likely injury, or of any coexisting trauma. A flash burn is unlikely to cause 
a deep burn, but a flame or contact burn may well cause full thickness injury. A 
fire in an enclosed space leads the clinician to suspect inhalational injury, while an 
explosion prompts one to consider fractures due to the patient being thrown some 
distance by the force. Mechanism of burn does not usually lead to an alteration in 
the treatment given, except in the case of chemical burns where thorough 
irrigation or neutralisation of the substance must be undertaken to prevent further 
injury. 
 
1.2.1.3 Burn depth 
Burns are also routinely classified by the depth of the dermis affected. Superficial 
burns involve the epidermal layer only, and will therefore heal within 2 weeks 
without scarring. Full thickness burns, at the other extreme, affect the entire 
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thickness of the dermis, and sometimes the tissue beneath. No viable epithelial 
structures remain. When left untreated, the wound becomes necrotic, then heals 
slowly by contracture and epithelialisation from the edges. This can take many 
months, and the patient is at risk of life-threatening infection, severe contractures, 
and the high metabolic demand of a healing wound. To reduce the burden of 
inflammatory mediators, speed up wound healing, and avoid functionally disabling 
contractures, full thickness wounds are excised and grafted, as early as possible. 
 In between these two extremes are burns which affect part of the dermis. They can 
be classified as superficial partial thickness and deep partial thickness. Their 
different clinical characteristics are summarised in Table 1. It is the deep partial 
thickness burns that can be the most difficult to predict in terms of their likely 
course and outcome. They can sometimes heal without treatment within 2-3 
weeks, or they can progress to become deeper over the following few days, 
requiring excision.  
 
 
Table 1: Characteristics of burn wound by depth 
Burn Depth Colour Sensation 
Superficial Partial 
Thickness 
 
Pink; blanches to touch Painful 
Deep Partial Thickness 
 
Pink/red; fixed staining Sensate to 
pinprick 
Full Thickness 
 
White Painless 
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1.2.2 Diagnosis of the Depth of Burning – Douglas Jackson, 1953 
Our current understanding of the pathophysiology of the burn wound is based around 
Douglas Jackson’s description of the burn wound in the British Journal of Surgery in 
1953, entitled ‘Diagnosis of the Depth of Burning’  (7). In this paper, he explains why it 
can initially be difficult to assess burn depth, because of the potential for wound 
progression. He divides the wound into three zones each displaying particular clinical 
and histological characteristics, and each having a different course and outcome: 
 
1.2.2.1 The Zone of Coagulation 
The central zone consists of the tissue damaged irreversibly by the initial insult. 
The clinical appearance is that of white, coagulated skin which, on microscopy, 
reveals obliteration of the lumina of the subpapillary plexus and capillary loops. 
 
1.2.2.2 The Zone of Stasis 
This zone surrounds the zone of coagulation in both peripheral and deep 
directions. Clinically it is red and blanches on pressure. Extended application of a 
tourniquet proximal to the burn on a limb causes the unburned skin to become 
cyanosed and the zone of stasis to remain red. This indicates a failure of 
metabolism within the zone of stasis to produce deoxygenated haemoglobin. At 
24 hours following injury, this zone shows complete stasis of blood flow with no 
blanching to pressure, and microscopically, dilated capillaries packed with 
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erythrocytes. Between three and seven days after the burn, the zone turns white 
and is indistinguishable from the zone of coagulation. This is due to the 
superficial dermis being necrotic, and the red cells previously present having been 
haemolysed.  
 
1.2.2.3 The Zone of Hyperaemia 
Lateral and deep to the zone of stasis lies the zone of hyperaemia. Initially red and 
blanching to pressure, this zone becomes cyanotic along with the rest of the limb 
on application of a proximal tourniquet. This indicates that both circulation and 
metabolism are intact. On biopsy, the epidermis is lost, but without structural 
damage to the dermis. By the seventh day this zone is completely healed. 
 
1.2.3 Current knowledge of the burn wound 
Much work has been done on investigating the course of the burn wound, and in trying 
to prevent the progression of the zone of stasis into necrotic tissue. 
 
1.2.3.1 Diagnosis of Wound Progression 
Histologically there has been some difficulty in identifying the zone of stasis as a 
distinct area as there are several variables to consider for any one burn. Not only 
does each burn vary in degree of intensity and depth of penetration through the 
dermis, even a standardised burn affects different dermal components at different 
depths of the dermis. In addition, a burn injury progresses with time, so in this 
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already complex picture, each element displays its individual course with time. In 
a full thickness burn, the intensity may have been so severe, that all changes could 
be seen in all structures and cells throughout the dermis, the zone of stasis (in its 
deep aspect) being located in an entirely different tissue, and therefore having a 
different set of histological features specific to that area, whether it be 
subcutaneous fat, muscle or bone. It is also important to note that while Jackson’s 
model described the zone of stasis as a 3-dimensional area extending beyond the 
zone of coagulation, the data from the histological studies cited below focus on 
the deep aspect only, comments on the lateral extension of the zone of stasis in the 
literature being notably absent. 
 
1.2.3.1.1 Dermal components 
Each dermal structure or cell type (collagen, epithelial and endothelial cells) 
exhibits a characteristic change when exposed to thermal injury, and some 
components are more sensitive than others to injury. Using a standardised 
partial thickness burn wound model, and a standardised time post-burn, Singer 
et al have shown that collagen is the least sensitive indicator of the depth of 
heat damage, with changes to a relatively superficial level. Epithelial cells are 
more sensitive than collagen to thermal damage, with cellular injury extending 
past the deep margin of collagen damage. Endothelial cells are the most 
sensitive to the burning insult; damaged endothelial cells can be seen alongside 
undamaged epithelial cells at the deepest surface of the burn wound. This 
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structural pattern of injury holds true for different standardised burn depths  
(8). 
 
1.2.3.1.2 Progression with time 
With a standardised partial thickness wound model, individual dermal 
components have been observed to progress at different rates over the course of 
4 days following thermal injury  (9). These changes are described in  
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Table 2. Of particular note is that, while the superficial dermal vasculature is 
irreversibly damaged and shows progressive signs of necrosis with time, the 
deeper dermal capillaries, which show evidence of stasis until 8 hours post 
injury, begin to regain their patency from 24 hours onwards. In clinical studies, 
the presence of patent vessels within the superficial capillary plexus has been 
shown to be of importance in predicting wound progression, with those wounds 
having no viable vessels within the superficial 20% of the dermis, evidencing 
wound progression over 48 hours  (10). 
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Table 2. to show progression of a standardised partial thickness burn wound in the guinea-pig, as 
described by deCamara et al  (9) (RBC = red blood cell; PMN = polymorphonuclear neutrophil) 
Time 
Post-
burn 
Epidermis Collagen 
bundles 
Appendages Blood vessels Nerves 
2h Signs of 
thermal injury 
to keratin, but 
keratin layer 
present. 
Extensive 
epidermal 
destruction. 
Some cell 
outlines visible 
Oedema 
fluid spaces 
between 
collagen 
bundles in 
superficial 
dermis. 
Deep dermis 
unaffected 
Most hair 
follicles 
preserved 
Endothelial cell 
damage to 
subepidermal 
capillaries with 
occlusion of 
lumina. 
Crenation of 
RBCs. 
Deeper dermal 
capillaries 
packed with 
RBCs but 
structure of 
vessels intact  
Axons swollen 
8h Wide 
separation of 
keratin from 
dermis. 
Coagulative 
necrosis of all 
epithelial cells. 
Loss of 
basement 
membrane 
continuity 
Oedematous 
collagen 
bundles 
which are 
displaced by 
oedema 
fluid 
 Disruption of 
superficial 
capillaries and 
haemorrhage 
into superficial 
dermis. Deep 
dermal vessels 
show signs of 
stasis. 
Fragmentation 
of myelin 
24h Keratin 
attached to 
dermis by 
debris. 
Basement 
membrane 
discontinuous 
Collagen 
more tightly 
packed 
 No new 
capillary 
changes. Some 
dermal vessels 
acquired 
lumina 
Progressive 
demyelination 
96h Sloughing of 
keratin and 
debris. 
Basement 
membrane not 
identifiable 
Superficial 
dermal 
collagen 
necrotic. 
Infiltration 
of PMNs 
Few 
epidermal 
cells around 
follicles 
Subepidermal 
capillary plexus 
obliterated. 
Deep vessels 
patent 
Swelling 
diminished. 
Progressive 
demyelination 
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1.2.3.1.3 Cell viability 
When diagnosing wound progression by viability of mesenchymal cells 
(fibroblasts, melanocytes, Langerhan cells), wound progression is evident 
over a 3-5 day period in human and animal models  (11) 
 
1.2.3.2 Causes of Wound Progression 
1.2.3.2.1 Vascular occlusion  
As described above, several studies have shown a link between capillary 
patency in the dermal vasculature and wound progression, suggesting that 
capillary patency may have a direct role in the progression of the wound  
(9,10,12). Three zones of the burn have been described, based on vascular 
patency alone. A zone of complete capillary occlusion, a zone of partial 
occlusion and a zone of capillary dilation, which correspond to Jackson’s 
zones of coagulation, stasis and hyperaemia, have been described in the 
mouse ear. The area of complete occlusion, or coagulation, in this 
experiment, increased in size by a factor of 10 over 48 hours, all of which 
became necrotic  (13). 
 
1.2.3.2.2 Leukocyte infiltration  
Neutrophils infiltrate the burn wound early in the inflammatory process, and 
their role is to ingest and kill bacteria. They produce proteases and defensins 
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within granules which are discharged by exocytosis into phagocytosed 
bacteria, or by degranulation into the interstitium. NADPH oxidase is 
activated on the cell membrane, producing toxic oxygen metabolites  (14). 
Although effective against bacterial invasion, there is also evidence to 
suggest that neutrophils may contribute to wound progression by damaging 
cells within the zone of stasis  (15). 
The course of inflammatory infiltrates has also been studied by Tyler et al. 
Superficial partial thickness burns and deep partial thickness burns show 
different patterns of leukocyte infiltration. An early neutrophil influx 
appears in all burns, which decreases by 48 hours in the superficial partial 
thickness burn, but persists in the deeper burn.  A later infiltrate of 
monocytes/macrophages is present in both depths of burn, but is delayed 
and of a lesser magnitude in the deep partial thickness burn. A rapid 
lymphocyte influx occurs in superficial partial thickness burns which does 
not occur in deep partial thickness burns  (12). Tyler proposes that it is the 
patency of the superficial plexus which allows or prevents the extravasation 
of lymphocytes, which in turn limits or fails to limit burn wound 
progression. 
 
1.2.3.2.3 Wound Dehydration  
Dressing of the wound has a role to play in the progression of the wound 
depth. Uncovered, debrided wounds have been shown to fare worst in a 
guinea-pig model, with full thickness necrosis ensuing, and no surviving 
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hair follicles at 1 week following a partial thickness injury. Wounds with 
intact blisters, or occlusive dressings, show less progression with no 
necrosis and a slow re-epithelialisation. Biological dressings show best 
results with complete healing in 1 week  (16). The same author showed two 
groups of wounds treated either without dressing, or with porcine split skin 
graft (SSG), both with complete stasis in vessels to below the level of the 
deepest hair follicle between 16 and 24 hours post-burn. From this point on, 
the biologically dressed burn showed restoration of the dermal circulation, 
starting at the deep surface 2 days after the injury, then progressing more 
superficially, and being completely restored by day 7. In contrast, the 
untreated burns showed some return of circulation, but this reached its 
maximum by day 2, and never reached the deepest hair follicles. Water 
content was also assessed by weight of biopsy before and after drying for 
both wounds. The porcine split skin graft (SSG) treated group did not show 
any evidence of dehydration, whereas the untreated burn became dehydrated 
by 16 hours, reaching a maximum by 2 days post-burn.  
 
1.2.3.2.4 Capillary Permeability, Oedema and Raised Interstitial 
Pressure  
Increased capillary permeability, part of the inflammatory process, allows 
extravasation of plasma proteins and leukocytes, leading to an altered 
osmotic gradient across the capillary wall. Fluid therefore accumulates in 
the interstitial space, causing oedema. This oedema raises the interstitial 
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pressure which in turn reduces capillary flow, and thus reduces the diffusion 
of nutrients to, and waste products from, the cell. The escape of a protein-
rich fluid into the interstitial space was studied in a guinea-pig model by 
Sevitt. He found that there was a two-phase response of the capillaries to 
burn injury of varying severity. All burns produced the delayed type of 
permeability, after 1-2 hours. An immediate permeability (within 1-2 
minutes of burn) was also displayed following burns of moderate and major 
severity. The delayed response (1-2 hours post injury) was confined to the 
dermis for superficial injuries, or affected the subdermal plexus or 
panniculus carnosus for more severe burns. In these most severe burns, the 
two phases of capillary leak became a continuum, but the deeper capillaries 
were not affected until later  (17). Sevitt postulated a separate mechanism 
for the two phases of leak, the first being due to a direct structural change 
caused by heat, and the second of chemical or neurochemical origin, and 
therefore potentially reversible. Studies in the mouse ear have shown 
oedema to be maximal at 6 hours following injury, remaining significantly 
greater than control until 9 hours, then to have returned to just under pre-
burn levels by 48 hours. On the contralateral, unburned ear, oedema is 
significantly higher (9% greater) than normal levels at 2 hours following 
burn, but returning to normal by 9 hours, indicating a systemic component 
to the oedema process  (13). 
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1.2.3.2.5 Apoptosis  
Apoptotic cells have been found in superficial and deep dermal burn 
wounds. Both epithelial and dermal fibroblasts are affected. The rate is 
much higher (average 45% of dermal fibroblasts) in deep partial thickness 
injury than in superficial dermal injury (6%) and the affected cells tend to be 
grouped in clusters in the deeper burns  (18). It is likely that either the initial 
injury, the persistent ischaemia from the stasis in the deep dermal 
vasculature or a combination of factors, is responsible for the cells 
undergoing apoptosis, and eventual necrosis. 
 
1.2.3.2.6 Vasoconstriction 
An initial intense vasoconstriction is evident within the arterioles of the burn 
wound, as a direct response to heat, with arterioles constricting to 20% of 
their original diameter for approximately 30 minutes  (13). A more 
prolonged, pharmacologically induced vasoconstriction has been 
investigated, by administering an intermittent infusion of epinephrine over a 
48 hour period. This led to progression of the necrotic area of the burn in a 
rabbit model  (19). 
 
1.2.3.2.7 Free Radicals and Ischaemia-Reperfusion Injury 
It has been postulated that free radicals form part of the intermediary 
process of wound progression. Free radicals are known to be produced as 
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part of normal cellular activity, such as oxidative phosphorylation in the 
mitochondria, where approximately 1% of oxygen is converted to 
superoxide radicals  (20).  Free radicals, e.g. superoxide radical (O.) and 
hydroxyl radical (OH.), are also produced by activated neutrophils. They are 
bacteriocidal and chemotactic for neutrophil recruitment and activation. 
Neutrophils generate free radicals via the nicotinamide adenine dinucleotide 
phosphate (NADPH) dehydrogenase pathway, and in xanthine oxidase 
activity  (20,21) and the prostaglandin system.  Cellular damage by free 
radicals occurs most commonly to lipids in the cell wall (where lipid 
peroxidation proceeds as a chain reaction). Superoxide radicals can generate 
hydroxyl radicals, both of which are extremely reactive, and damage 
endothelial cells, increasing the permeability of capillaries. They can also 
inactivate antiproteases, leading to unopposed protease activity, and further 
propagation of the inflammatory response. They are also formed during the 
auto-oxidation of compounds such as ascorbic acid, glutathione, cysteine, 
adrenaline and flavin coenzymes, where transition metal ions such as free 
iron play an enhancing catalytic role.  Defence against free radicals comes 
firstly from close control of biologic enzymatic reactions, and from 
chelation of metal ions which prevents their catalysis and further free radical 
generation. Secondly, there are specific free radical scavenging pathways, 
some of which are enzyme systems, such as superoxide dismutase 
(catalysing the downgrading of superoxide to hydrogen peroxide), catalase 
and glutathione peroxidase (reducing hydrogen peroxide to water and 
oxygen). Alpha-tocopherol (Vitamin E) intercepts lipid peroxyl radicals, 
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and ascorbic acid, uric acid and glutathione have scavenging properties  
(22). Free radicals are rendered ‘safe’ when they are reduced by addition of 
an electron donated by the free radical scavenger:  the latter becoming 
oxidised.  Oxidised free radical scavengers are regenerated by addition of an 
electron. In pathological states, a combination of increased free radical 
production and reduced energy supplies (ATP) preventing free radical 
scavenger regeneration, causes an imbalance in the system leading to free 
radical mediated damage to tissues.  
In the burn wound, in addition to free radical damage due to thermal injury, 
local ischaemia prevents energy dependent regeneration of the natural 
scavenging of the free radicals, which exacerbates local damage. During 
reperfusion of burn tissue, where energy supplies are depleted, oxygen 
delivery leads to increased production of the superoxide radicals which are 
converted to hydroxyl radicals, the most reactive radical species, causing a 
further episode of tissue damage. Unbridled free radical activity increases 
capillary permeability, leading to increased oedema and tissue pressure, 
decreased capillary flow and another cycle of ischaemia  (23). 
 
1.2.3.3 Prevention of Wound Progression 
1.2.3.3.1 Maintenance of vascular patency 
Heparin has been shown to delay both the lumen obliteration and the 
progression by more than 4 hours in a full thickness burn model in rats 
when given as a pre-treatment prior to the burn injury. However there was 
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no similar delay when heparin was given post-burn only  (24). A single 
study by Saliba et al treated a series of 7 patients, with 15 – 60% TBSA 
deep dermal and full thickness burns, with high doses of heparin 
intravenously, subcutaneously and topically. They found no wound 
progression, no oedema or shock, reduced fluid requirements, and reduced 
pain. Healing occurred spontaneously even in full thickness burns, without 
contractures  (25). No other studies have confirmed these findings. Baskaran  
(26) used a mouse back skin flap model in order to visualise directly the 
dermal vasculature. Full-thickness burn wounds were created, and labelled 
red cells injected into the animal to visualise capillary blood flow. Animals 
treated with Poloxamer-188, a surfactant, revealed absence of a zone of 
stasis, and a reduction of necrosis (judged by fluoroscein injection at 24h) of 
40% when compared to controls. Poloxomer-188 is known to be fibrinolytic 
and to increase blood clot permeability as well as inhibiting leukocyte 
chemotaxis, adhesion and migration. 
1.2.3.3.2 Inhibition of leukocyte adhesion  
Topical methyl-prednisolone has been shown to prevent progressive dermal 
ischaemia in partial thickness burn wounds in guinea-pigs when compared 
to emollient treated controls, and those treated with only intraperitoneal 
methyl-prednisolone  (27). This may be due its properties of preventing 
leukocyte adhesion or due to its inhibition of prostaglandin synthesis. The 
leukocyte- endothelial cell adhesion mechanism was investigated with 
relation to zone of stasis in a rabbit model by Mileski et al. Monoclonal 
antibodies to intercellular adhesion molecule 1 (ICAM-1), the endothelial 
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ligand bound by the neutrophil, and to the CD18 adhesion complex on the 
neutrophil were given prior to or 30 minutes following partial thickness 
burn injury. Progression of the burn as measured by laser Doppler 
flowmetry, did not occur at 72 hours post injury in those animals treated 
with either antibody, whether administered before or after injury. Control 
animals displayed significant wound progression  (28). Similar results were 
found in a rat model, where animals which received antibodies to CD18 post 
burn demonstrated maintained vessel patency, prevention of neutrophil 
migration and prevention of progression as measured by laser doppler, latex 
vascular casts and histology  (15). 
 
1.2.3.3.3 Prevention of dehydration 
As discussed above, wound cover with porcine split skin dressing has been 
shown to reverse capillary stasis and prevent progression to necrosis in a 
guinea-pig partial thickness wound model  (16). 
 
1.2.3.3.4 Restoration of capillary wall integrity and prevention of 
oedema  
Tarnow et al  (29) used an anti-inflammatory agent, D-myo-inositol-1,2,6-
triphosphate (IP3), in a full thickness rat burn model, measuring dermal 
blood flow with laser doppler. They showed a significantly increased wound 
perfusion in the IP3 treated animals when compared to the burned, saline 
treated controls. They concluded that IP3 prevents progressive dermal 
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ischaemia. While this study showed a slight increase in the wound 
perfusion, measured by LDI, in IP3 treated patients, there was no attempt to 
quantify wound progression, either by measurement of the size of the 
wound, or by follow-up to healing. 
An isomer of IP3 has been shown to reduce oedema formation in burns in a 
rat model, when given post-injury, decreasing both water loss into tissues, 
and albumin extravasation, and also by reducing the negative interstitial 
fluid hydrostatic pressure  (30). 
 
1.2.3.3.5 Inhibition of apoptosis 
Two studies from Australia have shown substances which decrease 
apoptosis, and promote wound healing, in animal models: 
A peptide inhibitor of c-Jun (a transcription factor) reduced UV-induced 
apoptosis in a keratinocyte cell line in-vitro. When the peptide was applied 
topically to the burn in an in-vivo mouse burn model, the size of the eschar 
was smaller in treated animals compared to controls. There was also a lower 
intensity of cells undergoing apoptosis in the area immediately adjacent to 
the wounds in treated animals when compared to controls. Re-
epithelialisation was also quicker in treated animals.  (31)  
Metallothionein-IIA, a cysteine-rich protein with antioxidant and metal 
sequestering properties, was used in a similar series of experiments. Its use 
increased cell viability, decreased apoptosis and promoted migration in an 
 21 
in-vitro keratinocyte cell line when compared to controls. When 
administered topically in-vivo in a mouse model, healing time was reduced, 
and eschar diameter was reduced compared to controls. Apoptosis was not 
measured for the in-vivo part of this study  (32). 
 
1.2.3.3.6 Vasodilators and anti-inflammatories 
Corticosteroids, indomethacin and acetylsalicylic acid (ASA) are known to 
inhibit prostaglandin (PG) synthesis. Topical methyl-prednisolone and 
systemic (intraosseous) infusion of indomethacin and ASA in a guinea-pig 
burn model have been shown to prevent the progressive ischaemia of a 
partial thickness burn when compared to control  (33). Furthermore, 
histological determination of levels of PG have been found to be reduced in 
burns treated with topical methylprednisolone  (34). This indicates that the 
prostaglandins have a role to play in the progression of dermal ischaemia. 
Imidazole, and two study compounds, UK38485 and U 63557A, all known 
to be specific thromboxane inhibitors were applied intraperitoneally 
(imidazole) and topically (UK38485 and U 63557A) to guinea-pig partial 
thickness burns. The rise in thromboxane levels seen in controls was not 
evident in any of the treatment groups. However PGE2 and PGF2a levels 
were not reduced in burnt animals (except in an additional group treated 
with methylprednisolone). At 3 weeks post-burn there was decreased tissue 
loss in the groups treated with UK38485 and U 63557A and imidazole, and 
at 6 weeks they were completely healed, in contrast to the control wound 
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which was still open and full thickness, and the methylprednisolone group 
which was partially healed. 
 
1.2.3.3.7 Prevention of reperfusion injury  
Nitric oxide, a labile nitroso compound, occurs naturally in the body during 
the conversion of L-arginine to citrulline by Nitric Oxide Synthase (NOS). 
It is a potent vasodilator and prevents aggregation and adhesion of platelets 
and neutrophils to endothelium, and to each other  (35,36). Three isoforms 
of NOS exist in humans. Two are constitutive, and one is inducible (iNOS). 
The two constitutive forms are neuronal (nNOS) and endothelial (eNOS). 
nNOS produces NO in neuronal cells as part of the cell signalling pathway. 
eNOS produces NO in endothelial cells, as part of the vasodilatory control 
mechanism. iNOS is mainly involved in inflammation. 
The production of NO in endothelial cells has been shown to be lacking 
following ischaemia, possibly contributing to reperfusion injury  (37). 
Infusion of L-arginine prior to the ischaemic event has been shown both to 
increase the amount of Nitric Oxide (NO) available (measured as nitrite + 
nitrate from microdialysis samples), and to prevent muscle necrosis in an 
ischaemia/reperfusion muscle flap model  (38). However there is a very 
limited time following reperfusion that addition of L-arginine can be 
successful in preventing neutrophil adhesion, suggesting that either the 
endothelial uptake of L-arginine, or the nitric oxide manufacturing system 
are damaged during the reperfusion injury  (37). Despite having possible 
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beneficial effects locally within the ischaemic areas of the wound, systemic 
administration of NO has been shown to contribute to macrophage 
dysfunction, stimulating production of Tumour Necrosis Factor alpha (TNF-
a) and Prostaglandin E2 (PGE2), potentially leading to suppressed 
lymphocyte function, and contributing to immunosuppression and Systemic 
Inflammatory Response Syndrome (SIRS). Macrophages in burnt mice have 
been shown to have increased levels of NO, TNFα and PGE2, together with 
increased expression of inducible Nitric Oxide Synthase (iNOS)  (39).  
Hypertonic saline dextran (HSD) resuscitation has been studied with regard 
to its effect on diene production, a result of lipid peroxidation from free 
radical injury. Pigs with 40% full thickness burns resuscitated using HSD 
showed a reduction in diene production during the 24 hour study period, 
compared with those resuscitated using Hartmann’s by the Parkland formula  
(40). The concomitant improvement in haemodynamic status may mean that 
the initial vasoconstriction is less prolonged, thus leading to a lesser 
reperfusion insult. Alternatively there may be some inherent property of the 
dextran solution which attenuates the inflammatory response. 
 
1.2.3.3.8 Maintaining oxygenation  
A single study investigating the effects of eight-hourly hyperbaric oxygen 
(each treatment lasting one hour) on the partial thickness rat burn wound 
over 3 days, showed a minimal, but statistically significant reduction in skin 
appendage and basement membrane destruction, and a lesser degree of 
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leukocyte infiltration of the wound  (41). These results may represent the 
benefit of increasing local tissue oxygen tension in preventing ischaemic 
necrosis, however the observation that some necrotic progression persists 
may be due to the increase in reactive oxygen species caused by the high 
levels of available oxygen, which in turn can cause cellular injury. 
 
1.2.3.3.9 Antioxidants 
Oxygen free radical scavengers often have a limited half-life and may be too 
large to enter the interstitial space. Initial experiments using antioxidants 
such as superoxide dysmutase (Mr 33,000Da; half-life 8-10mins), and 
catalase (Mr 250,000Da) were unsuccessful, probably for one of these 
reasons  (23). 
Kaufman et al used Compound-23, a free radical scavenger with a much 
smaller molecular weight (400Da) and stable for 12 hours, to treat deep 
partial thickness burn wounds and found an epithelialisation rate of 50% 
compared with 34% in controls, and the presence of 15 hair follicles per 
high power field, compared with 9 in controls  (23). Glutathione has been 
used in ischemic wound models as an antioxidant, and has been shown to 
improve the healing time of ischaemic wounds, associated with a rebalance 
in the matrix metalloproteinase (MMP)/ tissue inhibitors of matrix 
metalloproteinases (TIMP) ratio  (42). 
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1.2.3.4 Monitoring and Predicting Progression 
Current routine clinical practice is to prevent wound progression by 
optimising resuscitation with carefully titrated intravenous fluids in patients 
with large burns, and preventing desiccation with dressings. Monitoring the 
progress of these treatments relies on measurement of systemic parameters 
such as urine output, pulse and blood pressure and serum lactate. There is no 
equivalent measurement of the local burn wound environment in current 
routine clinical use. 
Parameters which could be measured, and may be linked to progression 
include blood flow or vascular patency, biochemical markers of ischaemia, 
nitric oxide production, interstitial pressure, leukocyte or cytokine 
concentration, hydration of the wound, free radical activity and apoptosis. 
Laser Doppler Imaging (LDI) is used in clinical practice to give information 
on the blood flow within the wound, but is only validated for its accuracy at 
48h post burn, and is not ideal as a continuous monitoring tool as it would 
require frequent exposure of the wound, risking wound desiccation, and 
infection. Confocal microscopy (FOCI) has been used only as research tool, 
and again the technique does not lend itself to the concept of continuous 
monitoring. Microdialysis is a monitoring device with the potential for 
continuous use throughout the period of early burn management, and could 
be used to monitor biochemical parameters of ischaemia, products of nitric 
oxide metabolism or cytokines. 
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1.2.3.4.1 Laser Doppler Imaging 
The Laser Doppler technique has been developed for monitoring differences 
in tissue perfusion. It is based on the principle that light is reflected from 
moving cells differently than from non-moving structures. Laser light 
undergoes a Doppler frequency shift when reflected from moving objects, 
and the change in the Doppler frequency shift can be measured from the 
return of light to photo-detectors inside the laser machine. This change in 
Doppler frequency shift, within a given volume of tissue, is termed ‘flux’ 
and is measured in arbitrary units. Early equipment (laser Doppler 
flowmetry) required direct contact between the probe and the skin, and could 
only assess a small area at once. The newest equipment (laser Doppler 
imaging, LDI) uses a scanning laser, a non-touch technique, and a computer 
system. The laser penetrates 1mm into the surface of the wound, and a 
colour-coded, two-dimensional image of the entire wound is produced, 
together with a high resolution photograph, for comparison. Flux is graded 
by the colours blue, green, yellow, pink and red, representing increasing 
perfusion. 
In the burn wound, the depth of injury is related to the depth of patent 
capillary circulation. In the inflammatory phase, blood flow is increased in 
the burn wound. Superficial burns have lost the epidermal surface barrier, 
and have a higher blood flow than the surrounding normal skin. This is 
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measured by the LDI as high flux. Full thickness burns have no intact 
microcirculation, and thus show up as low flux areas. 
LDI has been validated for clinical use in many studies. Kloppenberg et al 
investigated LDI flux values on days 1 and 4 following burn injury  (43). 
They showed a significant difference in LDI average perfusion, between 
spontaneously healing wounds and non-healing wounds. McGill et al showed 
good correlation of LDI at 36-72h post –burn, with wound outcome  (44). 
Riordan et al correlated LDI at 48 hours post burn with histological biopsy, 
and found that a LD perfusion index of >1.3 predicted a superficial injury 
with 95% sensitivity and 94% specificity  (21,45). They also performed 
serial LDI and biopsy on ten wounds at 24, 48 and 72 hours, and showed 
progressive deepening over time in 90% of cases. Hoeksema et al studied 40 
intermediate depth burns in humans  (46). They compared LDI diagnosis to 
clinical evaluation on Days 0, 1, 3, 5 and 8 post-burn. LDI was shown to be 
significantly more accurate than clinical diagnosis on Days 3 and 5 post-
burn, when predicting outcome as measured by time to healing or biopsy.  
LDI was at least as accurate as clinical evaluation on Days 0, 1 and 8. 
Accuracies from Day 3 onwards were >95%. On days 0 and 1, accuracies 
were lower (55%, 79.5% respectively) but comparison with final outcome 
measures before 48 hours does not take into account the possibility of wound 
progression. 
In this study, LDI was used to assess the depth of the burn wound at entry 
into the study and after removal of the probes, in order to assess wound 
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progression. Wound progression was diagnosed if the total area of low flux 
had increased. 
 
1.2.3.4.2 Fibre Optic Confocal Imaging  
Fibre optic confocal imaging or microscopy (FOCI) enables fluorescence 
imaging of cellular structure and blood vessels below the surface of the skin. 
It is a method of directly visualising the changes within the vasculature, 
such as vasodilatation and vessel leakage, via imaging of FITC-dextran 
injected into the circulation. This has been shown to enable diagnosis of the 
different zones of a burn, and assess the level of vasoconstriction and of 
capillary integrity, having a high correlation with histological sampling  
(47). 
 
1.2.3.4.3 Microdialysis 
Microdialysis is a technique by which interstitial fluid can be continuously 
monitored. It is minimally invasive, and provides a window into the 
dynamic physiology of the burn wound. See section 1.3 below. 
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1.3 Microdialysis 
1.3.1 History of Microdialysis 
Microdialysis is a technique by which the chemical composition of interstitial fluid can 
be continuously sampled in vivo. In its present form, it was conceived by Ungerstedt et 
al in 1974  (48) who used it to monitor neurotransmitters in the rat brain. Since then it 
has proliferated as a research tool in physiological and pharmacological studies  (49)  
(50). It has found uses in both in-vitro and in-vivo situations, and in animal and human 
studies. Recent uses have covered the fields of neurophysiology  (51), dermatology  
(52), liver transplantation  (53), and oncology  (54). Clinically, basic metabolite 
monitoring has been shown to be effective in detecting cerebral ischaemia in 
neurointensive care  (55), and warning of inadequate perfusion of skin and muscle flaps 
postoperatively in plastic surgery  (56). Edsander-Nord showed low glucose (2mmol/l), 
high LPR (100) and high glycerol (1000umol/l) in free flaps during their warm 
ischaemic time, with a return to normal values after anastomosis. Nielsen and Birke-
Sorensen showed accurate detection of flap ischaemia in their series of 78 intraoral 
flaps, suggesting an ‘alarm’level of glucose <1mmol/l and lactate >10mmol/l  (57). In 
the field of burns, it has been used to research histamine changes within experimental 
animal studies  (21,58). A clinical study in human burns in 2006, described some 
biochemical characteristics of the burn wound during fluid resuscitation, with trends 
towards higher LPR levels in burned skin when compared to unburned skin and 
controls, which did not correlate with systemic measurements. The authors concluded 
that local metabolic processes were not fully appreciated when examined systemically 
and that microdialysis offered a new method of monitoring the local environment  (59). 
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No study has yet assessed the biochemical differences between zones of the human burn 
wound. 
 
Figure 1: Microdialysis system, showing microdialysis pump on the left, microdialysis catheter (which is 
implanted in the tissue to be monitored) with membrane and double-lumen flow system (circled), 
collecting vial on the right.  The collecting vial is taken and placed in the analyser (far right) (Courtesy of 
M Dialysis) 
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Figure 2: Diagram to show flow through the microdialysis probe. Perfusate is pumped through the core of 
the probe to the semi-permeable membrane (dotted line). Analytes perfuse freely across the semi-
permeable membrane (large arrows). The fluid is then termed dialysate and exits the probe through the 
outer lumen (small arrows). (From www.ask.com/wiki/Microdialysis under Creative Commons CC-BY-
SA license) 
  
Figure 3: A schematic diagram showing the interaction between capillary supply to the tissues, the intra- 
and extracellular environment and the microdialysis probe (Courtesy of M Dialysis) 
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1.3.2 Principles of the technique 
Microdialysis uses the principle of dialysis to obtain a fluid sample with similar 
concentrations of small molecules, to the tissue to be studied. It consists of a 
probe with a semi-permeable membrane, which is positioned in the tissue of 
interest, and a pump system to circulate fluid past the semi-permeable membrane, 
allowing small molecules to diffuse into the system. The resulting sample is 
representative of the concentrations of these small molecules within the interstitial 
fluid of the tissues being studied. 
 The microdialysis system is composed of a microdialysis pump (capable of very 
low flow rates, 0.1 - 5 µl/min), a microdialysis probe containing a segment of 
semi-permeable membrane of a predetermined pore size, and a microvial 
collecting system, all of which are connected by tubing (Figure 1). The probe is 
implanted into the tissue of interest using a hollow needle introducer. The needle 
is withdrawn, leaving the probe in place within the tissue. The probe has a double 
lumen tube attached to one end by which fluid enters and exits the probe (Figure 
2). Fluid is pumped through the system, from a syringe which is preloaded in the 
pump. Before it enters the probe it is termed perfusate. As it enters the probe, it 
passes along the portion of tubing containing the semipermeable membrane. At 
this point, small molecules (relative to the pore size of the membrane) are free to 
pass between the interstitial fluid and the perfusate by diffusion (Figure 3). The 
slower the pump speed, the longer the time available for equilibration, and the 
closer to an equal concentration of these molecules in the dialysate and interstitial 
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fluid. Once it has passed the semi-permeable membrane, the fluid is termed 
dialysate. It continues to be pumped into the outer lumen of the tubing, and is 
collected in an exchangeable vial at the end of the system. So, the dialysate is a 
representative sample of the small molecule constituents of the interstitial fluid.  
The proportion of a particular substance in the dialysate as compared to the actual 
concentration in the sampling medium is termed ‘relative recovery’, and is 
expressed as a percentage. Relative recovery is increased with a lower flow rate. 
Absolute recovery is the amount of substance collected in the dialysate per unit 
time and is increased with a higher flow rate. 
Several different designs of probe are available with different arrangements for 
the flow pathway. Concentric (double-lumen) probes are the most common 
commercially available, with the membrane at the most distal point of the system. 
Fluid enters through the central portion of the tubing, which directs fluid to the tip 
of the membrane. The fluid then travels back past the semipermeable membrane, 
into the outer portion of the tubing and into a collecting vial. Thus only one entry 
point into the tissue is needed for a complete system. Another form of system is a 
linear probe, with the inflow connecting to the semipermeable membrane, which 
is then continuous in a linear fashion with the outflow tubing and collection vial. 
This means an entry and an exit point is needed, however of benefit is the 
improved retention of the probe in a mobile subject. The linear system was not 
available as a CE marked probe for clinical use at the time of these studies. 
 
 
 34 
1.3.2.1 Factors affecting substance recovery  (60,61) 
1.3.2.1.1 Flow rate 
Molecules transfer across the membrane passively, by diffusion. Since the 
probe is continuously perfused, equilibrium is never reached. Relative 
recovery is the dialysate concentration expressed as a percentage of the 
interstitial concentration. A faster flow rate increases the gradient for 
transfer, and gives a greater absolute recovery (mass of analyte recovered 
per unit time), but a lesser relative recovery, as the dialysate will be dilute. 
A high flow rate will also drain the surrounding tissue, altering the 
biochemical picture. A low flow rate gives the best relative recovery, and a 
dialysate which is most similar to the interstitial fluid itself. Therefore the 
lowest flow rate possible is accepted as being the best method of obtaining 
an accurate measure of the concentration of the tissue fluid in which the 
probe is situated  (61)  (21,55). Other factors to be considered in the 
determination of flow rate include the frequency of the sampling interval, 
and the volume needed for analysis of each sample. A flow rate of 0.3ul/min 
has been put forward by several authors as optimal, as this minimises the 
drainage of substances from the sampled tissue, but allows 9ul to be 
collected every 30 minutes, sufficient for analysis of a basic set of 
metabolites  (62)  (63)  (55).  
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1.3.2.1.2 Membrane Length 
The length of the semi-permeable membrane also has an effect on the uptake 
of a substance. The larger the surface area, the quicker the equalisation of 
concentration across the two sides of the membrane (Fick’s law). The longest 
commercially available probe is 30mm long. 
 
1.3.2.1.3 Pore Size 
The semi-permeable membrane can be manufactured with a pre-determined 
pore size to select for uptake of particular sized molecules. Although in 
theory, any molecule with molecular mass below the size of the pores will 
diffuse across, in reality, molecules approaching the size of the pore will 
display very limited recovery. The molecule must be less than a quarter the 
pore size to provide acceptable recovery  (61). Size of the following 
substances was taken into account when selecting pore size of the probe: 
Glucose 180 Da; Lactate 89 Da; Pyruvate 87 Da; Glycerol 92 Da; Amino 
acids 75-214Da. 
 
1.3.2.1.4 Perfusate composition 
The perfusion fluid usually contains an aqueous solution similar to the 
surrounding medium to prevent excessive washout of substances from the 
area adjacent to the probe. Perfusate can be altered to influence the diffusion 
pattern in a particular way. For example, facilitated transport has been 
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described by the addition of β-cyclodextrin to the perfusion fluid as a 
complexation agent for ibuprofen, increasing the relative recovery by 1.5 – 2 
times  (64). Lipophilic compounds or highly protein bound substances have 
also been recovered by altering the composition of the membrane or the 
perfusate  (65), and pH has been used to influence recovery  (66). 
Perfusion Fluid T1TM (CMA microdialysis, Sweden) is a basic perfusion 
solution which prevents depletion of salts from surrounding tissues.  
 
1.3.2.1.5 Tortuosity of sample matrix 
Cellular content and viscosity of the extracellular matrix will delay diffusion 
of substances into the probe. Thus in-vivo recovery will never equal in-vitro 
recovery  (67)  (68). In a clinical study, the ratio of in-vivo to in-vitro 
recovery differed between substances, but was constant for the same 
substance  (69). 
 
1.3.2.1.6 Temperature 
Molecules diffuse at different rates according to their radius, the viscosity of 
the suspending fluid, and the temperature (Stokes-Einstein equation). Thus 
microdialysis should ideally be undertaken at a constant temperature  (61). 
However, where recovery approaches 100%, the effect of temperature on the 
relative recovery will be minimal. 
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1.3.3 Microdialysis and the Dermis 
Microdialysis in the dermis has been used widely for over fifteen years to 
investigate pharmacokinetics of drug distributions from systemic administration 
and from topical preparations, and as a method of direct delivery of drugs into the 
skin. Other investigations can be categorised as follows: 
 
1.3.3.1 Inflammatory mediators  
Measurement of inflammatory mediators has been undertaken by several 
authors, investigating the skin’s role in the allergic response. The role of 
histamine, substance P and codeine in allergic responses of the skin have 
been studied  (70,71)  (72). The topography of plasma extravasation in 
response to histamine stimulation was studied using plasmapheresis fibres 
with a 3000 kDa cut-off  (73). Neurogenic inflammation, and the role of 
histamine and substance P, has been studied using the microdialysis 
technique as summarised by Schmelz and Petersen  (74). The use of 
microdialysis for studying the vascular response of skin to inflammatory 
stimuli, particularly when paired with laser-Doppler imaging has been 
extolled  (75). 
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1.3.3.2 Skin Metabolism  
Measurement of metabolism in the skin has been another field of interest 
within the literature. Cellular energy production relies on the substrate 
glucose which is converted to pyruvate in the presence of oxygen. If the 
environment becomes anaerobic, glucose metabolism and energy production 
can continue for a time, by conversion of glucose to lactate. If the 
environment remains anaerobic for too long, cell death occurs, with the 
release of glycerol from the cell wall. Glucose levels indicate the delivery of 
substrate to the tissue from the blood, i.e. perfusion of the tissue. The ratio 
of lactate to pyruvate indicates the proportion of aerobic activity, i.e. the 
supply of oxygen. Elevated glycerol levels indicate cell death. A reduced 
blood supply would lead to a low glucose level, together with a rise in 
lactate/pyruvate ratio, and this would be followed by a rise in glycerol, if 
blood supply is not restored. 
Glucose and lactate concentrations in the skin have been studied in normal 
subjects at rest during fasting and after glucose load (76-78) and during 
exercise  (79). 
 
Lactate and pyruvate was studied by Krogstad and Jansson, and the lactate/ 
pyruvate ratio (LPR) as a function of aerobic metabolism was introduced. 
These authors validated the technique of intradermal microdialysis, using 
ultrasonic measurement to ensure probes were accurately sited, and using 
various calibration techniques to allow absolute values to be estimated. 
They investigated changes in lactate and pyruvate in relation to the depth of 
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the probe within the dermis, and found both lactate and pyruvate levels to be 
higher the more superficial the probe. However they noted that the increase 
was equal for both substances, indicating an increase in metabolic rate in the 
more superficial layers, but no change in the aerobic status of the 
metabolism. They concluded that the LPR was unaffected by the depth of 
the probe in the dermis  (52,76). 
No studies could be found which measured the levels of glycerol in the 
dermis.  
The levels of uric acid, an antioxidant, in the dermis and its decline with age 
has also been reported  (80).  
 
1.3.4 Microdialysis in Burns Research 
Although microdialysis is an ideal tool with which to monitor the burn wound, 
very little research has been undertaken in this field to date. Work investigating 
the role of histamine in burn oedema has been undertaken in animal studies  
(58,81). 
C3a levels were found to be elevated in the subdermal tissue in deep partial 
thickness burns, which decreased after 24 hours in younger patients, but persisted 
in patients over 60 years, and this correlated with numbers of thrombosed 
subdermal vessel after 24 hours  (82). 
The only other clinical study was a series of six patients with burns >25% TBSA 
who were studied with two microdialysis catheters, one in the burn wound and 
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one in normal skin. Samples were collected 3 hourly until day 5. The presence of 
dermal ischaemia was noted, together with hyperglycaemia and raised glycerol 
when compared to normal volunteers  (59). 
Tissue ischaemia is the final common pathway in most of the theories about burn 
wound progression, and therefore measurement of ischaemic parameters should 
reflect the likelihood of impending tissue death. Changes in glucose, LPR and 
glycerol using the microdialysis method have been shown to accurately reflect 
tissue ischaemia in free flaps. Another proposed mechanism of wound progression 
involves changes in nitric oxide, and, while nitric oxide itself is too unstable to 
measure directly, monitoring nitric oxide precursors and metabolites, such as 
arginine and citrulline, is another possible way of predicting progression. 
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2 HYPOTHESES 
• The Microdialysis method can be used to detect changes in biochemistry within the 
burn wound with time. 
• Different zones of the burn wound are characterized by different biochemical profiles, 
and these profiles change with time. 
• Changes in the biochemistry of the zone of stasis can predict wound progression. 
 
Proving these hypotheses would further the understanding of burn wound progression, and 
provide a useful tool for clinical research aimed at modulating this progression. 
 
2.1 Research Plan 
Two clinical phases of this study were performed. The first was to establish baseline 
values in normal skin in healthy volunteers using the microdialysis technique. The 
second phase was to characterize biochemical differences between zones of the burn 
wound and changes with time post-burn. During the second phase, laser Doppler 
imaging was used as a method of detecting wound progression in order to correlate 
outcome with biochemistry. Dialysate was tested for products of aerobic and anaerobic 
glucose metabolism (glucose, lactate and pyruvate), and a marker of cell necrosis 
(glycerol). Metabolites associated with nitric oxide synthesis (Arginine, ornithine and 
citrulline) were tested with an amino acid assay, and additional assays of the spectrum 
of amino acids were performed concomitantly. The clinical studies were supported by 
calibration studies to test the validity of the results. 
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3  MATERIALS AND METHODS 
3.1 Microdialysis 
3.1.1 Microdialysis Equipment 
 
CMA60 Microdialysis catheter (CMA Microdialysis, Solna, Sweden) 
 
Figure 4: CMA 60 Microdialysis catheterwith needle introducer. Microvial also shown. 
Photograph courtesy of M dialysis, Solna, Sweden 
 
Probe consisting of a semipermeable membrane of length 30mm, and diameter 
0.6mm with a pore size of 20kDa. Inlet and outlet tubing connect the membrane to 
a pump and a collection vial. 
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CMA 107 microdialysis pump (CMA Microdialysis, Solna, Sweden)  
 
Figure 5: CMA 107 Microdialysis pump. Photograph courtesy of M Dialysis, Solna, Sweden 
 
A small, portable pump with adjustable flow rate from 0.1 – 5.0 µl /min. During 
this study a flow rate of 0.3µl/min was used. 
 
CMA106 syringe (CMA Microdialysis, Stockholm, Sweden). 
 
Figure 6: CMA106 Syringe. Photograph courtesy of M Dialysis, Solna, Sweden 
 
A plastic syringe holding 2.5ml of T1 perfusion solution, placed inside the 
CMA107 pump and attached to the inflow tubing of the CMA60 microdialysis 
catheter. 
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Microvials (CMA Microdialysis, Stockholm, Sweden)  
 
Figure 7: Microvials and Microvial rack. Photograph courtesy of M Dialysis, Solna, Sweden 
  
Small plastic vials used to collect microdialysate from the outflow tubing of the 
CMA60 catheter. These are removable, and used to transfer the samples to the 
CMA 600 analyser for analysis. A plastic storage rack to minimise evaporation 
during freezing was also used. 
 
T1 Perfusion Solution (CMA Microdialysis, Stockholm, Sweden)  
 
Figure 8: T1 Perfusion Solution. Photograph courtesy of M dialysis, Solna, Sweden 
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A sterile, isotonic solution which is perfused through the microdialysis catheter. 
Concentrations of electrolytes are as follows: Na+ 147 mmol/l (3.38 g); K+ 4 
mmol/l (156 mg); Ca2+ 2.3 mmol/l (92mg); Cl- 156 mmol/l (5.59 g); Osmolality 
290 mosm/kg; pH c.6 
 
3.1.2 CMA600 Analyser 
 
Figure 9: CMA 600 Analyser. Courtesy of CMA Microdialysis, Solna, Sweden 
 
CMA600 (CMA Microdialysis, Stockholm, Sweden) is a kinetic enzymatic 
analyser using colorimetric measurements. Imprecision is documented in the 
product literature to be <6% Relative Standard Deviation. Reagents are 
commercially available for analysis of glucose, lactate, pyruvate, glycerol, urea 
and glutamate. In this study, all except glutamate were used. The analyser allowed 
analysis of up to four substances during any one ‘run’. In these studies, glucose, 
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lactate, pyruvate and glycerol were studied in the first run. Samples were returned 
to the freezer before analysis of urea in a separate run. The order of analysis was 
glucose, lactate, pyruvate then glycerol. Therefore in the event of there being 
insufficient sample in a vial, the later analyses may have been missing. 
Consumption of sample was 0.2µl for lactate, and 0.5µl for each of glucose, 
pyruvate, glycerol and urea. A residual 2 µl was required in addition to the 
minimum volume for analysis, so total volume required for a full analysis was 
4.2µl. Time for each complete analysis was approximately 4 minutes. 
 
LabPilot Software (CMA Microdialysis, Stockholm, Sweden) was used to handle 
the data, including some of the graphical representations. 
 
Calibrator A (CMA Microdialysis, Stockholm, Sweden) was used as a calibration 
solution, as an internal standard, and as a reference solution in which microdialysis 
was undertaken to detect percentage recovery of substances. Published 
concentrations of substances within this solution were as follows:  Glucose 
5.55mmol/l; Lactate 2.5 mmol/l; Glycerol 475 µmol/l; Urea 13.3 mmol/l; Pyruvate 
250 µmol/l; Glutamate 25 µmol/l. 
 
3.1.3 Summary of Technique 
The CMA106 syringe was filled with T1 perfusion solution, and attached to the 
microdialysis catheter. The syringe was depressed until all air was expelled from 
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the microdialysis tubing, then the syringe was placed into the CMA107 pump, and 
a collecting vial was attached to the end of the catheter. The pump was turned on 
and the priming mechanism initiated. After the 5 minute automatic priming was 
completed, the pump returned to the preset perfusion rate of 0.3µl/min. The first 
collection vial was discarded and a new one attached. The microdialysis catheter 
was then placed either into a bath of calibration fluid (for calibration experiments, 
and normal volunteer study) or directly into the patient (for the clinical burn 
studies). 
Probe insertion was undertaken after local anaesthesia of the area was achieved. 
For normal volunteers expediency was not an issue, so topical EMLA cream was 
applied 30-60 minutes prior to probe insertion. For burn patients, delay was 
minimised by injecting 5ml of 1% lidocaine into the dermis in the sensate areas 
(Zones B and C). Microdialysis probes were inserted into the dermis using the 
insertion needle provided with the catheter. Catheters were secured with a suture 
into the burned areas, or with a clear adhesive Tegaderm dressing (3M, Bracknell 
UK) onto intact skin. A dressing of tulle gras, gauze and crepe bandage was used 
to protect the burn where necessary, and to keep the probe in place, preventing 
accidental dislodging.  
Samples were collected by exchanging each collection vial every 30 minutes. Each 
vial was labelled with a unique number, and placed into a storage tray. Once a 
complete tray of 12 vials was collected, this was placed into the freezer at -80oC. 
Samples were stored for up to 3 months before first analysis. Just prior to analysis, 
samples were removed from the freezer and defrosted at room temperature.  
Samples were analysed for glucose, lactate, pyruvate and glycerol, and then 
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refrozen. Urea analysis and amino acid analysis were performed after defrosting a 
second time.  
Before each batch was analysed, the CMA 600 ran an automatic calibration. For 
analysis of Study 1 Normal Volunteer samples, an internal standard was used by 
filling a collection vial with Calibrator A, and analysing this alongside the samples 
for each patient. 
Data were downloaded from the CMA 600 analyser. LabPilot, (CMA 
Microdialysis, Solna, Sweden) and Microsoft Excel were used to produce the 
graphical images, and SPSS Version 15.0 was used for statistical analysis and 
some graphical images of the lactate, pyruvate, glucose, glycerol and urea results. 
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3.2 Laser Doppler Imager 
 
Figure 10: moorLDI  Laser Doppler Imager 
 
Following enrolment into the study, and just prior to probe insertion, a laser Doppler 
image was taken. In order to provide a reference point for later calculations of area, a 
5cm standard line was drawn on the skin next to the wound. The patient was given laser-
protective glasses to wear, and the moorLDI laser Doppler imager (Moor Instruments 
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Ltd, Axminster, Devon) was turned on. The area to be scanned was cleaned of any 
debris and all dressing material was removed. The laser scanner was positioned 50-
70cm from the wound, and the exact distance recorded. The patient was asked to remain 
still, and the scan was taken. On completion of the study, a second LDI image was taken 
using the same protocol. The scanner distance, and the orientation of the wound was 
matched with the first scan as closely as possible. Images were interpreted using the 
colour coding as standard to the moorLDI software. Areas of full thickness burn were 
calculated by tracing the areas of low flow (<200 perfusion units), using the moorLDI 
software. Wound progression was deemed to have occurred if this area had increased 
between the first and second images. 
 
3.3 Amino Acid Analysis 
For determination of amino acids, the High Performance Liquid Chromatography 
(HPLC) method was used. Insufficient sample volumes remained in the vials, after 
analysis with the CMA600, to analyse every sample vial individually for amino acids, so 
samples were pooled in consecutive groups of four. This provided an average result for 
every 2 hours throughout the study period, for each patient. 
 
 
3.3.1 HPLC of amino acids 
Amino acids were determined by HPLC with fluorometric detection of o-
phthaldialdehyde derivatives, using a modification of the classical method of 
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Lindroth and Mopper (21). The system consisted of a ChromSpher ODS column 
(5µm, 150 x 3 mm, with guard column; Varian Chrompack, Walton-on-Thames, 
UK) with a CMA 280 fluorescence detector (maximum excitation, 340-360 nm; 
maximum emission 495 nm: CMA Microdialysis Ltd, Sweden). The derivatisation 
reagent was prepared by mixing 975µl of incomplete o-phthaldehyde reagent 
solution (Sigma, Poole, UK) with 25µl of 10% (v/v) mercaptopropionic acid in 
methanol (Sigma, Poole, UK). 
 
Derivatisation of dialysis samples and standards, as well as injection, was carried 
out with a CMA 200 refrigerated (8oC) autosampler (CMA Microdialysis Ltd, 
Sweden), which added 1.5 µl of derivatisation reagent to 5 µl of each sample or 
standard, and reacted for 60 seconds prior to injection. The mobile phase gradient 
consisted of 100mM sodium acetate buffer, pH 6.9, containing an organic modifier 
mixture (water; acetonitrile, methanol: 1:3:6 (v/v), increasing linearly from 8 to 
48% (v/v) over a period of 46 minutes. This was delivered at a flow-rate of 0.5 
ml/min, using a PM-80 twin-reciprocating pump with LC-26A vacuum degasser 
(BAS Technicol, Congleton, UK). Data were collected and analysed using 
EZChrom software (Aston Scientific, Stoke Mandeville, UK) after calibration with 
a range of standard amino acid solutions (10-80 µM) containing aspartate, 
glutamate, serine, glutamine, histidine, glycine, threonine, citrulline, β-alanine, 
arginine, alanine, taurine, GABA, tyrosine, ethanolamine, valine, methionine, 
tryptophan, phenylalanine, isoleucine, leucine, ornithine, lysine and putrescine. 
Other amino acids and primary amines were identified by co-elution with native 
compounds. 
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3.4 Calibration Studies 
3.4.1 Accuracy of Analyser 
A sample of calibration solution (Calibrator A, CMA Microdialysis, Solna, 
Sweden) was analysed with each run of analysis throughout the initial 
experiments, in order to assess the accuracy of the analyser. 
 
3.4.2 Experiment 1: The effect of sample storage conditions on accuracy 
of analysis 
Aim: To establish the effect of repeated freeze-thaw cycles or refrigeration of the 
microdialysis samples.   
Method: Each experiment was performed in triplicate. On Day 1, microdialysis 
vials (CMA, Sweden) were prepared with 30µl of calibration fluid (Calibrator A, 
CMA, Stockholm Sweden). Vials were labelled A1-3, B1-3 and C1-3. Vials were 
analysed for Glucose, Lactate, Pyruvate, Glycerol and Urea using the CMA600 
analyser (CMA, Sweden). After analysis, all vials were placed into microvial 
racks (CMA, Sweden). Vials A1-3 were put into the -80oC freezer. Vials B1-3 
were placed into a temperature controlled refrigerator at 5oC. Vials C1-3 were 
kept at room temperature (23oC). On Day 2, the vials were removed from their 
storage conditions and transported to the analyser. They remained at room 
temperature until analysis. Analysis was performed as above. Samples were then 
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returned to their respective storage conditions. On Day 3, samples were again 
removed from their storage conditions and analysed for the third time. 
Graphs were created using the average of each triplicate reading for each time-
point. Statistical calculations were performed using SPSS Version 15.0 for 
Windows. Results were analysed using two-way ANOVA, with a Post-hoc Tukey 
analysis. 
 
3.4.3 Experiment 2: The effect of sample volume on accuracy of analysis 
Aim: To establish the effect of the volume of the sample within the vial on the 
results of the analysis of glucose, lactate, pyruvate, glycerol and urea. 
 
Method: Each experiment was performed in triplicate. On Day 1, microdialysis 
vials (CMA, Sweden) were prepared with calibration fluid (Calibrator A, CMA, 
Stockholm Sweden). Vials were labelled A1-3, F1-3 and G1-3. Vials A1-3 were 
filled with 30µl. Vials F1-3 were overfilled almost to the capacity of the vial. 
Vials G1-3 were filled with 10 µl.  Vials were analysed for Glucose, Lactate, 
Pyruvate, Glycerol and Urea using the CMA600 analyser (CMA, Sweden). After 
analysis, all vials were placed into microvial racks (CMA, Sweden) and put into 
the -80oC freezer. On Day 2, the vials were removed from the freezer and 
transported to the analyser. They remained at room temperature until analysis. 
Analysis was performed as above. Samples were then returned to the freezer. On 
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Day 3, samples were again removed from the freezer and analysed for the third 
time. 
Graphs were created using the average of each triplicate reading for each time-
point. Statistical calculations were performed using SPSS Version 15.0 for 
Windows. Results were analysed using two-way ANOVA, with a Post-hoc Tukey 
analysis. 
 
3.5 Study Design 
3.5.1 Power Calculations 
A power calculation was performed based on the only clinical microdialysis study 
in burns available at the time. This was a study which showed a difference in 
histamine levels from different depths of burn in pigs (21). There were no other 
studies on biochemical parameters from different zones of burn wounds, or on 
human burns, available prior to the commencement of this study, so it was not 
possible to perform a power calculation with any greater accuracy. 
The values used in the power calculation were based on Fig 2 of the Papp et al 
paper and are shown in Table 3. Power was calculated with SPSS for Windows 
using the method described by D’Amico et al (21). With a sample size of 5 in each 
group, the power to detect the estimated difference between the groups at the 5% 
significance level was over 95%. 
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Table 3: Estimated values of histamine (mmol/l) with time for Group 1(unburned skin), Group 2 
(1second thermal burn) and Group 3 (9 second thermal burn) from Papp 2005 
 1 hour 2 hours 6 hours 12 hours 24 hours 
Group 1 mean 240 210 40 25 100 
Group 2 mean 65 50 25 25 130 
Group 3 mean 30 20 15 10 10 
Standard deviation 60 60 10 10 40 
 
This calculation showed a statistical difference could be shown in this group with 
a sample size of 5 patients. Since this study is not directly comparable to our 
study, it was decided to increase the sample size to 10 patients in each group, to 
allow for the possibility of smaller differences in the biochemical parameters 
measured in humans in this study. 
 
3.6 Protocol for Clinical Study 1: Normal volunteers 
3.6.1 Aims 
• To establish a normal range of metabolites for healthy skin using the 
microdialysis technique 
• To ascertain if the normal range alters with the raised temperature 
environment experienced by the burns patients during their treatment 
• To validate probe insertion technique 
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3.6.2 Methods 
3.6.2.1 Volunteer Recruitment 
Ethics Committee approval was obtained from the Black Country Research Ethics 
Committee (Ref 05/Q2702/76). A Participant Information Sheet was produced 
(Appendix A) and the protocol was explained to the volunteers together with 
potential risks. Informed consent was obtained. Eleven healthy male volunteers 
were recruited. Volunteers were asked to refrain from drinking alcohol or caffeine 
during the six hours prior to the study, and during the study period.  
 
3.6.2.2 Analgesia 
Each volunteer had 5g EMLA cream (AstraZeneca, UK) applied to the skin on the 
dorsal surface of the non-dominant forearm, under an occlusive dressing 
(Tegaderm, 3M) for 60 minutes, prior to probe insertion. 
 
3.6.2.3 Equipment set-up and calibration 
The CMA60 microdialysis catheter was connected to a syringe containing T1 
Perfusion Solution (CMA, Sweden), and connected to the CMA 107 microdialysis 
pump set at a flow rate of 0.3µl/min. After the initial flush sequence, the probe was 
placed into a sterile calibration solution, Calibrator A (CMA, Sweden), a sample 
of which was taken before probe insertion to act as an internal standard. The probe 
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was left in this solution and microdialysis undertaken for 60 minutes, sample vials 
being collected half hourly.  
 
3.6.2.4 Probe insertion 
Aim: to assess the reproducibility of the catheter insertion technique, and to ensure 
all microdialysis samples were taken from the dermal layer. 
The EMLA cream was removed from the volunteer’s arm, and the arm tested for 
anaesthesia. The CMA60 probe was then inserted intradermally into the dorsal 
forearm skin using the insertion needle provided. The needle was then withdrawn, 
and the catheter held in place by a Tegaderm dressing. The pump was loosely 
bandaged to the upper arm to allow free movement. Depth of the probe and total 
depth of the dermis was measured ultrasonically with a Sonosite 180Plus 
(SonoSite Inc, USA). Distance from epidermis to probe and distance from 
epidermis to junction of dermis and subcutaneous fat was measured (Figure 11). 
Probe depth was expressed as a percentage of the total depth of the dermis. 
Throughout this experiment, air temperature measurements were taken adjacent to 
the forearm containing the probe using a calibrated thermometer (Comark, UK) 
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Figure 11: Ultrasound image of the skin and subcutaneous layers of the forearm following 
microdialysis probe insertion. Microdialysis probe, dermis and subcutaneous fat are 
indicated 
 
 
3.6.2.5 Equilibration Period 
Aim: To allow normalization of the probe environment and to assess the effect of 
insertion trauma.  
The first 90 minutes was designated the equilibration period. The volunteer was 
asked to sit in a temperature monitored room, and was free to eat and drink, watch 
television or read. Microdialysis samples were collected at 30 minute intervals.  
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3.6.2.6 Study Period 1 
Aim: To obtain a baseline reading at room temperature 
The next 60 minutes was designated Study Period 1. Room temperature was 
maintained and a further 2 samples obtained at 30 minute intervals. Air 
temperature was measured. 
 
3.6.2.7 Study Period 2 
Aim: To assess the effect of raised temperature  
Immediately following this the volunteer was entered into Study Period 2. The 
volunteer was asked to lie on the bed, and the Aragona CTC Thermal Ceiling 
(Aspira, Sweden) was switched on. Air temperature measurements were taken. 
Two further microdialysis samples were collected at 30 minute intervals. The 
presence of sweating local to the probe site was also noted.  
 
3.6.2.8 Study Period 3 
The volunteer was returned to room temperature for Study Period 3, with a further 
two samples collected at half hourly intervals. Air temperature was measured. 
 
3.6.2.9 End of Study 
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At the end of Study Period 3, the probe was removed from the forearm and 
returned to the calibration solution for a further hour. The volunteer was then 
allowed to leave, and the probes were discarded.  
 
3.6.2.10 Labelling and Storage of Samples 
Labelling of sample vials is summarised in Table 4. Samples were stored at -80oC 
before analysis, and were analysed within 12 weeks of collection. 
 
3.6.2.11 Statistical Analysis 
Repeated measures ANOVA was used to test for differences during the calibration 
period. 
To allow tissues to respond to change in temperature and to allow for the slight 
delay in flow from probe to sample collection vial (approx. 2 mins), the second 
sample from each study period was used for statistical analysis. Repeated 
measures ANOVA was also used to detect differences between the three 
temperature study periods. 
Analysis of the ambient temperatures between the study periods was performed 
using a paired T-test 
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Table 4: Labelling of samples relative to study protocol 
Vial Code Time 
(hours:minutes) 
Description of study period 
NV__C1 0:00 Calibration solution 
NV__01 0:30 Probe in Calibration solution 
NV__02 01:00 Probe in Calibration solution 
NV__03 01:30 Probe in Volunteer; Equilibration Period 
NV__04 02:00 Probe in Volunteer; Equilibration Period 
NV__05 02:30 Probe in Volunteer; Equilibration Period 
NV__06 03:00 Probe in Volunteer; Study Period 1 (Room Temperature) 
NV__07 03:30 Probe in Volunteer; Study Period 1 (Room Temperature) 
NV__08 04:00 Probe in Volunteer; Study Period 2 (Raised Temperature) 
NV__09 04:30 Probe in Volunteer; Study Period 2 (Raised Temperature) 
NV__10 05:00 Probe in Volunteer; Study Period 3 (Room Temperature) 
NV__11 05:30 Probe in Volunteer; Study Period 3 (Room Temperature) 
NV__12 06:00 Probe in Calibration solution 
NV__13 06:30 Probe in Calibration solution 
NV__C2 07:00 Calibration solution 
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3.7 Protocol for Study 2: Small Burns 
3.7.1 Aims 
The aims of this study were as follows: 
• To characterize the different zones of the burn wound biochemically. 
• To assess whether wound progression could be predicted by the local 
biochemical changes within the first 36 hours following injury. 
 
3.7.2 Materials and Methods 
3.7.2.1 Recruitment 
Ethical approval was granted from the Black Country Research Ethics 
Committee (Ref 05/Q2702/76). A participant information sheet and consent 
form were prepared (Appendix A). Informed consent was obtained prior to 
enrolment. Potential participants were identified by the on-call burns doctor 
and the Researcher was contacted. The patient was approached as soon as 
possible after admission to the hospital. 
Ten patients were recruited. Any patient admitted to the Burns Unit at Selly 
Oak Hospital with total burn <15% total body surface area (TBSA) was 
considered for inclusion (Table 5). Exclusion criteria are defined in Table 6. 
  
Each patient fitting the inclusion criteria had the study explained, and was 
given a participant information sheet. Due to the nature of the study, it was 
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necessary that the study must be started as soon as possible after admission. 
Consent was sought immediately after the explanation was given. Where 
consent was given, enrolment ensued. 
 
Table 5: Inclusion criteria 
Criteria Study 1 Study 2 Study 3 
Age 18-80 
 
18-80 18-80 
Gender Male  Male or Female 
(except during 
pregnancy) 
Male or Female 
(except during 
pregnancy) 
Size of Burn N/A <15% TBSA.  >30% TBSA.  
Site of Burn N/A Includes arm or 
leg 
Includes arm or 
leg 
Time of Burn N/A Admitted within 
6 hours of burn 
Admitted within 
6 hours of burn 
Administrative Volunteer able 
to understand 
trial 
Patient able to 
understand trial 
Patient able to 
understand trial 
 
Table 6: Exclusion criteria 
Criteria Study 1 Study 2 Study 3 
Current Co-
morbidity 
Ongoing medical 
condition or 
medication. 
Ongoing medical 
condition or 
medication. Co-
existing trauma 
Ongoing medical 
condition or 
medication. Co-
existing trauma 
Past Medical 
History 
History of skin 
disease 
History of skin 
disease 
History of skin 
disease 
Alcohol and 
Caffeine 
Alcohol/caffeine 
consumed within 
12h 
  
Allergy Allergy to 
polyurethane or 
polyamide 
Allergy to 
polyurethane or 
polyamide 
Allergy to 
polyurethane or 
polyamide 
Other clinical 
trial 
Treatment in 
other clinical 
trial within past 
30 days 
Treatment in 
other clinical 
trial within past 
30 days 
Treatment in 
other clinical 
trial within past 
30 days 
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3.7.2.2 Equipment set-up 
Once initial clinical assessment of the burn was completed, and any 
necessary therapy commenced (e.g. analgesia, debridement of blisters), the 
study was started. Details of the distribution and depth of the burns, were 
recorded for correlation with the results. 
Three CMA60 probes were set up on a sterile trolley. T1 perfusion solution 
was drawn into the CMA106 syringe, attached to the CMA60 probe and 
inserted into the CMA107 pump. The pump was set to a flow rate of 
0.3µl/min. The flush sequence was allowed to progress and was collected in 
a sample vial to check the correct functioning of the equipment. This sample 
vial was discarded on insertion of the probe. 
 
3.7.2.3 Selection of Probe Location and Probe Insertion 
Zone of coagulation was defined as an area of non-blanching, anaesthetic 
skin within the area injured. Zone of stasis was defined as an area of 
blanching skin, with epithelial loss, adjacent to the area defined as zone of 
coagulation. The area of unburned skin chosen for the insertion of the third 
probe was an area distant from the injured skin, if possible contralaterally in 
a matched area. If this was not possible, a site greater than 10cm from an 
injured area was chosen. 
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Where possible, probe insertion took place immediately following blister 
debridement and cleaning of the wound which took place under sedation 
with morphine and midazolam, or with morphine alone, as per unit protocol. 
Prior to insertion of the probes a total of 5ml Lidocaine 1% was injected 
intradermally at two of the three areas to be studied: the zone of stasis (as 
defined above) and the normal area of unburned skin. The zone of 
coagulation (centre of burn) is insensate, so anaesthesia was deemed to be 
unnecessary. 
 
Once anaesthesia was attained, a microdialysis probe was placed 
intradermally at each of these sites using the insertion needle provided with 
the probe. Dressings were standardised: Jelonet, gauze and crepe. This was 
the standard dressing applied for the first 48 hours within the Burns Unit at 
the time of commencement of the trial.  
 
3.7.2.4 Data collection 
Microdialysate samples were collected every 30 minutes throughout the first 
36 hours following injury. Time was measured as number of hours after 
reported time of burn. Patient activity, medical intervention and events such 
as theatre visits were noted throughout the study period.  
Medical notes were reviewed subsequent to patient discharge, and events in 
relation to surgical procedures, skin grafting and wound healing were noted. 
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3.7.2.5 Laser Doppler Imaging 
The Moor LDI Laser Doppler machine was calibrated and set up according 
to the manufacturer’s instructions. The distance of the scanning laser from 
the patient was noted, and an initial scan of the burnt area chosen for 
microdialysis was taken before probe insertion. A second scan was taken of 
the same area, at the end of the study, just prior to removal of the 
microdialysis probe. The distance of the scanning laser from the patient was 
matched to that of the first scan. The graphics package supplied with the 
moorLDI machine was used to calculate the total area of low perfusion 
within the wound. Wound progression was deemed to occur if the area of 
perfusion coloured blue (<200 perfusion units) had increased between the 
first and second images. 
 
3.7.2.6 End of Study 
At the end of the 36 hour study period, the microdialysis probe was 
removed, and all other treatment for the burn continued as normal. 
 
3.7.2.7 Analysis of samples – Glucose, Glycerol, Lactate, Pyruvate, 
Urea 
Sample vials were placed into the freezer at -80oC for storage until analysis. 
Analysis was undertaken within 3 months in all cases. Analysis of glucose, 
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glycerol, pyruvate and lactate was performed using the CMA600 analyser 
(CMA, Sweden) and glucose, lactate, pyruvate and glycerol reagents (CMA, 
Sweden). Samples were refrozen at -80oC pending the Urea analysis which 
was undertaken as a batch analysis at the end of the entire study period 
using the same analyser, and urea reagent (CMA, Sweden).  
 
3.7.2.8 Calculated Results 
Lactate: Pyruvate Ratio was calculated by dividing the Lactate result 
(µmol/l) by the Pyruvate result (µmol/l) for each individual time point. This 
method provides an estimation of the aerobic state of the tissue and controls 
for the placement of the probe in different levels of the dermis (21). LPR 
<25 was interpreted as being predominantly aerobic, and LPR>25 
predominantly anaerobic metabolism. 
 
3.7.2.9 Analysis of samples – Amino Acids 
Following analysis of glucose, glycerol, lactate, pyruvate and urea, the 
remainder of each sample was then pooled in groups of 4 consecutive 
samples to allow analysis of amino acids. 
 
3.7.2.10 Statistical Analysis 
SPSS Version 15.0 for Windows was used to analyse the results. Values 
were grouped into 6-hour time blocks from the purpose of analysis of time-
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related trends. Generalised Estimating Equations were used to detect 
differences between time blocks and between zones. A subgroup analysis 
was performed for patients attending theatre during the study period. 
For the amino acid analysis, a 2-way ANOVA (GraphPad Prism software, 
version 5) was used. Variables were time post-burn and probe location. 
 
3.7.2.11 Late addition to protocol for measurement of serum urea 
A late addition was made to the protocol for collection and microdialysis of 
serum urea. This was in order to attempt in vivo calibration using the 
endogenous reference method (See section 5.2). This was agreed by the 
Research Ethics Committee by way of a minor amendment. Serum samples, 
which had already been taken for routine clinical use, were collected from 
frozen storage in the hospital biochemistry laboratory, defrosted, and the 
excess serum used for microdialysis. Serum was drawn from the top of the 
tube into a 1ml syringe. One of the probes which had been used previously 
for the dermal microdialysis of the same patient was set up as previously 
described. The microdialysis probe was placed into the syringe of serum, 
and microdialysis was undertaken for three continuous 30 minute periods. 
Microdialysis samples were analysed in the usual way. This had to be 
undertaken after the completion of the dermal microdialysis in all cases 
because there was insufficient equipment (probes and pumps) in order for 
this to be done synchronously. Microdialysis results were compared to 
results from standard laboratory analysis and to zone C results, taken at the 
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closest time to the drawn blood. Only patients recruited after S06 were 
included as the blood samples of patients prior to this had been discarded by 
the laboratory. 
 
 
3.8 Protocol for Study 3: Large Burns 
3.8.1 Aims 
The aims of this study were as follows: 
• To characterize the different zones of the burn wound biochemically. 
• To assess whether wound progression could be predicted by the local 
biochemical changes within the first 36 hours following injury 
• To compare the biochemical behaviour of large burn wounds with that of small 
burn wounds 
 
3.8.2 Materials and Methods 
3.8.2.1 Recruitment  
Ethical approval was granted for this study. A participant information sheet 
and a consent form were prepared, similar to those for Study 2 (Appendix 
A). In addition, an assent form was prepared to seek the agreement of 
relatives of any patient who was unable to give consent due to the severity 
of their injuries. Informed consent was obtained from all conscious patients 
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prior to enrolment. Assent was gained from the next of kin of any patient 
who was unconscious, prior to enrolment. Potential participants were 
identified by the on-call burns doctor and the Researcher was contacted. The 
patient or relative, where appropriate, was approached as soon as possible 
after admission to the hospital. 
Recruitment of ten patients was planned. Any patient admitted to the Burns 
Unit at Selly Oak Hospital with total burn greater than 30% total body 
surface area (TBSA) was considered for inclusion (See Table 5). Exclusion 
criteria are defined in Table 6. 
 
Each patient fitting the inclusion criteria had the study explained, and was 
given a participant information sheet. Due to the nature of the study, it was 
necessary that the study must be started as soon as possible after admission. 
Consent, or assent, was sought immediately after the explanation was given. 
Where consent, or assent, was given, enrolment ensued. 
 
3.8.2.2 Equipment set-up  
Once initial clinical assessment of the burn was completed, and any 
necessary therapy commenced (e.g. analgesia, intravenous fluid therapy, 
debridement of blisters), the study was started. Details of the distribution 
and depth of the burns, was recorded for correlation with the results. 
Three CMA60 probes were prepared as for study 2 (See 3.7.2.2) 
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3.8.2.3 Selection of Probe Location and Probe Insertion 
Probe site selection and probe insertion was performed as for Study 2 (See 
3.7.2.3).  
 
3.8.2.4 Data collection 
Microdialysate samples were collected every 30 minutes throughout the first 
36 hours following injury. Patient activity, medical intervention and events 
such as theatre visits, and the addition of vasoconstrictors such as 
noradrenaline, were noted throughout the study period.  
Medical notes were reviewed subsequent to patient discharge, and events in 
relation to surgical procedures, skin grafting and wound healing were noted. 
 
3.8.2.5 End of Study 
At the end of the 36 hour study period, the microdialysis probe was 
removed, and all other treatment for the burn continued as normal. 
 
3.8.2.6 Analysis of samples 
All samples were stored and analysed as for Study 2. 
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3.8.2.7 Statistical Analysis  
SPSS Version 15.0 for Windows was used to analyse the results. 
Generalised Estimating Equations were used to detect differences between 
time blocks and between zones.  
For the amino acid analysis, a 2-way ANOVA (GraphPad Prism software, 
version 5) was used. Variables were time post-burn and probe location. 
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4 RESULTS 
Results of the metabolic parameters glucose, lactate, pyruvate and glycerol, and the 
standard urea are presented in sections 4.1-4.4 and the results of amino acid 
metabolism, with particular reference to nitric oxide metabolism, are presented in 
section 4.5.  
 
4.1 Results of calibration experiments 
4.1.1 Error margin of CMA600 analyser 
Results of analysing the calibration fluid are detailed in Appendix B, Tables 6-9 
(Columns C1 and C2). Below is the mean and percentage error (standard 
deviation divided by the mean) for each substance. 
 
Glucose:  5.68 mmol/l (+/- 4%) 
Glycerol:  487 µmol/l (+/- 6%) 
Lactate:  2.47 mmol/l (+/- 10%) 
Pyruvate:  241 µmol/l (+/- 5%) 
 
4.1.2 Results of calibration experiments – Storage conditions 
Raw data are presented in Appendix B, Tables A1-A5, Columns A, B, C.
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4.1.2.1 Glucose 
Glucose results are shown in Table 7 and Figure 12. Statistically significant results 
are recorded below the table. 
Table 7 to show mean and standard deviation of glucose results from microdialysis 
samples stored at different temperatures over 3 successive days 
 Mean Glucose Concentration (SD) mmol/l  
 Freezer -80oC Fridge 2-5oC Room 22oC  
Day 1 5.99 (0.14) 6.08 (0.51) 5.93 (0.08) 
Day 2 5.96 (0.17)a 5.66 (0.29)b 5.56 (0.03) 
Day 3 5.61 (0.05) 5.50 (0.05)c 5.45 (0.08)d 
a: On Day 2, samples stored in the freezer were more concentrated than those stored at 
room temperature (P=0.046) 
b,c: For samples stored in the fridge, there was a significant decrease in concentration 
between Day 1 and Day 2 (P=0.033), and between Day 1 and Day 3 (P=0.005).  
d: Samples stored at room temperature, became less concentrated with time, and this 
reached significance by Day 3 when compared to Day 1 (P=0.017).  
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Figure 12: to show mean and standard deviation of glucose results from microdialysis 
samples stored at different temperatures over 3 successive days 
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4.1.2.2 Lactate 
Lactate results are shown in Table 8 and Figure 13. Statistically significant results 
are recorded below the table. 
Table 8 to show mean and standard deviation of lactate results from microdialysis samples 
stored at different temperatures over 3 successive days 
 Mean Lactate Concentration (SD) mmol/l  
 Freezer -80oC Fridge 2-5oC  Room 22oC  
Day 1 2.72 (0.08) 2.72 (0.14) 2.73 (0.09) 
Day 2 2.56 (0.04)b 2.60 (0.09) 2.55 (0.05)e 
Day 3 2.72 (0.03)a,c 2.53 (0.02)d 2.53 (0.04)f 
 
a: On Day 3, freezer-stored samples were more concentrated than room temperature 
(P=0.006), and fridge-stored samples (P=0.008). 
b,c: For samples stored in the freezer, there was a significant drop in concentration 
between Day 1 and Day 2 (P=0.014), and an increase between Day 2 and Day 3 
(P=0.018). 
d: For samples stored in the fridge, there was a significant fall in concentration between 
Day 1 and Day 3 (P=0.005). 
e,f: For samples stored at room temperature, there was a significant fall in concentration 
between Day 1 and Day 2 (P=0.007), and samples on Day 3 were also significantly less 
concentrated than Day 1 (P=0.004).  
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Figure 13 to show mean and standard deviation of lactate results from microdialysis 
samples stored at different temperatures over 3 successive days 
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4.1.2.3 Pyruvate 
Pyruvate results are shown in Table 9 and Figure 14 below.  Statistically significant 
results are recorded below the table. 
Table 9 to show mean and standard deviation of pyruvate results from microdialysis 
samples stored at different temperatures over 3 successive days 
 Mean Pyruvate Concentration (SD) mmol/l  
 Freezer -
80oC 
Fridge 2-
5oC  
Room 
22oC  
Day 1 233 (8) 233 (4) 246 (5)a 
Day 2 247 (8)d 244 (11) 242 (4)b 
Day 3 225 (4)e 226 (9)f 221 (11)c 
 
a: On Day 1, room temperature-stored samples were more concentrated than samples 
stored in the fridge (P=0.048).  
b,c: For samples stored at room temperature, there was a fall in concentration between 
Day 2 and Day 3 (P=0.003), and between Day 1 and Day 3 (P=0.001).  
d,e: For samples stored in the freezer, there was a rise in concentration between Day 1 
and Day 2 (P=0.045), and a fall between Day 2 and Day 3 (P=0.003). 
f: For samples stored in the fridge, there was a significant fall in concentration between 
Day 2 and Day 3 (P=0.009). 
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Figure 14 to show mean and standard deviation of pyruvate results from microdialysis 
samples stored at different temperatures over 3 successive days 
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4.1.2.4 Glycerol 
Glycerol results are shown in Table 10 and Figure 15. Statistically significant 
results are recorded below the table. 
Table 10 to show mean and standard deviation of glycerol results from microdialysis 
samples stored at different temperatures over 3 successive days 
 Mean Glycerol Concentration (SD) mmol/l  
 Freezer -80oC Fridge 2-5oC  Room 22oC  
Day 1 464 (12) 467 (4) 480 (3)a,b 
Day 2 486 (8)c,d,f 463 (6) 464 (5)j 
Day 3 459 (3)e,g 451 (8)h,i 445 (6)k,l 
 
a,b: On Day 1, the room temperature stored sample group were more concentrated than 
the fridge-stored (P=0.029) and freezer-stored sample groups (P=0.008). 
c,d: On Day 2, freezer-stored samples were more concentrated than room temperature 
(P=0.001), and fridge-stored samples (P<0.001). 
e: On Day 3, freezer-stored samples were more concentrated than room temperature 
stored ones (P=0.014). 
f,g: For samples stored in the freezer, there was an increase between Day 1 and Day 2 
(P=0.001), and a fall between Day 2 and Day 3 (P<0.001). 
 
 81 
h,i: For samples stored in the fridge, there was a fall in concentration between Day 2 and 
Day 3 (P=0.041), and between Day 1 and Day 3 (P=0.008) 
j,k,l: For samples stored at room temperature there was a fall in concentration between 
Day 1 and Day 2 (P=0.007), between Day 2 and Day 3 (P=0.002), and between Day 1 
and Day 3 (P<0.001).  
 
 
 
Figure 15 to show mean and standard deviation of glycerol results from microdialysis 
samples stored at different temperatures over 3 successive days 
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4.1.2.5 Urea 
Urea results are shown in Table 11 and Figure 16. Statistically significant results 
are recorded below the table. 
Table 11 to show mean and standard deviation of urea results from microdialysis samples 
stored at different temperatures over 3 successive days 
 Mean Urea Concentration (SD) mmol/l  
 Freezer -80oC Fridge 2-5oC  Room 22oC  
Day 1 13.9 (0.1) 14.1 (0.2) 14.0 (0.2) 
Day 2 14.0 (0.1) 13.7 (0.1)e 13.7 (0.1)g 
Day 3 14.4 (0.3)a,b,c,d 13.8 (0.1)f 13.7 (0.1)h 
  
a,b: On Day 3, Freezer-stored samples were more concentrated than Room- (P<0.001) 
and Fridge-stored samples (P<0.001). 
c.d: For samples stored at -80 oC, there was a significant rise in concentration between 
Day 1 and Day 3 (P=0.001), and between Day 2 and Day 3 (P=0.004). 
e,f: For samples stored in the fridge, there was a fall in concentration between Day 1 and 
Day 2 (P=0.011), and between Day 1 and Day 3 (P=0.049). 
g,h: For samples stored at room temperature, there was a fall in concentration between 
Day 1 and Day 2 (P=0.037), and between Day 1 and Day 3 (P=0.020). 
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Figure 16 to show mean and standard deviation for urea results from microdialysis 
samples stored at different temperatures over 3 successive days 
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4.1.3 Results of calibration experiments – Volume studies 
 
Raw data are presented in Appendix B, Tables A1-5, Columns A,D,E. The 
following results were recorded: 
 
4.1.3.1 Glucose 
Results are shown in Table 12 and Figure 17. Statistically significant results are 
recorded below the table. 
Table 12 to show mean and standard deviation of glucose results from microdialysis 
samples of different volumes stored in the freezer over 3 successive days 
 Glucose Mean (SD) mmol/l  
 High Volume Medium Volume Low Volume 
Day 1 5.97 (0.19) 5.99 (0.14) 5.94 (0.14) 
Day 2 5.54 (0.12)a,d 5.96 (0.17) 5.80 (0.12) 
Day 3 5.89 (0.14)e 5.61 (0.05)b,c,f,g 6.09 (0.23)h 
 
a: On Day 2, High volume samples were less concentrated than Medium volume 
samples (P=0.006).  
b,c: On Day 3, Medium volume samples were less concentrated than both High 
(P=0.047), and Low volume samples (P=0.002). 
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d,e: For High volume samples, the concentration dropped between Day 1 and Day 2 
(P=0.005), but increased between Day 2 and Day 3 (P=0.017). 
f,g: For Medium Volume samples, concentration dropped significantly between Day 2 
and Day 3 (P=0.017), and it was significantly lower on Day 3 than Day 1 (P=0.011). 
h: For Low volume samples, there was a significance rise between Day 2 and Day 3 
(P=0.042). 
 
The mean glucose value for all glucose samples, in volume and storage experiments, 
was 5.798mM. Standard deviation was 0.273mM. All except one glucose value were 
within 2 standard deviations of the mean. 
 
Figure 17 to show mean and standard deviation of glucose results of microdialysis samples 
of different volumes, stored in the freezer over 3 successive days 
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 Lactate 
Results are shown in Table 13 and Figure 18. Statistically significant results are 
recorded below the table. 
 
Table 13 to show mean and standard deviation of lactate results from microdialysis 
samples of different volumes stored in the freezer over 3 successive days 
 Lactate Mean (SD) mmol/l  
 High Volume Medium Volume Low Volume 
Day 1 2.75 (0.04) 2.72 (0.08) 3.15 (0.64)a,b 
Day 2 2.67 (0.08) 2.56 (0.04) 2.64 (0.08)c 
Day 3 2.65 (0.02) 2.72 (0.03) 2.71 (0.11)d 
 
a,b: On Day 1, Low volume samples were more concentrated than High (P=0.041), and 
Medium volume samples (P=0.029). N.B. This mean value is skewed by one of the 
triplicate readings for low volume on day 1, which outlies the other results. 
c,d: For Low volume samples, there was a significant fall in concentration between Day 
1 and Day 2 (P=0.012), and between Day 1 and Day 3 (P=0.026). 
 
The mean value for all lactate samples was 2.683mM. Standard deviation was 
0.210mM. All except one lactate value were within 2 standard deviations of the mean.  
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Figure 18 to show mean and standard deviation of lactate results of microdialysis samples 
of different volumes, stored in the freezer over 3 successive days 
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4.1.3.2 Pyruvate 
Results are shown in Table 14 and Figure 19. Statistically significant results are 
recorded below the table. 
 
Table 14 to show mean and standard deviation of pyruvate results from microdialysis 
samples of different volumes stored in the freezer over 3 successive days 
 Pyruvate Mean (SD) µmol/l  
 High Volume Medium Volume Low Volume 
Day 1 233 (2) 233 (8) 248 (4)a,b 
Day 2 250 (8)e 247 (8)f 250 (3) 
Day 3 241 (6) 225 (4)c,d,g 245 (6) 
 
a,b: On Day 1, Low volume samples were more concentrated than High (P=0.004), and 
Medium volume samples (P=0.005). 
c,d: On Day 3, Medium volume samples were significantly lower than High (P=0.004), 
and Low volume samples (P=0.001). 
e: For High volume samples, there was a significant rise in concentration between Day 1 
and Day 2 (P=0.002). 
f,g: For Medium Volume samples, there was a rise between Day 1 and Day 2 (P=0.012), 
and a fall between Day 2 and Day 3 (P<0.001).  
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The mean value for all pyruvate samples was 238.83µM. Standard deviation was 
10.87µM. All except one pyruvate value were within 2 standard deviations of the mean.  
 
 
Figure 19 to show mean and standard deviation of pyruvate results of microdialysis 
samples of different volumes, stored in the freezer over 3 successive days 
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4.1.3.3 Glycerol 
Results are shown in Table 15 and Figure 20. Statistically significant results are 
recorded below the table. 
 
Table 15 to show mean and standard deviation of glycerol results from microdialysis 
samples of different volumes stored in the freezer over 3 successive days 
 Glycerol Mean (SD) µmol/l  
 High Volume Medium Volume Low Volume 
Day 1 481 (11) 464 (12)a,b 491 (6) 
Day 2 483 (12) 486 (8)e 489 (18) 
Day 3 474 (6) 459 (3)f 510 (6)c.d,g,h 
 
a,b: On Day 1, Medium volume samples were less concentrated than High (P=0.048) 
and Low volume ones (P=0.003). 
c.d: On Day 3, Low volume samples were more concentrated than High (P<0.001) and 
Medium volume samples (P<0.001). 
e,f: For Medium volume samples, there was a rise in concentration between Day 1 and 
Day 2 (P= 0.014), and a fall between Day 2 and Day 3 (P=0.004). 
g,h: For Low volume samples, there was a rise in concentration on Day 3 when 
compared with Day 1 (P=0.030) and Day 2 (P=0.017). 
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The mean value for all glycerol samples was 473.92µM. Standard deviation was 
18.29µM. All except one glycerol values were within 2 standard deviations of the mean.  
 
 
Figure 20 to show mean and standard deviation of glycerol results of microdialysis samples 
of different volumes, stored in the freezer over 3 successive days 
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4.1.3.4 Urea 
Results are shown in Table 16 and Figure 21. Statistically significant results are 
recorded below the table. 
 
Table 16 to show mean and standard deviation of urea results from microdialysis samples 
of different volumes stored in the freezer over 3 successive days 
 Urea Mean (SD) mmol/l  
 High Volume Medium Volume Low Volume 
Day 1 13.4 (0.5)a 13.9 (0.1) 14.3 (0.2) 
Day 2 14.1 (0.1)f 14.0 (0.1) 14.7 (0.3)b,c 
Day 3 13.1 (0.7)d,e,g 14.4 (0.3) 14.4 (0.2) 
 
 
a: On Day 1, there was a significant difference between High and Low volume samples 
(P=0.002). 
b,c: On Day 2, Low volume samples were more concentrated than both High (P=0.048), 
and Medium volume samples (P=0.016). 
d,e: On Day 3, High volume samples were less concentrated than Low (P<0.001), and 
Medium volume samples (P<0.001). 
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f,g: For High volume samples, there was a rise in concentration between Day 1 and Day 
2 (P=0.014), and a fall between Day 2 and Day 3 (P=0.001). 
 
The mean value for all urea samples was 13.96mM. Standard deviation was 0.46mM. 
All except four urea values were within 2 standard deviations of the mean. 
 
Figure 21 to show mean and standard deviation of urea results of microdialysis samples of 
different volumes, stored in the freezer over 3 successive days 
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4.2 Results of Clinical Study 1 – Normal Volunteers 
Eleven volunteers were recruited to undergo microdialysis of normal skin, to give a 
baseline for the burns studies. Volunteer characteristics are detailed in Table 17. All 
volunteers were male. Due to technical problems, all collection vials for NV01 were 
empty. Results for depth of probe insertion, and temperature readings were retained as 
the protocol was followed in full. 
Table 17: Characteristics of volunteers recruited to Study 1  
Patient number Age Ethnic Origin Comorbidities/ Medications 
NV01 37 Chinese None 
NV02 26 White British None 
NV03 33 White British Mild asthma 
NV04 28 Asian Gilbert’s syndrome 
NV05 26 White British None 
NV06 40 White British Pain/ Gabapentin 200mg bd 
NV07 30 White British Asthma/ Becotide 100mcg bd 
NV08 41 White British None 
NV09 38 White British None 
NV10 41 White British None 
NV11 30 White British Psoriasis 
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4.2.1 Ambient Temperature 
Air temperature readings are shown in Table 18. Mean (SD) temperatures were 
23.8 (0.89)oC for Study Period 1, 33.3 (2.35)oC for Study Period 2 and 25.3 
(1.84)oC for Study Period 3. There was no significant difference between Study 
periods 1 and 3, and a significant difference when comparing study period 1 with 
study period 2 (P<0.01), and comparing study period 2 with study period 3 
(P<0.01). 
Table 18 to show air temperature during each study period, for each volunteer 
Volunteer 
number 
Study Period 1 
Temperature, oC 
Study Period 2 
Temperature, oC 
Study Period 3 
Temperature, oC 
NV01 22.8 37.1 25.4 
NV02 23.3 31.6 23.7 
NV03 22.6 35.2 26.3 
NV04 23.5 31.7 23.1 
NV05 24.5 31.6 24.8 
NV06 24.7 32.8 25.4 
NV07 25.5 36.0 28.5 
NV08 23.5 32.1  
NV09 23.0 33.1 24.2 
NV10 24.0 31.9 27.0 
NV11 23.7 33.0 24.2 
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4.2.2 Probe Depth 
Ultrasound measurements were collected for 10 out of 11 probes. The ultrasound 
machine was not available for NV10. In one patient, only the depth of the probe 
was measured, and not the thickness of the skin. As a result, this patient is not 
represented on the graph, however it had been noted that the probe was within the 
dermis throughout its length. In all cases the probe was sited within the dermis. 
Probe depths are represented in Error! Reference source not found.. 
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Figure 22: Scatter plot to show depth of microdialysis probe in the dermis as a 
percentage of total dermal thickness, for each patient 
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4.2.3 In-vitro probe calibration 
Raw data calibration values for each probe are shown in Appendix B, Tables A6-
A9. Recovery for each probe and for each substance was calculated as a 
percentage of the calibration solution value. The mean (SD) recovery was 99.5 
(17.1) % for glucose; 107.3 (13.1) % for pyruvate; 108.2 (15.2) % for lactate; 
113.7 (23.1) % for glycerol. There was no significant difference between recovery 
at the start and end of the experiment (P>0.05 for all analytes; Wilcoxon signed 
rank test). 
 
 
4.2.4 Equilibration Period 
Raw data are shown in Appendix B, Tables A10-A14. 
Mean and standard deviations are shown for glucose, lactate, pyruvate, 
lactate/pyruvate ratio (LPR) and glycerol in Figure 23,  
 
Figure 24, Figure 25,  
 
 
Figure 26, & Figure 27. There was no significant difference for lactate, pyruvate 
or glucose individually when comparing any of these time points with any other. 
For the calculated LPR, there was a significant difference between the 1st (P<0.01) 
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and 2nd (P<0.05) samples within the equilibration period when compared with the 
5th sample. For Glycerol, there was a significant difference between the 1st sample 
and all other samples (P<0.01).  This shows that insertion of the probe has no 
significant effect on results of glucose, lactate and pyruvate individually. There is 
a significant effect of probe insertion on LPR, lasting 1 hour, and on glycerol, 
lasting 30 minutes.
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Figure 23: Boxplot to show dermal glucose (mmol/l) during each half hour 
period after probe insertion in healthy volunteers 
 
 
 
 
Figure 24: Boxplot to show dermal lactate (mmol/l) during each half hour 
period after probe insertion in healthy volunteers 
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Figure 25: Boxplot to show dermal pyruvate (µmol/l) during each half 
hour period after probe insertion in healthy volunteers 
 
 
 
 
Figure 26: Boxplot to show dermal LPR during each half hour period 
after probe insertion in healthy volunteers. 30 and 60 minute values are 
significantly lower then at 150 minutes (P<0.01, P<0.05 respectively) 
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Figure 27: Boxplot to show dermal glycerol (µmol/l) during each half hour 
period after probe insertion into healthy volunteers. Values at 30 minutes 
are significantly higher than at the subsequent time points (P<0.01). 
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4.2.5 The Effect of Raised Temperature 
Raw data are detailed in Appendix B, Tables A15-A19. Comparison of the means 
for the three groups revealed no significant difference for any of the substances 
tested (Glucose P=0.853, Lactate P=0.7281, Pyruvate P=0.8914, LPR P=0.5045, 
Glycerol P=0.6889), (Figure 28,  
 
 
 
Figure 29,  
Figure 30,  
 
Figure 31,  
Figure 32). There was no evidence of any effect of raised ambient temperatures of 
up to 33oC on glucose, lactate, pyruvate, glycerol or LPR microdialysis readings.  
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Figure 28: Boxplot to show dermal glucose in healthy volunteers under 
differing ambient temperatures (Study period 1=23oC, Study period 2=33oC, 
Study period 3=25oC) 
 
 
 
 
 
Figure 29: Boxplot to show dermal lactate in healthy volunteers under 
differing ambient temperatures. (Study period 1=23oC, Study period 2=33oC, 
Study period 3=25oC) 
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Figure 30: Boxplot to show dermal pyruvate in healthy volunteers under 
differing ambient temperatures. (Study period 1=23oC, Study period 2=33oC, 
Study period 3=25oC) 
 
 
 
F
igure 31: Boxplot to show dermal glycerol in healthy volunteers under differing 
ambient temperatures. (Study period 1=23oC, Study period 2=33oC, Study period 
3=25oC) 
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Figure 32 Boxplot to show dermal LPR in healthy volunteers at differing ambient 
temperatures. (Studyperiod 1=23oC, Study period 2=33oC, Study period 3=25oC) 
 
 
 
 
 
4.2.6 Normal Ranges 
Normal range for each substance was calculated as the 95% Confidence Interval 
of the mean for all the results taken during the study period. These were as 
follows: 
Glucose: 3.81-7.75 mmol/l 
Lactate: 0.72-5.76 mmol/l 
Pyruvate: 73.2-327 µmol/l 
Boxplot of LPR for study periods 1 (23C), 2 (33C) and 3 (25C)
Median (dotted line), interquartile range (boxplot), mean and SD (blue bars) and outliers are shown.
Study period 1, 2 and 3 correspond to columns 07, 09, 11 respectively in Appendix 1, Table 19
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LPR: 10.1 – 21.3 
Glycerol: 7-446 µmol/l 
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4.3 Results of Clinical Study 2 – Small Burns 
Between 1st November 2006 and 31st October 2007, 184 patients were admitted to the 
burns unit with acute burns <15%TBSA. The following patients were unsuitable for the 
study: 91 were admitted more than 8 hours after injury; 2 had co-existing trauma; 1 had 
inhalation injury; 32 had no suitable area for insertion of a microdialysis probe (23 due 
to flash burns to the face without significant other injury; 9 had very small burns <1% 
TBSA with no area suitable for probe insertion). A further 10 were outside the 18-80 
age group; 2 could not give full consent due to learning difficulties; 2 were prisoners. 
Of the remaining 44 patients, the majority had significant comorbidities. Twelve 
patients were made known to the researcher within 8 hours of burn injury, and fulfilled 
the inclusion criteria for the study. All of these were invited to take part. Two patients 
declined to participate having read the participant information leaflet. Ten patients were 
recruited. Patient characteristics are detailed in  
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Table 19. Average Total Body Surface Area (TBSA) burn was 7.5% (Range 3-12%).  
 
4.3.1 Deviations from protocol, missing and anomalous results 
4.3.1.1 Deviations from protocol 
The following patients had deviations from the protocol described in the methods 
section. Reasons are described below: 
S02: Biobrane TM applied to burn instead of Jelonet and gauze. This was requested 
by the consultant in charge of the patient’s care, immediately after probe insertion 
and was not anticipated beforehand. LDI images were taken prior to Biobrane 
application, and it had been removed prior to the second LDI image. 
Patient 
Number 
Age Se
x 
Burn 
%TBSA 
(FT/DD) 
Time 
from 
burn to 
1st 
sample 
Mechanism Co-morbidity Pre-admission 
Medication 
S01 50 F 6 (3) 10h Contact None None 
S02 36 M 4 (1) 7h Flame None None 
S03 43 M 6.5 (2) 7.5h Hot fat/ flame None None 
S04 19 F 9 (3) 9.5h Flame None None 
S05 19 F 11 (7.5) 6.5h Flame None None 
S06 42 M 7(3) 12h Contact Heavy facial 
bruising. 
Alcoholism. 
Depression 
Chlordiazepoxide 
S07 67 F 3(2.5) 7.5h Flame None None 
S08 29 M 5.5(4) 7.5h Lightning None None 
S09 59 F 8(4) 7h Flame IDDM, 
Bipolar 
disorder, 
Hypertension 
Dosulepin, 
Simvastatin, 
Aspirin, Frusemide, 
Lisinopril, Adalat, 
Doxazosin, Insulin, 
Metformin 
S10 68 F 12 
(5DD) 
9.5h Scald IHD Tamoxifen, 
Diazepam, 
Lisinopril, 
Bendrofluazide 
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S03: Probe C pulled out by patient at +21.30h (Sample 30). 
S06: Co-morbidity and medication was not described by patient on admission. 
Facial bruising was present, but there were no fractures. 
S07: Probe broken on insertion, but not identified until further into the study, so 
no values were acquired for probe ‘C’. 
S08: Study terminated early (+21h, Sample 29) as patient taken to theatre for 
excision of burn including site where probes located. 
S09, S10: Patients taken to theatre, during study period, for excision and grafting 
at sites distant from probes. Probes remained in situ. Both patients were taken to 
theatre between 18 and 24 hours post-burn. 
 
4.3.1.2 Missing Results 
Data points were missed for one of three reasons:  
1) insufficient volume in the sample vial for analysis was noted on occasion;  
2) blood in the sample vial meant the vial had to be discarded since the large 
proteins would be detrimental to the analyser, and because red blood cells 
could undergo metabolism within the sample vial, and alter results;  
3) sampling errors occurred very infrequently whereby a sample vial was not 
taken at the correct time, or was mislabelled. These missing results are 
detailed in Appendix C, Table 20.  
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Table 19: Patient Characteristics 
 
 
4.3.1.3 Anomalous Results 
Results which were suspected of being anomalous have been highlighted, and the 
reason for the anomaly indicated, in Appendix C, Table 21. The majority of these 
samples were of very low sample volume, and showed very low results for all 
analytes. These results are indicated on the graphs below, and have been retained 
for purposes of statistical calculation. The few results which had been mislabelled 
were corrected before the graphs and statistical calculations were created. A note 
has been made under the relevant graph, and in Appendix C, Table 21. 
Patient 
Number 
Age Se
x 
Burn 
%TBSA 
(FT/DD) 
Time 
from 
burn to 
1st 
sample 
Mechanism Co-morbidity Pre-admission 
Medication 
S01 50 F 6 (3) 10h Contact None None 
S02 36 M 4 (1) 7h Flame None None 
S03 43 M 6.5 (2) 7.5h Hot fat/ flame None None 
S04 19 F 9 (3) 9.5h Flame None None 
S05 19 F 11 (7.5) 6.5h Flame None None 
S06 42 M 7(3) 12h Contact Heavy facial 
bruising. 
Alcoholism. 
Depression 
Chlordiazepoxide 
S07 67 F 3(2.5) 7.5h Flame None None 
S08 29 M 5.5(4) 7.5h Lightning None None 
S09 59 F 8(4) 7h Flame IDDM, 
Bipolar 
disorder, 
Hypertension 
Dosulepin, 
Simvastatin, 
Aspirin, Frusemide, 
Lisinopril, Adalat, 
Doxazosin, Insulin, 
Metformin 
S10 68 F 12 
(5DD) 
9.5h Scald IHD Tamoxifen, 
Diazepam, 
Lisinopril, 
Bendrofluazide 
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4.3.2 Urea Standards and Recovery Calculations 
The results of the laboratory analysis of serum urea, and the microdialysis 
analysis of the serum and dermal (Zone C) urea are detailed in Table 20. This part 
of the study was an addition to the protocol after recruitment of patient S05, by 
which time the serum samples of the previous patients had been discarded. Four 
patients had serum taken at the same time as dermal microdialysis (S02, S04(2), 
S05(2), S06(1)). 
Table 20:  to compare urea results of hospital laboratory analysis (lab) with microdialysis (MD) of serum 
and with microdialysis of skin. Urea measured in mmol/l. Sampling time is also recorded. 
Patient  Urea  
serum/lab 
Urea  
serum/MD 
Urea  
Unburned 
skin/MD 
S01  3.3  4.96 
Time 6/11/06 06:00  6/11/06 15:00 
S02  4.0  3.9 
Time 9/11/06 11:58  9/11/06 11:45 
S03  5.6  6.135 
Time 27/1/07 05:22   27/1/07 09:30 
S04 (1)  3.1  4.337 
Time 30/1/07 20:10  30/1/07 22:00 
S04 (2)  3.4  4.09 
Time 31/1/07 13:17  31/1/07 13:00 
S05 (1)  4.1 7.6; 6.9; 5.2 4.634 
Time 4/4/07 19:30  4/4/07 22:30 
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S05 (2)  2.9 5.2; 6.1; 3.8 4.4 
Time 5/4/07 08:30  5/4/07 08:30 
S06 (1)  3.8 2.6; 3.3; 
 
4.15 
Time 20/5/7 14:00  20/5/7 14:00 
S06 (2)  5.2* 3.1; 4.9; 5.7 7.482 
Time 21/5/7 09:00  21/5/7 02:00 
S07 (1)  3.7 4.2; 3.2 4.238 (ZoneB) 
4.145 (ZoneA) 
Time 23/5/7 14:00  23/5/7 15:30 
S07 (2)  7.7 4.8; 5.6; 7.6 8.986 (ZoneB) 
Time 24/5/7 09:00  24/5/7 09:00 
S08  7.0 12.5 12.54 
Time 1/6/07 01:00  1/6/07 13:30 
S09 (1)  6.3 4.9; 8.7; 8.5 7.842 
Time 30/7/7 00:30  30/7/7 02:00 
S09 (2)  13.3 12.7; 5.9; 16.1 14.37 
Time 31/7/7 13:00  31/7/7 07:00  
S10 (1)  6.3  7.492 
Time 23/8/7 23:45  24/8/7 03:00 
S10 (2)  6.5  10.17 
  25/8/7 11:00  25/8/7 05:00 
*small volume sample 
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4.3.3 Biochemical Characteristics by Zone 
4.3.3.1 Trends with Time post-burn 
No patients were recruited at less than 6.5 hours post-injury. Time-blocks 
were grouped as follows: Block 1: 6.5-12h; Block 2: 12.5-18h; Block 3: 
18.5-24h; Block 4: 24.5-30h; Block 5: 30.5-36h. 
Zone A = Zone of Coagulation. Zone B= Zone of Stasis. Zone C = 
Unburned skin. 
 
4.3.3.1.1 Glucose. 
Time-related trends for all zones are shown in Figure 33. 
In Zone A, there were changes in glucose levels with time for some 
individual patients, but overall, glucose in Zone A was constant, with 
no statistically significant differences over time.  
Glucose in Zone B showed an upward trend with time. Glucose in 
Block 1 was significantly lower than Block 2 (P<0.001), and Block 5 
(P<0.01) 
Glucose in Zone C showed the most marked upward trend. Glucose in 
Block 1 was significantly lower than in Block 2 and Block 5 
(P<0.001). Glucose in Block 2 was significantly lower than in Block 3 
and Block 5 (P<0.001). Glucose in Block 3 was significantly lower 
 114 
than in Block 5 (P<0.05). In over half of the patients, glucose in Zone 
C was below the normal range (see Section 4.2.6) for the first 12 
hours. Patient S09 exhibited swinging glucose levels. Patient S10 was 
hyperglycaemic for the majority of the time. 
 
Figure 33: Boxplot to show trends in glucose with time for each zone 
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Time Blocks refer to time post-burn as follows: 1= 6.5-12h; 2= 12.5-18; 3= 18.5-24; 4= 24.5-30; 5= 
30.5-36. Boxplot shows minimum, 1st quartile, median, 3rd quartile and maximum. Outliers are 
annotated with patient number. Significant differences between zones are indicated for each Time Block
B xplot to show Glucose by zone for each time block
Time blocks refer to time post-burn as follows: 1=6.5-12h, 2=12.5-18h, 
3=18.5-24h, 4= 24.5-30h, 5=30.5-36h. Boxplot shows minimum, 1st quartile, 
median, 3rd quartile and maximum. Near outliers (o) and far outliers (*) are 
annotated with patient number. Significant differences between zones are 
indicated for each time block. 
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4.3.3.1.2 Lactate 
Time-related trends are illustrated in Figure 34. 
For the majority of patients, lactate in Zone A was stable with time. 
There were no statistically significant differences between time 
blocks.  
Lactate in Zone B showed an initial peak, above the normal range, 
over the first few hours in most patients. When analysed by time 
blocks, lactate showed a slight tendency to decline with time. There 
was a statistical difference between Blocks 3 and 5 with Block 5 being 
significantly lower than Block 3 (P<0.05). 
Lactate in Zone C showed an initial peak, above the normal range, 
then a marked downward trend towards the end of the study period. 
Lactate in Blocks 1, 2 and 3 was significantly higher than in Block 5 
(P<0.001).  Lactate in Block 4 was significantly lower than in Block 3 
(P<0.05). 
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Figure 34: Boxplot to show trends in lactate with time for each zone 
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Boxplot to show lactate by zone and time block
Time blocks refer to time post-burn as follows: 1=6.5-12h, 2=12.5-18h, 
3=18.5-24h, 4= 24.5-30h, 5=30.5-36h. Boxplot shows minimum, 1st quartile, 
median, 3rd quartile and maximum. Near outliers (o) and far outliers (*) are 
annotated with patient number. Significant differences between zones are 
indicated for each time block. 
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4.3.3.1.3 Pyruvate 
Time-related trends are shown in Figure 35.  
With one exception, S10, pyruvate in Zone A was stable with time. 
There were no statistically significant differences between time 
blocks.  
Pyruvate in Zone B showed a slight upward trend to Block 2 then a 
slight downward trend. There was a small difference between Blocks 
1 and 2 with Block 1 being significantly lower than block 2 (P<0.05). 
There was a difference between Blocks 3 and 4 with Block 3 being 
significantly higher than Block 4 (P<0.01). 
Although there was a wide spread in individual results, overall 
pyruvate in Zone C was stable with time. There were no statistically 
significant differences between time blocks.  
Patient S09 showed notable peaks of pyruvate in all zones, which 
were not matched by lactate levels. 
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Figure 35: Boxplot to show trends in pyruvate with time for each zone 
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3=18.5-24h, 4= 24.5-30h, 5=30.5-36h. Boxplot shows minimum, 1st quartile, 
median, 3rd quartile and maximum. Near outliers (o) and far outliers (*) are 
annotated with patient number. Significant differences between zones are 
indicated for each time block. 
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4.3.3.1.4 Lactate:Pyruvate Ratio (LPR) 
LPR trends are illustrated in Figure 36.  
LPR in Zone A was stable with time. There were no statistically 
significant differences between time blocks. Most patients had LPR 
results consistently below 25, with the exception of S06, S09 and S10. 
LPR in Zone B was also stable with time. There were no statistically 
significant differences between time blocks. More patients had LPR 
results above 25 for a significant period of time (S02, S05, S07, S08, 
S09, S10), than in Zone A. 
LPR in Zone C showed a marked downward trend throughout the 
study period. LPR in Block 1 was significantly higher than in Block 5 
(P<0.01). LPR in Blocks 2 and 3 was significantly higher than in 
Block 5 (P<0.001).  Block 1 was significantly higher than Block 2. 
Block 2 was significantly higher than Block 3 (P<0.05), and Block 3 
was significantly higher than Block 4 (P<0.01). Patients S02, S04, 
S05, S06 and S10 had LPR readings over 25. 
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Figure 36: Boxplot to show trends in Lactate/Pyruvate ratio with time for each zone 
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median, 3rd quartile and maximum. Near outliers (o) and far outliers (*) are 
annotated with patient number. Significant differences between zones are 
indicated for each time block. 
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4.3.3.1.5 Glycerol 
Glycerol trends are illustrated in Figure 37. 
Glycerol in Zone A showed some variation with time. Block 1 was 
significantly higher than Block 5 (P<0.01). Block 2 was significantly 
higher than Block 5 (P<0.05).  Patients S05, S07 and S08 showed 
extremely high peaks of glycerol in the early hours following reported 
burn injury. Patients S06, S09 and S10 showed high peaks later in the 
study period. 
Glycerol in Zone B overall was stable with time. There was no 
statistical difference between time blocks. Only patients S09 and S10 
showed a variation from this course, with a high peak at around 12 
hours from burn injury. 
Overall glycerol results in Zone C were stable, with a slight elevation 
in Block 3. Glycerol in Block 3 was significantly higher than in Block 
4 (P<0.001). There were no extreme peaks of glycerol as in the other 
two zones, and all readings were under 500µmol/l. There was a 
downward trend in S06 and S10, and a cyclical pattern in S04, but the 
remainder showed a very stable course. 
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Figure 37: Boxplot to show trends in Glycerol with time for each zone 
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indicated for each time block. 
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4.3.3.1.6 Urea 
Urea trends are illustrated in Figure 38. 
There was no significant difference in urea between the time blocks 
for any of the three zones. 
 
Figure 38: Boxplot to show trends in Urea with time for each zone 
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4.3.3.1.7 Summary of results by time 
Overall, there was an initial ischaemic picture within the unburned 
skin and zone of stasis which lasted until 16-24 hours post burn. This 
was evidenced by low glucose and high LPR values. There was also a 
peak in glycerol seen at the start of the study within the zone of 
coagulation. 
 
4.3.3.2  Comparison of Zones 
4.3.3.2.1 Glucose (Figure 33) 
Glucose in Zone C was initially low, being significantly lower than 
Zone A (P<0.001) and Zone B (P<0.05), for Block 1 and lower than 
Zones A and B in Block 2 (P<0.001), but being indistinguishable from 
the other zones by 18 hours post-burn. 
 
4.3.3.2.2 Lactate (Figure 34) 
Lactate in Zone C started high, and declined with time towards the 
levels in Zone A. Lactate in Block 1 was significantly higher in Zone 
C than in Zone A (P<0.01), and this persisted into Block 2, with a 
significant difference between Zones A and C (P<0.05). 
Lactate in Zone B followed a similar pattern, being higher than Zone 
A (P<0.001) for Block 1. 
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4.3.3.2.3 Pyruvate (Figure 35) 
Overall, pyruvate levels were constant for all zones. There were some 
slight differences for Blocks 1 and 3, but no overall trends. Pyruvate 
in Block 1 was significantly higher in Zone C than in Zone A 
(P<0.05). 
Pyruvate in Block 3 was significantly higher in Zone C than in Zone 
A (P<0.05), and higher in Zone A than Zone B (P<0.01). 
 
4.3.3.2.4 LPR (Figure 36) 
There was an overall trend in higher LPR in Zones B and C at the 
beginning of the study, returning to the baseline level of Zone A by 
Block 3. LPR in Block 1 was significantly higher in Zone C than in 
Zone A (P<0.05) and in Zone B than Zone A (P<0.01). 
LPR in Block 2 was significantly higher in Zone B than in Zone A 
(P<0.05). 
 
4.3.3.2.5 Glycerol (Figure 37) 
Glycerol was highest in Zone A for the first three time blocks. In 
Block 1, this reached significance when compared to both Zones B 
and C (P<0.05). 
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Glycerol in Block 2 remained significantly higher in Zone A than in 
Zone B (P<0.01). 
Glycerol in Block 3 was also significantly higher in Zone A than in 
Zone B (P<0.05). 
 
4.3.3.2.6 Urea (Figure 38) 
Urea was overall constant throughout the time zones and between the 
zones. Urea in Block 1 was significantly lower in Zone A than in Zone 
C (P<0.05). 
Urea in Block 5 was significantly higher in Zone B than in Zone C 
(P<0.05).  
There was good concurrence in urea results between zones for each individual patient (
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Figure 39, Figure 40, Figure 41,  
 
 
Figure 42, Figure 43, Figure 44, Figure 45, Figure 46,  
 
 
 
 
 
 
 
Figure 47 and Figure 48). 
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Figure 39: Urea results for Patient S01 showing concurrence between zones 
 
 
Figure 40: Urea results for Patient S02 showing concurrence between zones 
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Figure 41: Urea results for Patient S03 showing concurrence between zones 
 
 
 
 
 
Figure 42: Urea results for Patient S04 showing concurrence between zones 
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Figure 43: Urea results for Patient S05 showing concurrence between zones 
 
Figure 44: Urea results for Patient S06 showing concurrence between zones 
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Figure 45: Urea results for Patient S07 showing concurrence between zones 
 
 
Figure 46: Urea results for Patient S08 showing concurrence between zones 
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Figure 47: Urea results for Patient S09 showing concurrence between zones 
 
 
Figure 48: Urea results for Patient S10 showing concurrence between zones 
 
 
4.3.3.3 Trends with Theatre Episode 
Two patients (S09 and S10) were taken to theatre within the study period. 
Both patients were taken to theatre during Block 3. Differences in the 
glycerol levels are illustrated in Figure 49,  
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Figure 50 and Figure 51. 
 
Figure 49: Boxplot to show the differences in glycerol levels between patients 
attending theatre and patients not attending theatre for Zone A 
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Figure 50: Boxplot to show the differences in glycerol levels between patients 
attending theatre and patients not attending theatre for Zone B 
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Figure 51: Boxplot to show the differences in glycerol levels between patients 
attending theatre and patients not attending theatre for Zone C 
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In all three zones, there was a greater measured glycerol in the dialysate of 
the two patients attending theatre, during and for some time after their 
operative procedure. 
This difference was significant in Zone A during Block 3 only (P<0.001, 
Figure 49). In Zone B, glycerol was significantly higher in the theatre group 
during Block 3 (P<0.001), but significantly lower by Block 5 (P<0.05,  
 
 
Figure 50). Glycerol in Zone C was significantly higher during Block 3 in 
the group which went to theatre (P<0.01). This difference persisted into 
Zone 4 (P<0.01, Figure 51). 
 
Differences in LPR were also noted (Figure 52, Figure 53, Figure 54). 
Although there was a trend towards higher LPR results in Blocks 3, 4 and 5 
in Zones A and B of the patients who went to theatre, this was not 
statistically significant (Figure 52, Figure 53). 
Interestingly, in Zone C, LPR was significantly lower in patients who had 
attended theatre for Block 3 (P<0.001), Block 4 (P<0.05), and Block 5 
(P=0.01) (Figure 54). 
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Figure 52: Boxplot to show the differences in LPR in Zone A between patients 
attending theatre and patients not attending theatre 
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Figure 53: Boxplot to show the differences in LPR in Zone B between patients 
attending theatre and patients not attending theatre 
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Figure 54: Boxplot to show the differences in LPR in Zone C between patients 
attending theatre and patients not attending theatre 
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4.3.4 Laser Doppler Images 
All ten patients had LDI taken at the beginning of the study. Time between 
reported burn and first LDI ranged from 6 – 11.5 hours. Nine patients had 
LDI taken at the end of the study. One patient (S08) did not have an end-
point LDI, as the burn was excised at 24 hours, and he was withdrawn from 
the study. Time from burn to final LDI ranged from 36 – 49 hours. Plates 1-
10 show the laser Doppler images for patients S01-S10. Position of Probe B 
is indicated on the images with a black dotted line. Table 21 summarises the 
results. 
A technical error occurred with the laser Doppler imager, resulting in 
suboptimal images for Patients S01 and S03. In both cases, the site of Probe 
B was not included within the visible part of the image, so progression at the 
site of the probe could not be assessed. However in both cases, a comment 
on overall progression of the wound could be made as the majority of the 
wound was imaged.  
For patients S06 and S09, the initial images showed lower than expected 
blood flow globally. In S06, the first image was so poor that no comment on 
progression could be made about the wound globally. However, since there 
was moderate to good flow (yellow/pink colour) surrounding Probe B in the 
final image, it was assumed that there could not have been any wound 
progression here. In wound S09, enough of the wound was recognisable in 
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the initial LDI image to allow an interpretation on wound progression both 
globally, and around Probe B.  
Five patients showed evidence of overall wound progression; only one of 
these showed evidence of progression at the site of the probe. Three patients 
showed no evidence of wound progression in the wound as a whole. Table 
21 details these results. 
Table 21 to show results of LDI for each patient 
Patient LDI Time 
post-burn 
Area blue 
(cm2) 
Evidence 
of wound 
progression 
Colour over 
stasis probe 
Evidence of 
progression 
over probe 
S01 9 0.6  n/a  
 36 0 No n/a n/a 
S02 6 0  Yellow  
 48.5 8.12 Yes Green/blue Yes 
S03 6.5 25.87  Yellow/green  
 38.5 52.9 Yes n/a n/a 
S04 8 13.7  Yellow  
 43.5 35.91 Yes Yellow/red No 
S05 6 54.67  Yellow/green  
 45 78.2 Yes Yellow/green No 
S06 11.5 n/a  Unrecordable  
 36.5  n/a Yellow/Pink No 
S07 6.5 13.37  Yellow  
 49 26.11 Yes Yellow/Red No 
S08 6.5     
 n/a n/a n/a n/a n/a 
S09 7 17.86  Blue  
 48.5 5.3 No Yellow/Green No 
S10 9 18.44*  Blue  
 42 * No Yellow/green No 
 
* Full extent of wound not visible on either scan, so exact measurement would have been 
inaccurate. There does not appear to be any significant progression. 
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4.3.5 Biochemical correlation to LDI findings 
Table 22 shows a summary of the correlation between biochemistry (LPR and 
glycerol), LDI and wound outcome. LPR levels of above 25 are universally 
accepted as signifying anaerobic conditions. Glycerol of 450µmol/l was taken as 
the upper limit of normal as per results of Study 1 (Section 4.2.6). Results of 
individual patients are correlated to their LDI images in the paragraphs below:  
Table 22: Wound outcomes and possible predictive factors 
Patient LPR>25 
for more 
than 2h 
Glycerol 
>450 
LDI Progression Healing 
Zone: A B C A B C General Probe 
B 
Excision Graft 
take/Healing 
S01 N N N N N N N n/a Day 2 Good 
S02 N Y Y N N N Y Y N >2 weeks 
S03 N N n/a N N n/a Y n/a Day 5 Good 
S04 N N Y N N Y Y N N >2 weeks 
S05 N Y Y Y N N Y N Day 2 Burn 
progression. 
Regrafted 
S06 Y N N Y N N n/a N Day 5 Good 
S07 Y Y n/a Y N n/a Y N Day 2 Graft failure at 
distant site 
S08 N Y N N N N n/a n/a Day 1 Good but with 
overgranulation. 
Healing >6 
weeks 
S09 Y Y N Y Y N N N Day 1 Graft loss neck 
(distant site). 
Regrafted 
S10 Y Y Y Y Y N +/- N Day 1 Graft loss 
 
 
 144 
Patient S01 
Figure 55: Graph to compare glucose with LPR and glycerol, in the Zone of Coagulation, for patient S01. 
Results within the boxed area were noted to be low across all analytes, and from a low volume sample. 
 
In Figure 55, there was a gentle decline in glucose levels to 16 hours, followed by a peak and 
another decline. The highest glucose reading was marginally outside the normal range, the 
rest being with the normal range. LPR was stable throughout, and well below ischaemic 
levels, apart from a single high reading at +24.5h. Glycerol was well within the normal range, 
and shows a cyclical pattern.  
Figure 56: Graph to compare glucose with LPR and glycerol, in the Zone of Stasis, for patient S01. Arrow 
indicates a low volume sample. 
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Glucose levels in Figure 56 varied with time in the same manner as seen in the zone of 
coagulation (above) and unburned skin (below). Glucose results were within the normal range 
at all times, as were LPR values and glycerol. A single result (arrowed) showed low readings 
across all analytes and is likely to be anomalous. There was no evidence of an ischaemic 
environment. 
Figure 57: Graph to compare glucose with LPR and glycerol, in the Unburned skin, for patient S01 
 
Glucose in Figure 57 showed a similar course to Figure 55, but without the early peak. The 
initial low-normal level was followed by a peak at +18-20h, but was still within normal limits. 
LPR in this area was initially borderline ischaemic, falling rapidly as glucose levels increased. 
Glycerol was within normal range throughout, and there was evidence of the cyclical change 
seen in the other zones, with peaks at 17h and 23h, and an additional one at 32h. 
Summary for S01 
Biochemical parameters show little evidence of ischaemia in any of the zones. LDI (Plate 1), 
although suboptimal, gives an overall impression of improvement in wound perfusion over 
the study period, and there is no clear evidence of wound progression.
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Patient S02 
Figure 58: Graph to compare glucose with LPR and glycerol, in the Zone of Coagulation, for patient S02 
 
Figure 58 shows glucose levels within the normal range throughout the study period. This 
patient was recruited at 7.5 hours post injury and there was no initial peak of glycerol evident. 
LPR and glycerol show a stable course, with no ischaemia. 
Figure 59: Graph to compare glucose with LPR and glycerol, in the Zone of Stasis, for patient S02 
 
Figure 59 shows a low glucose for the first few hours with a corresponding elevation in LPR 
which entered the ischaemic range for 3 hours. Throughout the remainder of the study there 
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was no other notable event, and levels were non-ischaemic. There was no elevation in 
glycerol. 
Figure 60: Graph to compare glucose with LPR and glycerol, in the Unburned skin, for patient S02 
 
In Figure 60, there is a more profound reduction in glucose and elevation in LPR indicating 
an ischaemic environment lasting 4 hours for glucose and persisting for 12 hours for LPR. 
There was no corresponding rise in glycerol.  A background cyclical trend in glycerol was 
seen. 
Summary for S02 
Biochemical parameters indicated some evidence of ischaemia for a short period in the zone 
of stasis (Figure 59), and for a lengthier period in the unburned skin (Figure 60). No 
corresponding rise in glycerol was seen. LDI showed some patchy areas of reduced perfusion 
of the burn, which were less well perfused at the end of the study, but had not progressed to 
full thickness injury (Plate 2).
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Patient S03 
Figure 61: Graph to compare glucose with LPR and glycerol, in the Zone of Coagulation, for patient S03 
 
Figure 61 showed constant levels of glucose lactate and glycerol within their normal ranges 
throughout the study period. The saw-toothed appearance over the first few hours was seen in 
each of the analytes, which is suspicious of an artifactual cause. 
Figure 62: Graph to compare glucose with LPR and glycerol, in the Zone of Stasis, for patient S03 
 
Figure 62 showed a steady state of glucose throughout the study period. LPR was within 
normal range for the entire time, as was glycerol. There is no evidence of ischaemia. 
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Figure 63: Graph to compare glucose with LPR and glycerol, in the Unburned skin, for patient S03 
 
Figure 63 had incomplete readings due to a faulty probe. Readings which were present were 
all within the normal ranges.  
Summary of S03. 
All readings for all zones were within the normal range, although there was a significant 
amount of missing data for the unburned skin  (Figure 63). The 48h LDI image was 
suboptimal as an incomplete image was captured, and the position of the hand was different. 
Nevertheless, there is a suggestion of wound progression over the dorsum of the hand (Plate 
3). 
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Patient S04 
Figure 64: Graph to compare glucose with LPR and glycerol, in the Zone of Coagulation, for patient S04 
 
Figure 64 showed a steady state of parameters within the normal range. There was a baseline 
sinusoidal pattern to the glycerol results noted in several patients over all zones.  
 
Figure 65: Graph to compare glucose with LPR and glycerol, in the Zone of Stasis, for patient S04 
 
Figure 65 showed no evidence of ischemia, all parameters being within the normal range. An 
interaction between glucose and LPR could be seen here with a pattern of opposing peaks and 
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troughs. Each trough in glucose was accompanied by a peak in LPR and vice versa. The 
sinusoidal pattern in glycerol can be seen here. 
 
Figure 66: Graph to compare glucose with LPR and glycerol, in the Unburned skin, for patient S04 
 
Figure 66 showed an initial ischaemic period lasting 8 hours for glucose and 14 hours for 
LPR. Glycerol levels were a little higher than in some of the other patients, but were not 
outside of the normal range. There was a cyclical pattern to the glycerol. 
Summary of Patient S04 
Ischaemia was longer lasting in the unburned skin of this patient (Figure 66), but not present 
in the zone of stasis (Figure 65). LDI showed evidence of wound progression (Plate 4). 
 152 
Patient S05 
Figure 67: Graph to compare glucose with LPR and glycerol, in the Zone of Coagulation, for patient S05. 
The scale for glycerol has been reduced, leaving the first three points off the graph, in order to make the 
baseline fluctuations visible 
 
Figure 67 showed a high initial peak of glycerol, reaching above 1800µmol/l at 7h post-burn, 
and remaining above the normal range until 9 hours post-burn. Glucose and LPR did not show 
any evidence of ischaemia.  
Figure 68: Graph to compare glucose with LPR and glycerol, in the Zone of Stasis, for patient S05 
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Figure 68 showed a profound trough in glucose which lasted for 6 hours and was 
accompanied by a rise in LPR which remained in the ischaemic range for 12 hours, and 
remained borderline ischaemic for the remainder of the study period. Glycerol changed 
cyclically, but remained within the normal range. 
 
Figure 69: Graph to compare glucose with LPR and glycerol, in the Unburned skin, for patient S05. 
Arrowed results were under the detection limit for glycerol 
 
Figure 69 showed a trough in glucose and a peak in LPR which corresponded to that seen in 
the zone of stasis (Figure 68) but this normalised by 18 hours post-burn, lasting for 8 hours 
and 10 hours for glucose and LPR respectively. Glycerol remained unaffected. 
 
Summary for S05 
There was evidence of a significant period of ischaemia affecting the zone of stasis (Figure 
68) and the unburned skin (Figure 69). LDI showed progression of the burn (Plate 5).
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Patient S06 
Figure 70: Graph to compare glucose with LPR and glycerol, in the Zone of Coagulation, for patient S06. 
Arrowed results were from a low volume sample and were consistently low across all analytes 
 
Figure 70 showed an initial fall in glucose with an elevation in LPR, which returned to non-
ischaemic values by 22 hours post burn. Towards the end of the study there was a second 
ischaemic period with a fall in glucose, a rise in LPR and some peaks of glycerol outside of 
the normal range. This period was unusual as many of the high results were isolated with 
lower results interspersed, however the general trend seemed to be that of ischaemia. 
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Figure 71: Graph to compare glucose with LPR and glycerol, in the Zone of Stasis, for patient S06 
 
Figure 71 showed a short ischaemic period for glucose and a corresponding borderline-high 
peak in LPR. Glycerol remained in the normal range. 
Figure 72: Graph to compare glucose with LPR and glycerol, in the Unburned skin, for patient S06 
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Figure 72 showed swinging glucose levels, but without the mirroring of LPR, which 
suggested a non-ischaemic cause. Two single high readings of LPR were unrelated to the 
other readings. Glycerol remained within the normal range. 
 
Summary of S06 
Zone of coagulation (Figure 70) showed evidence of ischaemic metabolism and an unusual 
event towards the end of the study period resulting in fitful production of glycerol. There was 
a short early ischaemic period in zone of stasis (Figure 71) which was not evident in the 
unburned skin (Figure 72). LDI evidence of wound progression in this patient was difficult to 
interpret because the initial scan was not informative. The final image showed a well perfused 
zone of stasis, and a poorly perfused zone of coagulation (Plate 6).
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Patient S07 
Figure 73: Graph to compare glucose with LPR and glycerol, in the Zone of Coagulation, for patient S07 
 
Figure 73 showed non-ischaemic levels of glucose but borderline-ischaemic levels of LPR 
throughout. There was an initial high peak of glycerol of over 1700 µmol/l at 8 hours post 
burn, but for the remainder of the time glycerol remained within normal limits. 
Figure 74: Graph to compare glucose with LPR and glycerol, in the Zone of Stasis, for patient S07 
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Figure 74 showed normal levels of glucose, but there was evidence of ischaemia from LPR 
readings between 16 and 30 hours post burn. There was no elevation in glycerol outside of the 
normal range.  
 
There were no results for unburned skin in S07 as the patient had pulled out the probe. 
 
Summary for S07 
There was evidence of prolonged ischaemia in the zone of stasis, but no significant rise in 
glycerol (Figure 74). There was evidence of wound progression on LDI (Plate 7). 
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Patient S08 
Figure 75: Graph to compare glucose with LPR and glycerol, in the Zone of Coagulation, for patient S08 
 
Figure 75 showed glucose within the normal range throughout. An interaction between LPR 
and glucose was evident but neither remained in the ischaemic range for more than half an 
hour. Glycerol showed an early high peak of over 400 µmol/l at 7.5 hours post injury, but was 
within the normal range for the remainder of the time. 
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Figure 76: Graph to compare glucose with LPR and glycerol, in the Zone of Stasis, for patient S08 
 
Figure 76 showed a slight decline in glucose in the first few hours after recruitment, and this 
was accompanied by a rise in LPR which remained within the ischaemic range for 4 hours 
and was borderline ischaemic until the premature end of the study period. 
Figure 77: Graph to compare glucose with LPR and glycerol, in the Unburned skin, for patient S08 
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Figure 77 showed normal glucose, LPR and glycerol levels throughout the shortened study 
period. 
 
Summary for S08 
The study period was curtailed by the patient being taken to theatre for burn excision. There 
was evidence of an ischaemic environment in the zone of stasis (Figure 76). LDI results could 
not be correlated as there was no LDI image for the end of the study period (Plate 8).
 162 
Patient S09 
Figure 78: Graph to compare glucose with LPR and glycerol, in the Zone of Coagulation, for patient S09. 
Arrows indicate low volume samples with low results for all analytes (full arrow) or some results (dashed 
arrow) 
 
Figure 78 had many intermittent low readings for all analytes during the first few hours. 
These were all low volume samples (arrowed), indicating possible spurious results. On 
observing the other zones, it appeared that glucose remained in the normal or high range 
within the first 12 hours. LPR remained within the normal range within this time, but did 
become moderately elevated at and beyond 16 hours following injury. A peak of glycerol 
occured at 19h, the time at which this patient was taken to theatre.  
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Figure 79: Graph to compare glucose with LPR and glycerol, in the Zone of Stasis, for patient S09. 
Arrows indicate low volume samples with low results for all analytes (full arrow) or some results (dashed 
arrow) 
 
Figure 79 showed elevated glucose for four hours, with a peak at 14 hours post-burn. LPR 
showed a steadily increasing course which reached ischaemic levels at 16 hours and lasted 
until the end of the study period at 36 hours. There was a high peak of glycerol at 20h during 
the theatre episode. 
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Figure 80: Graph to compare glucose with LPR and glycerol, in the Unburned skin, for patient S09 
 
Figure 80 showed a similar pattern of glucose to the other two zones. LPR did not become 
ischaemic and showed a downward trend after 20h.  Glycerol remained within normal limits 
throughout although data was missing from this probe during the theatre episode due to it 
being displaced when the patient was positioned on the table, and reinsertion was not possible 
until after the procedure had finished. 
Summary of S09 
This patient was known to be diabetic, which explains the high levels of glucose not seen in 
the other patients. There was an increase in LPR in the zone of stasis which commenced 
before, and continued after the theatre episode, indicating ischaemia in this zone only (Figure 
79). Interestingly, the opposite trend occurred in the unburned skin, which became less 
ischaemic following theatre (Figure 80). A peak of glycerol occurred at the time of theatre in 
zones of coagulation (Figure 78) and stasis (Figure 79). Assessment of progression on LDI 
was inconclusive in this patient due to the poor initial image (Plate 9).  
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Patient S10 
 
Figure 81: Graph to compare glucose with LPR and glycerol, in the Zone of Coagulation, for patient S10. 
Arrow indicates low volume samples with low results for all analytes. Diamond arrows indicate very high 
volume samples due to pump malfunction. 
 
 
 
Figure 81 showed higher levels of glucose than other patients initially. An initially ischaemic 
LPR level dropped within the first few hours to reach non-ischaemic levels by 15 hours post-
burn. From 20h it then steadily increased, reaching borderline ischaemic levels again by the 
end of the study period. There was a single peak of glycerol at 21h, which coincided with a 
theatre episode. 
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Figure 82: Graph to compare glucose with LPR and glycerol in the Zone of Stasis, for patient S10. Arrows 
indicate low volume samples with low results for all analytes (full arrows) or some analytes (dashed 
arrows). Diamond arrow indicates very high volume samples 
 
Figure 82 showed high glucose levels, similar to the zone of coagulation, and an initially high 
LPR which dropped into the normal range by 15h, and then steadily climbed again after 22h. 
A peak of glycerol was seen at 21h. 
Figure 83: Graph to compare glucose with LPR and glycerol, in the Unburned skin, for patient S10. 
Arrows indicates low volume samples with low results for all analytes (full arrow), or some analytes 
(dashed arrow). Diamond arrow indicates very high volume sample 
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Figure 83 showed low glucose which climbed rapidly into the high range by 14 hours post 
burn. LPR was initially high, but rapidly fell to non-ischaemic levels by 15 hours, and 
remained there. There was no peak in glycerol in this zone which remained within the normal 
range throughout the study. 
 
Summary of S10 
Initially high glucose in zones of coagulation (Figure 81) and stasis (Figure 82) was unusual. 
Interestingly, the high glucose came together with high LPR values, which could indicate 
hypoxia, but not necessarily ischaemia. LPR and glycerol appeared to be affected, in both of 
these zones, by the visit to theatre at 20h, but the unburned skin is not (Figure 83). LDI 
evidence of progression was borderline, with no progression at the site of the Zone of stasis 
probe (Plate 10).  
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4.4 Results of Clinical Study 3 – Large Burns 
Two patients were recruited into this group over the time period. This small number was 
mainly due to the fewer numbers of patients presenting with large burns. Two patients 
with large burns could not be recruited because a study on smaller burns was already 
underway at the time of their admission, so the microdialysis pumps were already in 
use. Large burn patients are analysed separately, and compared to the small burn group. 
4.4.1 Patient Details 
Patient L01 was aged 31 years and sustained a 35%TBSA flame burn to her face, 
arms, chest and back in a house fire. There was evidence of inhalational injury 
and suspicion of cyanide poisoning. Probes A and B were sited on the chest, and 
probe C in the left leg. Probe insertion was 15 hours after injury, and took place in 
theatre, whilst the patient was undergoing escharotomies to the arms. Serum 
lactate was >3 mmol/l post-operatively, and took some time to normalise. 
Hypovolaemia was noted post-operatively, requiring 2.5 litres of colloid in 
addition to calculated crystalloid requirement in the last 12 hours of the 
resuscitation period.  She was on noradrenaline throughout the study period. 
Patient L02 was aged 37 years and had a 50% flame burn to his arms, chest, legs, 
face and neck. He commenced the study 7 hours after injury. Probes were inserted 
whilst he was in theatre, during which he had an escharotomy to his right arm, and 
excision of the thigh and left arm burns. Propofol was used for induction of 
anaesthesia. Probes were sited on the right arm, as this was the only area of full-
thickness burn which was not excised during the theatre visit. He was nursed on 
ITU throughout the study, and at 44 hours post-burn he had a further theatre visit 
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for change of dressings. During this theatre episode, no propofol was given as the 
patient was already sedated with morphine and midazolam. Although the study 
had been completed by this time, measurements were restarted for the theatre 
visit, at the end of which the probes were removed in order for burn excision to 
take place. There was no opportunity to take laser Doppler images of this patient. 
 
4.4.2 Biochemical Characteristics of Zones 
4.4.2.1 Glucose (Figure 84, Figure 85) 
Glucose in three zones showed a slow upward trend in patient L01 from 
around 4 mmol/l at the start of the study to around 6 mmol/l by the end 
(Figure 84). This was consistent with the results from the small burns 
(Figure 33). Patient L02 (Figure 85) showed an initial peak, then trough in 
the glucose results for all zones, but most marked in Zone C. This was 
different from all of the small burn patients. From 20 hours onwards, there 
was a slow climb in Zones A and B, more in keeping with the patterns seen 
in the small burn patients. In Zone C, however there was a more pronounced 
trough at 20 hours, a second peak and trough by 28 hours, and then a rapid 
climb to join the levels of A and B by 32 hours. 
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Figure 84: Graph to show changes in glucose with time for each zone in patient L01 
 
Figure 85: Graph to show changes in glucose with time for each zone in patient L02 
 
 
4.4.2.2 Lactate Pyruvate Ratio (Figure 86, Figure 87) 
For patient L01 (Figure 86), the LPR in Zone A is initially high, falling to 
non-ischaemic levels by 21 hours, but remaining higher than the other 
zones. LPR in zones B and C remains below 25 throughout, except for the 
initial reading for zone B. This was in contrast to the overall pattern for the 
small burns, where Zones B and C showed the higher LPR readings (Figure 
36). Patient S10 was the only patient in the small burns group to show high 
LPR readings in Zone A at the beginning of the study period (Figure 81). 
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In patient L02 (Figure 87), all three zones had LPR readings which 
remained below 25 for the entire study period. There was a slow climb in 
LPR in zone B throughout the study, and this zone had the highest readings 
for the majority of the time. The results here were entirely consistent with 
results from patients with small burns. 
 
Figure 86: Graph to show changes in LPR with time for each zone in patient L01 
 
Figure 87: Graph to show changes in LPR with time for each zone in patient L02 
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4.4.2.3 Glycerol (Figure 88, Figure 89) 
Patient L01 (Figure 88) had an initial peak of glycerol in Zone A at 
recruitment, followed by a fall, then a second, higher peak at 18 hours post-
burn. This early peak could correspond to that seen in some of the small 
burn patients recruited early in the post-burn period (Figure 67, Figure 73, 
Figure 75), although as this patient was not recruited until 15 hours post-
burn. It is more likely that the peak seen here is a reflection of the theatre 
episode during which the probes were inserted, and as such corresponds to 
the peak seen in S09 (Figure 78, Figure 79) and S10 (Figure 81, Figure 82). 
There is a subtle corresponding peak in Zone B. An additional peak in 
glycerol in Zone A, during her hypovolaemic episode in ITU, is not 
mirrored in Zone B as significantly as it was in patients S09 and S10 during 
their theatre visits. For Zones B and C there was a subtle mirroring of the 
two peaks and troughs, but with measurements not exceeding 400 µmol/l. 
There was then a gradual decline with time in these zones. 
Patient L02 (Figure 89) showed an initial high peak in glycerol in Zone A, 
which declined with time. Since patient L02 was recruited within 7 hours of 
the burn, this is consistent with the peak seen in Zone A of those small burn 
patients who were recruited early (Figure 67, Figure 73, Figure 75). It may 
have been added to by the theatre visit. Unfortunately samples from Zone B 
contained blood in the initial stages, so had to be discarded, thus no 
comment can be made as to the presence or absence of a corresponding peak 
in Zone B during this time. The second theatre visit at 44h did not cause a 
glycerol peak in any zone. 
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Figure 88: Graph to show changes in glycerol with time for each zone in patient L01 
 
 
Figure 89: Graph to show changes in glycerol with time for each zone in patient L02 
 
 
 
4.5 Amino Acid profiles with time and by zone for all burn patients 
There was sufficient microdialysate to analyse the amino acids on eight patients. These 
were S02, S04, S05, S06, S08, S09, S10, L01. Age range of these patients was 19-68 
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years, with 3 male and 5 female patients. Percentage total body surface area (%TBSA) 
burn was 4 - 35%. Catheter insertion occurred at 6.5 – 12h post burn. 
4.5.1 General Trends 
The following amino acids and related amines exhibited no statistically significant 
changes in levels in the 28 hours post-burn injury, either with respect to time or to 
the location zone of the catheter: alanine, β-alanine, ethanolamine, γ-aminobutyric 
acid (GABA), glutamine, isoleucine, leucine, lysine, methionine, phenylalanine, 
serine, taurine, threonine, tryptophan, tyrosine and valine (data not shown).   
 
4.5.1.1 Excitatory amino acids 
Two-way ANOVA revealed a significant effect of both time (p<0.0001) and 
catheter location (p=0.0008) on aspartate levels (Figure 90). Aspartate 
decreased over time at all three locations but the rate of decrease was slower 
in Zones A and B. In Zones B and C, the level of aspartate at 14h was 
significantly lower than that at 6h (Student’s t-test, p<0.05) and remained so 
thereafter. In contrast, in Zone A, aspartate levels did not significantly differ 
from the 6h time point at any stage of the period of microdialysis. 
With respect to glutamate, a tendency towards a gradual decrease over the 
28-hour monitoring period was also observed at all three sites, most notably 
in Zones B and C (Figure 91). However, this decrease did not achieve 
statistical significance at any time point. Probe location had no effect on the 
glutamate levels measured. 
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Figure 90: Barchart to show changes in aspartate levels with time post-injury for each zone. Mean and 
Standard Error bars are shown. * p<0.05 in comparison to 6-8h level for zone of stasis. # p<0.05 in 
comparison to 6-8h level for normal skin. Coagulation zone = Zone A; Stasis zone = Zone B; Normal skin 
= Zone C 
 
Figure 91: Barchart to show changes in glutamate levels with time post-injury for each zone. Mean and 
Standard Error bars are shown. Coagulation zone = Zone A; Stasis zone = Zone B; Normal skin = Zone C 
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4.5.1.2 Arginine and metabolites  
Two-way ANOVA demonstrated no association between time after burn 
injury and levels of arginine, or of its amino acid metabolites, citrulline and 
ornithine. However, probe location had a highly significant effect on 
arginine levels (p=0.0004) and ornithine (p=0.0068) levels, with arginine 
being highest in Zone A, and lowest in Zone C, and the reverse being true 
for ornithine. Citrulline also tended to show lower levels in the Zone A, 
although this did not reach statistical significance. Figure 92 shows the time 
course of the ratio of ornithine to arginine levels as an indicator of arginase 
activity whilst Figure 93 illustrates the ratio of citrulline to arginine as a 
measure of nitric oxide synthase activity. In both cases, examination of the 
Zone C data reveals that the ratios increased over the first 18-20h, reflecting 
utilization of arginine, before then declining to basal levels. In Zone B, both 
ratios remain fairly constant throughout, whilst in Zone A, there is a 
tendency for the ratios to fall, although this did not reach statistical 
significance.  Two-way ANOVA revealed a highly significant effect of 
probe location on ornithine to arginine ratio (p=0.0003) and a lesser effect 
of probe location on citrulline to arginine ratio, approaching significance 
(p=0.06). Post-hoc Bonferroni tests suggested that the ratio of ornithine to 
arginine in Zone C was higher than in Zone A at 10h, 12h and 14h post-
implantation, although this difference did not quite reach statistical 
significance (p>0.05 but < 0.10).  
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Figure 92: Barchart to show changes in ornithine/arginine ratio with time post-injury for each zone. Mean 
and Standard Error bars are shown. Coagulation zone = Zone A; Stasis zone = Zone B; Normal skin = 
Zone C 
 
 
Figure 93: Barchart to show changes in citrulline/arginine ratio with time post-injury for each zone. Mean 
and Standard Error bars are shown. Coagulation probe = Zone A; Stasis probe = Zone B; Normal skin 
probe = Zone C 
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4.5.1.3 Other amino acids  
Two-way ANOVA indicated a gradual increase in glycine with time post-
burn (p<0.0001), but there was no difference related to catheter location. 
Comparison with the respective levels at 6h using Student’s t-test did not 
reveal a significant difference at any time point. 
 
4.5.2 Amino Acid Trends in Individual Patients 
Since patients had different outcomes with regard to wound progression and graft 
take, the individual amino acid profiles were reviewed. Statistical analysis was not 
possible due to the small numbers involved 
4.5.2.1 Taurine  (Figure 94, Figure 95, Figure 96, Figure 97, Figure 98, 
Figure 99, Figure 100, Figure 101) 
Four patients (Figure 96, Figure 98, Figure 99, Figure 100) showed levels of 
Taurine >100 µM in the zone of stasis, during the study period. In Figure 99 
and Figure 100, these occurred in the time following being taken to theatre. 
In Figure 99, the results peaked at 120 µM within 2 hours of the start of the 
operation and declined with time. In Figure 100, the levels continued to rise 
postoperatively, and at the end of the study period measured 161 µM. In 
Figure 96, the first two measurements following probe insertion (6-8h, and 
8-10h post burn) were 114 µM and 107 µM respectively, and levels 
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declined following this. In Figure 98, only the first result was elevated at 
106 µM. 
In all patients where serum measurements were available, Taurine levels in 
serum were higher than in skin at the corresponding time.  
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Figure 94: Barchart to show Taurine levels 
by zone over time post-burn for S02.  
 
Figure 95: Barchart to show Taurine levels 
by zone over time post-burn for S04.  
 
Figure 96: Barchart to show Taurine levels 
by zone over time post-burn for S05. Blue 
bars indicate serum levels 
 
 
Figure 97: Barchart to show Taurine levels by zone 
over time post-burn for S06. 
 
Figure 98: Barchart to show Taurine levels by zone 
over time post-burn for S08.  
 
Figure 99: Barchart to show Taurine levels by zone 
over time post-burn for S09.  
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Figure 100: Barchart to show Taurine levels 
by zone over time post-burn for S10. Blue 
bars indicate serum levels 
 
Figure 101: Barchart to show Taurine levels 
by zone over time post-burn for L01.  
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4.5.2.2 Citrulline/Arginine ratio and Ornithine/Arginine ratio 
Citrulline/Arginine ratios and Ornithine/Arginine ratios are shown 
for patients S02 (Figure 102, Figure 103), S04 (Figure 104, Figure 
105), S05 (Figure 106, Figure 107), S06 (Figure 108, Figure 109), 
S08 (Figure 110, Figure 111), S09 (Figure 112, Figure 113), and 
S10 (Figure 114, Figure 115).  
Five patients had higher Citrulline/Arginine (Cit/Arg) ratios during 
the study period, S05, S06, S08, S09 and S10 (Figure 106, Figure 
108, Figure 110, Figure 112, Figure 114). In most, the three zones 
did not show much variation, but in S05 (Figure 106), Zone C was 
markedly higher, and in S10 (Figure 114), Zone B showed a 
noticeable upward trend towards the end of the study period, not 
seen elsewhere. 
In patient S02 (Figure 102), Cit/Arg was stable at a low level across 
all zones. Orn/Arg (Figure 103) showed an increase at 19h which 
then declined again in zones of stasis but persisted in unburned skin. 
This change occurred at around the same time as the increase in 
ischaemic conditions noted in Figure 60. 
In Patient S04 (Figure 104), Cit/Arg remained low throughout. 
Figure 105 showed Orn/Arg to be elevated in the unburned skin, 
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which was concurrent with the ischaemic environment seen in this 
zone in Figure 66. 
In patient S05 (Figure 106), Cit/Arg ratio in Zone A was 0.2-0.4, it 
was moderately raised in the Zone B (0.4-0.6), and much higher in 
Zone C (>1) (Figure 106). This was associated with very low levels 
of Arginine in Zone C (not shown), a high Orn/Arg ratio 1.5 – 2.7 
(Figure 107), and higher Ornithine in Zone C than in Zone A (not 
shown). Raised ratios of Orn/Arg and Cit/Arg were evident at the 
same time as the ischaemic periods in the unburned skin (Figure 
69). In the zone of stasis, there was also evidence of ischaemia 
(Figure 68). 
 
Patient S06 had high Cit/Arg ratios (>0.7) in all zones throughout 
the study (Figure 108), associated with low Arginine levels. 
Orn/Arg ratio for this patient was also high throughout the study 
period, with Zone C ratios being consistently highest (Figure 109). 
Citrulline levels were constant with no large differences between 
zones. Ornithine levels were highest in the Zone C with a peak in 
the middle of the study period. There was no related ischaemic 
period in any of the zones for this patient. 
Figure 110 showed a moderate, constant ratio of Cit/Arg in all zones 
for patient S08. This was stable throughout the study period, and 
there was no difference between zones. Orn/Arg ratio was slightly 
elevated, but all zones showed similar results (Figure 111). 
 184 
Citrulline, Arginine and Ornithine individually did not show any 
marked trends. There was evidence of ischaemia in zone of stasis 
and unburned skin over this period (Figure 76, Figure 77). 
Figure 112 showed incomplete data for patient S09, but with a 
tendency towards elevated Cit/Arg ratios in Zones B and C, 
associated with elevation of Citrulline. There was insufficient data 
to assess Zone A. A more marked pattern was seen in Orn/Arg 
ratios with Zone C reaching ratios of up to 1 (Figure 113). This was 
associated with high levels of Ornithine. These findings do not 
correlate with patterns of ischaemia seen in Figure 78, Figure 79 and 
Figure 80. 
Figure 114 showed moderate levels of Cit/Arg initially, for patient 
S10, which increased in Zones A and B following the theatre 
episode. Zone C levels remained low. A similar pattern was seen for 
Orn/Arg in Figure 115, with highest ratios in Zones A and B.  
 
The changes for both Figure 112 and Figure 114, were associated 
with a decreasing Arginine level and increasing Citrulline levels. 
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Figure 102: Histogram to show Cit/Arg ratio by zone with time for patient S02 
 
 
Figure 103: Histogram to show Orn/Arg ratio by zone with time for patient S02 
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Figure 104: Histogram to show Cit/Arg ratio by zone with time for patient S04 
 
 
 
Figure 105: Histogram to show Orn/Arg ratio by zone with time for patient S04 
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Figure 106: Histogram to show Cit/Arg ratio by zone with time for patient S05. Blue bars 
represent serum levels. 
 
Figure 107: Histogram to show Orn/Arg ratio by zone with time for patient S05. Blue bars 
represent serum levels. 
 
  
0.2	  0.4	  
0.6	  0.8	  
1	  1.2	  
1.4	  
Ci
t/
Ar
g	  
Ra
ti
o	  
Hours	  post-­‐burn	  
CIT/ARG	  for	  S05	  
A	  B	  C	  S	  
0	  
0.5	  
1	  
1.5	  
2	  
2.5	  
3	  
O
rn
/A
rg
	  ra
*o
	  
Hours	  post-­‐burn	  
ORN/ARG	  for	  S05	  
A	  
B	  
C	  
S	  
 188 
Figure 108: Histogram to show Cit/Arg ratio by zone with time for patient S06 
 
 
Figure 109: Histogram to show Orn/Arg ratio by zone with time for patient S06 
 
  
0.2	  
0.4	  
0.6	  
0.8	  
1	  
1.2	  
1.4	  
Ci
t/
Ar
g	  
ra
*o
	  
Hours	  post-­‐burn	  
CIT/ARG	  for	  S06	  
A	  
B	  
C	  
0.3	  
0.5	  
0.7	  
0.9	  
1.1	  
1.3	  
1.5	  
O
rn
/A
rg
	  ra
*o
	  
Hours	  post-­‐burn	  
ORN/ARG	  for	  S06	  
A	  
B	  
C	  
 189 
Figure 110: Histogram to show Cit/Arg ratio by zone with time for patient S08 
 
 
Figure 111: Histogram to show Orn/Arg ratio by zone with time for patient S08 
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Figure 112: Histogram to show Cit/Arg ratio by zone with time for patient S09. Blue bars 
indicate serum levels. 
 
 
Figure 113: Histogram to show Orn/Arg ratio by zone with time for patient S09. Blue bars 
indicate serum levels. 
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Figure 114: Histogram to show Cit/Arg ratio by zone with time for patient S10. Blue bar 
indicates levels from  the combined dialysate of two serum samples taken at the beginning and 
end of the study period 
 
 
Figure 115: Histogram to show Orn/Arg ratio by zone with time for patient S10. Blue bar 
indicates levels from the combined dialysate of two serum samples taken at the beginning and 
end of the study period 
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5 DISCUSSION 
Burn injury is a traumatic insult, which triggers a cascade of events within the human 
body. These include both systemic and local responses. Much work has been done on 
the systemic component of the burn injury, and the majority of treatments for burns 
are monitored using systemic parameters. Local response to injury has an effect on 
the duration of healing and the presence and quality of scarring, and yet little work 
has been done on monitoring the burn wound. Douglas Jackson’s model of the zones 
of burn injury, together with the concept of wound progression, remains the 
hypothetical model for managing the burn wound. Clinical examination remains the 
mainstay of wound monitoring, and traditionally this is undertaken at presentation, 
and repeated at 48 hours at which point progression of the wound has already 
occurred.  Laser Doppler Imaging has been an attempt at objectively measuring depth 
of wound, and has been validated for use at 48hours post injury (45), but is not 
suitable as a method of continuous monitoring.  
Microdialysis has been used within other specialties where monitoring of the local 
environment provides vital information. Monitoring of the brain following 
neurological injury has allowed investigation of secondary injury in the field of 
neurosurgery  (83). Measurements in transplanted livers warn of vascular 
insufficiency and rejection ahead of systemic parameters and could potentially lead to 
an improved graft survival rate  (84)  (85). 
The aim of this thesis was to investigate the possibility of using microdialysis to 
monitor the burn wound, using it to understand and ultimately prevent wound 
progression.  
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Since the Jackson model indicates capillary stasis, and therefore ischaemia as a 
mechanism by which wounds progress, glucose metabolites were chosen as a marker 
for wound ischaemia, and glycerol for cell death. These metabolites have been shown 
to signal ischaemia and cell death in other tissues  (55)  (85)  (57). 
Although these metabolites have been previously studied in other tissues, no normal 
range could be found for them in the dermis. A few studies in normal volunteers had 
been performed of lactate and glucose in human dermis using the microdialysis 
technique (Table 23). Pyruvate had also been studied in some of these experiments, 
but results were expressed as LPR only with no pyruvate values specified. No studies 
investigating glycerol had been undertaken. The normal volunteer results in this thesis 
have allowed a normal range of glucose, lactate, pyruvate, LPR and glycerol to be 
calculated. 
Lactate and glucose levels in this thesis were consistent with the higher levels 
reported in the literature, in particular those taken after a glucose load, during oral 
glucose tolerance test conditions. There was a wider range in the patients in this thesis 
than that published in the literature.  
There is some difficulty in direct comparison, since many of the results in the 
literature had not been published as raw data. Jansson and Krogstad both used the ‘no 
net flux’ method to calibrate the probes in vivo over 3 hours, and then performed a 
linear regression to calculate the percentage recovery of the probes  (52)  (76). This 
percentage was then used to calculate the published result. Glucose was calibrated by 
the ‘hot loss’ technique, adding labelled glucose to the perfusion fluid and calculating 
the amount of glucose lost through the membrane during dialysis. Petersen used the 
‘no net flux’ method for both lactate and glucose quantification  (77)  (78). All 
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authors used relatively high flow rates.  Also, microdialysis probes were of different 
specification (See Table 23) 
The studies cited in the literature have used fasting subjects, with or without a 
subsequent glucose tolerance test. For reasons of matching the conditions of the 
volunteers in this study as closely as possible with the burns patients in the 
proceeding studies, the subjects in thesis were not starved. Therefore the values 
obtained for both glucose and lactate would not be expected to be as extreme, or with 
such a narrow range as those obtained in the fasting state or following the glucose 
challenge. 
 
Table 23: table to compare lactate and glucose results from dermal microdialysis in normal 
volunteer experiments in the literature 
Author n Lactate Range 
(mmol/l) 
Glucose Range 
(mmol/l) 
Comments 
Petersen, 199276 7  5.3  
 
Flow rate 3µl/min. Single 
dialysis fibre, 216µm d, 2kDa 
pore, 20mm length. Recovery 
20.5+/- 0.7%.  
Jansson, 199686 7 1.001+/- 0.024  
 
5  
10 after OGTT 
(data from 
graph) 
Flow rate 3 µl/min. Probe 
0.3mm d, 35mm length, 
50kDa pore size. Recovery 
48%. Fasted subjects. 
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Petersen, 199987 8 
 
 
10 
2.48 +/- 0.17  
 
2.52 +/- 0.32  
raised by 18% 
after OGTT 
 
5.49 +/-0.18  
 
6.31 +/- 0.18 
raised by 41% 
after OGTT 
Flow rate 3 µl/min. Recovery 
20.1 +/- 0.9% for lactate, 14.3 
+/- 0.5% for glucose. Results 
calculated using no net flux 
method. Subjects fasted 
initially, followed by oral 
glucose tolerance test 
(OGTT). 
Krogstad, 199651 15 1.171 +/- 0.228  5.2 +/- 0.8  Flow rate 2.5µl/min. Probe 
0.3mm d, 35mm length, 
50kDa pore size. Recovery 
calculated at 36 +/- 9% 
Breuning 10 0.72-5.76  3.81-7.75 Flow rate 0.3µl/min. Probe 
0.6mm d, 30mm length, 
20kDa pore size. Raw data. 
Patients not starved 
 
5.1 Discussion of Results of Burns 
Clinical identification of burn wound zones 
The sites chosen for the monitoring of progression of the burn wounds in this study 
were based on the wound model described by Douglas Jackson in 1953.  (7). His 
method of clinically determining the zones involved a tourniquet test, and described 
the blood flow and presence of de-oxygenated blood to indicate patency of the dermal 
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plexus and the metabolic state of the tissue in order to identify the three different 
zones (See Section 1.2.2). In order to follow this method, it would have been 
necessary to recruit only patients with a burn on a limb (i.e. amenable to the use of a 
proximal tourniquet), thus vastly reducing the number of patients meeting the 
inclusion criteria, and rendering the study non-viable in the two year time frame.  
The zone of coagulation was easy to identify without a tourniquet as an area of full 
thickness burn. Unburned skin was chosen rather than zone of hyperaemia as this was 
also easy to select, and provided a good control. A different method of identification 
of the zone of stasis was employed: an area within the same burn wound as the full 
thickness burn, and immediately adjacent to it, which showed epithelial loss, but 
showed blanching to pressure at the time of recruitment. This method was used to 
define the zone of stasis throughout the study. It was felt that this method identified 
the zone which, in clinical practice, is most often observed to convert into full 
thickness burn in adverse conditions. The placement of the probe in this area was 
supported by the distinct differences in the results between this zone and the other two 
probe sites in the study. 
Consideration was given to the statistical methods used in this study. A power 
calculation was performed at the study design stage, and based on the only other burn 
study to attempt to measure differences between zones of a burn wound using the 
microdialysis technique (58). Repeated measures analysis was not possible due to 
missing values. Analysis of time-related trends was therefore undertaken using 
Generalised Estimating Equations. It was felt that an overview of the trends with time 
was what was required of this study, and a decision was made to group the data into 
six-hour blocks (12 samples in each time block in most instances) for statistical 
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analysis. A post-hoc Tukey analysis was used to identify differences between time 
blocks and between zones. 
 
Within Zone A, equivalent to Jackson’s zone of coagulation, Glycerol showed 
significant changes with time, the first two 6-hour time blocks being higher than the 
final one. On observing the data more closely, it was seen that those patients recruited 
within 7 hours of burn injury showed high peaks of glycerol in this zone only. This 
can be interpreted as evidence of the primary injury. The cells in this zone have 
recently been damaged, and cell wall breakdown products (including glycerol) are 
abundant in the interstitial spaces. This early peak resolves within a few hours to a 
quiescent background level similar to that in the surrounding zones. The second 
significant elevation at 12-18h is accounted for by two patients who were taken to 
theatre within the study period. This is discussed further below. One patient showed 
glycerol levels which did not fit in to any pattern displayed by the other patients. High 
peaks and troughs were seen in zone A for patient S06, which are preceded by spikes 
in LPR. There is no clear explanation for this, but differences from the other patients 
included co-existing soft tissue trauma, and alcohol/drug withdrawal symptoms.  
There was no significant change in glucose, lactate, pyruvate or LPR with time in 
Zone A. This is consistent with the injury to the zone of coagulation. Heat injury 
causes obliteration of most of the normal tissue architecture in a full thickness burn, 
and denaturation of most cellular elements. Without these functioning elements, there 
is no direct nutritional supply from the vascular structures, and little, if any, metabolic 
activity. It would be expected that glucose, LPR and glycerol would all remain 
constant in this zone.  
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Though no statistically significant trend was observed for the group, two individuals 
showed ischaemic LPR levels, one of whom also had the unusual glycerol course. 
In summary for zone A, the zone of coagulation, there was evidence of a response to 
the burn injury within 7 hours of the injury, and a further peak of glycerol in those 
attending theatre. 
Glucose in Zone B showed a statistically significant upward trend with time. This 
may indicate return of blood flow to the area. In only 1 patient, S05, was the glucose 
level in this zone below 2mmol/l, a level comparable to that of a non-vascularised free 
flap  (56). In this patient the low glucose was accompanied by a rise in LPR to >25, 
indicating ischaemia, but there was no rise in glycerol to indicate cell death. There 
was evidence of wound progression in this patient, although not over the area 
containing the probe. 
According to Jackson, the zone of stasis has a static circulation with vessels which are 
in spasm, or filled with microthrombi. This would be expected to interfere with 
glucose delivery to Zone B. Since the cells remain viable initially, it might be 
expected that glucose within the zone of stasis would start to fall, as it is used for 
cellular metabolism, but not replenished by the circulation, leading eventually to cell 
death and wound progression if the blood flow is not restored. The findings of this 
study are contrary to this, the indications being a return to circulation and a restoration 
of normal glucose levels.  
LPR in Zone B did not show any statistically significant variation with time and 
therefore no evidence of ischaemia. However when studying the raw data, it was clear 
that there were some trends for individual patients. These were not picked up with the 
statistical methods used, due to the size of the time blocks chosen for comparison. 
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The majority of patients showed an initial rise in LPR within the first few hours after 
probe insertion, followed by a steady decline from hour 10 onwards. This would 
indicate an intitially ischaemic environment, probably due to vasoconstriction in 
response to the burn, which improves with time, indicating restored blood flow to this 
zone, rather than wound progression. This is also consistent with the LDI results 
showing most patients not to have progression around the zone B probe. Patients S07 
and S09, were an exception and continued to show an upward trend. Patient S07 
showed evidence of wound progression on LDI (although not over the probe site), but 
for S09, LDI comparison was inconclusive. 
Zone B did not show any significant change in glycerol during the study period, 
except for the two patients attending theatre. This would indicate that for the majority 
of patients within this study, conditions were not so severe as to cause any further 
cellular damage in this zone. Interestingly, some patients did show evidence of wound 
progression on LDI in the wider zone B area through this study period. It may be 
possible that the presence of the microdialysis catheter had some protective effect on 
the zone immediately surrounding it, preventing cell death despite unfavourable 
conditions causing progression of the wound in other parts.  A possible mechanism 
for this could be the provision of hydration to this area from the perfusate of the 
catheter in an area under threat from desiccation. The movement of water from the 
probe into the surrounding tissues has been previously noted  (86). Another possibility 
is that the mechanism for wound progression is not related to ischaemia, although any 
mechanism causing cell death would be expected to produce a rise in glycerol, even if 
LPR was unaffected. Other work distinguishing between necrosis and apoptosis has 
favoured the former in burn progression  (87) 
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In summary for zone B, the zone of stasis or peripheral partial thickness area, there 
was no evidence of any ischaemic trends for the group as a whole, though a few 
patients showed individual ischaemic levels of glucose and LPR. The only rise in 
glycerol was seen in the two patients who attended theatre. There was no 
corresponding evidence of wound progression from LDI. 
 
An unburned area, Zone C, was chosen on a contralateral limb, or an area >10cm 
distant from the burn to reflect the systemic effect of the burn and its initial treatment. 
All patients showed an initially low glucose, more than half of them below the normal 
range, and most showing a fall within the early hours. Glucose remained significantly 
low for the first 12 hours, when compared to the final time block, before increasing 
gradually in all patients.  This trend is consistent with the stress response following 
injury, with vasoconstriction of an intact cutaneous vascular bed. This was corrected 
in the hours following admission, allowing return of cutaneous perfusion. Glucose 
increase with time may also reflect another facet of the stress response, the release of 
glucocorticoids leading to gluconeogenesis and anti-insulin effects. Falling lactate 
levels, a constant pyruvate level, a significantly declining LPR and a stable glycerol 
level all support this explanation. The combination of a low glucose and high LPR 
indicates an ischaemic environment. The lack of a corresponding rise in glycerol 
confirms that this vasoconstriction is not harmful to the uninjured tissue. 
Glycerol was significantly higher in Block 3 due to peaks in patients S04, S06 and 
S10. These peaks were all within the normal range, except for patient S04 which 
briefly exceeded the upper limit by a small margin. Glycerol was otherwise stable, 
and within the normal range, which is consistent with the clinical knowledge that 
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distant unburned skin is not in danger of necrosis following a burn wound elsewhere. 
A subtle, cyclical fluctuation of glycerol could be seen in all three zones, when 
inspecting the individual results. This may reflect a systemic release of 
glucocorticoids, and the resulting breakdown of fat, releasing glycerol in the nearby 
subcutaneous layer, or the normal production of glycerol form the pilosebaceous units  
(88). 
In summary for Zone C, the unburned tissue distant to the wound, there were 
statistically significant changes including a low glucose and a high LPR when 
compared to the other zones. Glucose increased, and LPR decreased with time, 
indicating a normalizing physiology. There was no raised glycerol at any point. 
 
Samuelsson et al was the only other paper to investigate the burn wound in humans 
using microdialysis. Patients had more severe injuries (>25% body surface area burn). 
The zone chosen for their ‘burned skin’ catheter was that of a deep dermal burn area, 
and probably correlates somewhere between Zone A and Zone B of this study. Their 
‘uninjured’ catheter corresponds to Zone C. Measurements were taken 3 hourly from 
Day 1-5 post-burn, with complete data only available for Day 2-4. There were no 
results from earlier in the post-burn period. Data was analysed by grouping into 1 day 
time blocks. Statistical comparison was undertaken between injured patients and 
controls only. There was no statistical comparison between days of injury. A rise in 
glucose was seen with time in the injured area, consistent with our own results, and 
absolute values for their Day 1-2 were consistent with the data in this thesis. LPR 
results were significantly higher than controls for both injured and uninjured patients, 
and were highest on Day 2 (47 for burned skin and 33 for uninjured skin). These 
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results were higher than in our patients. Glycerol was significantly higher than 
controls on Days 3 and 4 (136.6umol/l in burned and 123.3umol/l in uninjured skin). 
These values were consistent with those in this thesis. There was no comment about 
an early peak of glycerol, and it is assumed that the measurements had not been 
started within 7 hours of injury. There was no mention of high glycerol during 
surgery, however it was noted that sampling was interrupted during theatre. 
 
Biochemical Trends with Theatre Episodes 
Elevated glycerol levels were observed in both of the small burn patients who were 
taken to theatre within the study period, and this occurred in Zones A and B. Patient 
S09 did not have results for Zone C in this time period, but patient S10 did not show 
any simultaneous rise in glycerol in Zone C. Peaks of glycerol also occurred in Zone 
A of the large burn patient L01 at the time of theatre visit (15h), and in patient L02 at 
time of probe insertion during first theatre visit (7h), but not on a subsequent theatre 
visit at 44h. One interpretation of these finding is that both Zones A and B contain 
some viable cells which are susceptible to secondary injury, and that a secondary 
injury may be caused during the anaesthetic or operative process, leading to cell death 
and glycerol release. Another interpretation is that there is a confounding factor 
associated with the theatre visit. Propofol, an anaesthetic agent, contains 2.25% 
glycerol in its preparation. It is possible that the rise in glycerol seen during each 
theatre episode is related to the use of this drug. It may be seen in Zones A and B 
only, due to the damaged endothelium allowing the drug to leak into the extracellular 
fluid. It is not seen in Zone C as this area contains intact endothelium. The 
observation in patient L02 that a peak in glycerol is seen on a first theatre visit (where 
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propofol was administered), but not on a second visit (where propofol was not given) 
adds circumstantial evidence to this argument. This reasoning does not explain the 
peak in glycerol in Zone A in patient L01 at 18h, since no theatre visit occurred at this 
time, and there was no documentation of propofol administration at this time. One 
other paper investigated the influence of propofol on metabolism  (89). This study 
showed no difference in subcutaneous fat metabolism when fat harvest under general 
anaesthetic with propofol was compared to local anaesthetic. No studies investigated 
the effect of propofol on dermis or in a wound. 
In summary, the three patients in this study who attended theatre all showed some 
striking findings not seen in other patients. A high level of glycerol in the burned 
areas (Zones A and B) could be evidence of a secondary injury, although a 
confounding factor such as leakage of glycerol is also a possible explanation. 
 
LDI 
LDI assessment at the beginning and end of the study was undertaken to assess for the 
presence of wound progression, in particular over the area where Probe B was sited.  
There was LDI evidence of progression of the wound in the area of the probe located 
in Zone B in only one patient.  
Interestingly, there was LDI evidence of progression of part of the wound, but not in 
the area adjacent to the probe, in a further four patients. One explanation for this is 
could be that the presence of the microdialysis probe has a protective effect, possibly 
due to hydration. This has not been previously documented. 
There was evidence of no progression in the wound in 2 patients. There were 
problems with one of the scan images in 5 patients, and this affected the diagnosis of 
progression in 3 patients. One patient did not complete the study, so did not have a 
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48h LDI scan. In two patients, there was a malfunction in the scanner, meaning a 
portion of the scan was missing. For both of these patients it was possible to make a 
comment on global progression from the appearance of the scan picture, but it was not 
possible to identify progression over the location of the probe in zone B. In another 
two patients, there was a problem with low flow for the initial images, most likely due 
to reduced skin temperature from exposure of the wound. No comment on global 
progression could be made. However, since the probe in Zone B was within a well 
perfused area in the second scan, it can be assumed that there was no progression in 
this zone, and so a result has been ventured on this in the table.  
 
The presence of Glycerol >450µmol/l (outside the normal range) or LPR >25 
(universally accepted ischemic level) for at least 2hours in each zone was compared to 
LDI evidence of global wound progression. Some correlation could be drawn when 
comparing LPR>25 for >2h in Zone B or Zone C with evidence of wound 
progression. Of the five patients who showed clear evidence of wound progression in 
part of the wound, three had LPR>25 in at least one of these zones. Of two patient 
who clearly showed no progression, one did not have LPR>25 for a sustained length 
of time. No correlation could be made between glycerol and LDI progression. There 
were too many incomplete results in this study to enable a valid conclusion to be 
drawn on this matter.  
 
Comparisons to wound healing could not be made due to the wide variation in the 
management, and in the timing of surgical procedures.  
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In summary, although the dataset was incomplete due to technical issues, there was 
evidence of wound progression in five patients, but in only one of them was this 
evident over the site of probe B. A possible protective effect of the microdialysis 
method must be considered. 
 
In order to be able to draw a conclusion on the relationship between LPR or glycerol 
monitoring and wound progression, more patients would need to be studied, or a 
standardized animal model of wound progression used. If this study were to be 
repeated, it would be vital to ensure that the patients were normothermic before the 
initial scan, and that the LDI machine was fully functional, with a backup machine 
where possible. 
 
Amino Acids 
Local and systemic responses to burn injury include vasodilation and increased 
permeability, both of which are mediated by nitric oxide (NO)  (90). Nitric oxide is 
formed from Arginine by the enzyme Nitric Oxide Synthase (Figure 116). Nitric 
oxide itself is a very volatile substance, and its presence is usually measured by proxy 
markers, the most frequently used being either nitrite/nitrate ratio, or 
Citrulline/Arginine ratio. 
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Figure 116: Metabolism of Arginine bia the nitric oxide synthase adn arginase routes. Copied 
from YC Luiking et al. Sepsis: An Arginine Deficency State? Crit Care Med 2004 32(10): 2135, 
with permission from Lipincott Williams and Wikins 
 
 
Much of the work in this area examines NO production from markers in the systemic 
circulation, with very little information on the burn wound itself. Two animal studies 
measured higher levels of NO (represented by nitrite/nitrate) in the wound, one using 
a mouse ear burn model which was then homogenized  (91) and the other a mouse 
foot model with perfusion of the subcutaneous space  (92). Inoue showed generally 
increased levels of NO which were inhibited by the administration of the NO inhibitor 
L-NAME. Neither investigated more specifically the site of NO production within the 
injured area. In a burn wound animal model, NO induction by giving intravenous L- 
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arginine, was found to significantly reduce plasma extravasation in the burn wound, 
but to increase diuresis and proteinuria  (93). Infusion of L-arginine prior to the 
ischaemic event in an ischaemia-reperfusion model increased the amount of NO 
available and prevented necrosis  (38). The limited time window for success suggests 
that the either the endothelial uptake of L-arginine, or the nitric oxide manufacturing 
system are damaged during the reperfusion injury  (37). 
Blood flow in the wound, related to nitric oxide has been investigated by Lindblom et 
al  (93) They found no difference between those treated with a NO synthase inhibitor 
NG-nitro-L-arginine (L-NNA), or precursor, L-Arginine, in blood flow in the full 
thickness burn area, but found that L-NNA reduced blood flow in the surrounding 
partial thickness area, indicating that NO has a role in blood flow in this area. 
 
Inducible Nitric Oxide Synthase (iNOS) upregulation has been measured from 
histological specimens of human burn wounded skin. Paulsen et al showed that there 
was increased iNOS expression in keratinocytes at the healing borders of the burn 
wound, none in the eschar, and baseline levels in the adjacent unburned skin. 
Expression within the endothelium of capillaries, and arteriolar smooth muscle was 
noted, but not formally compared between zones. They conclude that NO has a role in 
both the acute burn wound and the ongoing healing process (94). 
No studies have attempted to measure NO production continuously within the wound. 
As mentioned above, NO is volatile, must be measured by proxy markers. The amino 
acids citrulline and arginine are small enough to diffuse into the microdialysis 
catheter so could be collected using the microdialysis method. Since the method of 
analysis involved the use of HPLC, results for all amino acids were available and 
were therefore analysed in this study for any interesting findings. 
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The majority of amino acids in this study showed no significant change with regard to 
catheter location or time post-burn injury. This confirms the validity of the 
experimental method, and strengthens the argument that those amino acids showing 
changes are reflecting true alterations in physiology within the wound.  
 
Arginine metabolism  
Amino acids involved in nitric oxide and urea cycle metabolism showed significant 
differences between zones in this study. Extracellular arginine levels were 
consistently higher in the wounded areas than in the uninjured skin, with the zone of 
coagulation showing the highest levels at each time point.  
Arginine is the only substrate for nitric oxide (Figure 116). Arginine can also be 
converted to urea and ornithine by arginase. This pathway is involved in collagen 
synthesis and cell proliferation. Both pathways co-exist in the healing wound  (95)  
(96) 
Arginine is transported into the cell by specific transporters in response to 
inflammatory cytokines  (97)  (98)  (99), and this process is co-induced with iNOS  
(100)  (101)  (102)  (103)  (104)  (105)  (106), increasing the capacity to form NO. 
Thus the high extracellular arginine found in the burned areas may indicate a loss of 
cellular uptake, and a decreased capacity for intracellular NO synthesis.  
Arginine levels measured in an incised surgical wound model have been previously 
shown to be undetectable in the wound fluid  (95). The disparity between this study 
and the findings in this thesis may be explained by the thermal mechanism of injury, 
which causes a wide zone of injury, and involves denaturation of proteins. 
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Decreased endothelial cell nitric oxide synthesis has been linked to reperfusion 
injury  (37) Thus the higher level of arginine in the injured zones in our study 
may indicate a sensitivity to secondary injury, and thus wound progression. 
 
 
Nitric oxide synthase activity utilizes arginine and produces citrulline, and thus 
nitric oxide synthesis can be measured indirectly by the ratio of 
citrulline/arginine in the extracellular fluid. Citrulline/Arginine ratio showed the 
highest levels in unburned skin, with levels reaching a peak at 18 hours, then 
declining. Levels were relatively constant in Zone B.  
High citrulline/arginine ratios, and low arginine levels in the unburned skin 
perhaps reflect the intact mechanism of cellular uptake and nitric oxide 
synthesis.  This is consistent with findings of increased NO production in the 
peripheral tissues causing vasodilatation and systemic capillary leak, 
summarized by Rawlingson  (90) However it differs from the work by Paulsen 
et al which suggests decreased iNOS expression in the surrounding unburned 
skin, though this work concentrated on keratinocyte expression, and mostly 
referred to timepoints beyond Day 1  (94). 
The reduced levels within the burned tissue have little to compare to within the 
literature, and may indicate an interesting finding that the wound itself shows an 
incomplete response or ability to respond to the insult.  
 
 
Arginine can also be converted to urea and ornithine by arginase. This pathway 
is involved in collagen synthesis and cell proliferation. Both the nitric oxide and 
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the arginase pathways co-exist in the healing wound  (96)  (95). 
Ornithine/Arginine ratio is therefore an indirect marker of arginase activity. 
Arginase has been found to be upregulated in wound-derived fibroblasts as 
compared to normal dermal fibroblasts in surgical wounds in the rat  (107).  
Schaffer et al looked at the time course of nitric oxide synthesis in incised 
wounds and wound cells using radiolabelled arginine in a murine model  (95). 
They found that arginine itself was virtually undetectable in the wound and 
postulated that this was due to its immediate use. Labeled citrulline peaked at 24 
hours then declined slowly, indicating that this was the peak of nitric oxide 
synthesis. Ornithine continued to rise until day 10 when it plateaued, indicating 
that arginase activity followed this pattern.   
 
 
Ornithine/arginine ratio in this thesis showed significant differences between 
zones, being highest in the unburned skin. In Zones A and B, the ratio remained 
relatively constant with time. In Zone C, unburned skin, it appeared to increase 
until 22 hours post-burn, and then began to decline, though this difference with 
time did not attain statistical significance. The differences between zones 
indicated a loss of arginase activity within the burned areas and this may 
indicate damage to the cellular uptake mechanisms or the enzymatic pathways.  
 
 
An animal study by Schwacha et al did not show a significant difference 
between excisional wounds and excisional plus burn wounds in the amount of 
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arginase activity in wound homogenates at Day 3  (108). This study did not 
perform a comparison to uninjured skin. 
A human study by Debats et al showed increased levels of citrulline, ornithine 
and nitric oxide in skin graft donor site wounds compared to plasma  (109). 
Arginine was slightly lower in the wound compared to plasma (but not 
significantly different). This would indicate an increase in arginase activity in 
the wound. Arginase was measured directly; Arginase-1 was not present in 
control skin, but present in PMNs in the wounded skin. Arginase-2 was present 
in keratinocytes, smooth muscle and endothelial cells in both wounded and 
control skin, but the wounded area showed additional staining in macrophages, 
fibroblasts and PMNs, with significantly more quantities in the wounded skin. 
There was no difference between measurements at Day 2 and 5. As discussed 
above, the burn wound has different features from a surgical wound, and is not 
directly comparable, but it is interesting to see similar changes in the incised 
wound in this model, to those seen in the unburned skin in the burn patients in 
this thesis, adding strength to the argument that the normal healing processes 
are attenuated in the burn wound itself, but are present in the apparently 
uninjured skin distant from the wound. 
 
Five patients showed particularly high Citrulline/Arginine ratios. This was 
accompanied by a similar rise in Ornithine/Arginine in most of these patients, 
indicating changes in both the nitric oxide synthase and arginase pathways. 
 
Further study of individual patterns in Citrulline, Ornithine and Arginine 
supported evidence of a rise in Nitric Oxide production in two patients in Zone 
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B: S09 and S10. These patients both exhibited a decline in Citrulline/Arginine 
ratio in Zone C after their theatre episodes (at 19h for S09 and 20h for S10).  
Citrulline/Arginine and Ornithine/Arginine ratios showed similar trends across 
the study period and between zones, in all patients except for S04, which 
showed a high Ornithine level in Zone C. Two patients, S10 and to a lesser 
extent S02, showed evidence of increase in Ornithine/Arginine ratio in Zone B. 
Four patients, S04, S05, S06, S09, showed evidence of markedly elevated 
Ornithine/Arginine ratio in Zone C, particularly patients S05 and S09.  
There was no consistent correlation of either Citrulline/Arginine or 
Ornithine/Arginine ratios with ischaemia as shown by raised LPR. 
 
It might be expected that the ‘normal skin’ would be the most stable 
physiologically, and yet it is here that the greatest changes appear to be 
occurring. One explanation is that the ‘normal skin’ has a physiological 
response to the catheter implantation, whereas the traumatized tissue has a 
lesser (or different) reaction to the new insult. 
 
Examination of the individual results did not reveal any patterns with regard to 
changes in Citrulline/Arginine or Ornithine/Arginine in relation to episodes of 
ischaemia as measured by sustained periods of LPR>25. It was noted that the 
two patients who attended theatre showed raised Citrulline/Arginine ratios 
consistent with increased NO production in Zone B, following the theatre 
episode. This may be due to a secondary insult, or possibly a direct effect of 
glycerol in the tissues. However care must be taken with interpretation as this is 
a very small subgroup. 
 213 
 
 
Localised changes in amino acid metabolism can be affected by systemic 
disease. Holowatz showed that arginase was upregulated in patients with 
hypertension  (110). The decrease in arginine available for nitric oxide 
production was evidenced by attenuated dermal reflex vasodilatation. This 
patient group was a heterogenous one in terms of age and comorbidity and some 
variation in individual results may be attributable to other factors such as these. 
 
Although the data in this thesis is observational, it has shown a difference in the 
response of the three zones to injury with both the nitric oxide synthase and 
arginase pathways affected to varying degrees, with the most profound effect 
being on the arginase pathway. These results could be interpreted as a loss of 
the ability of cells in the burn wound to uptake or to process Arginine, possibly 
due to the thermal damage to endothelial cells beyond the immediate borders of 
the wound. Further study would be necessary to differentiate the effect of probe 
insertion from that of the burn injury, and to further distinguish the effect of the 
changes seen on wound healing or wound progression. 
 
Excitatory amino acids and skin: Aspartate and Glutamate 
Aspartate and glutamate have been proposed as chemical transmitters of 
mechanoreceptor responses in the skin, and there is evidence for the 
involvement of both ionotropic and metabotropic glutamate receptors in 
mediating this  (111-113).  Supporting evidence has shown aspartate and 
glutamate levels in skin biopsies were lower in motor neuron disease patients 
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with the levels associated with the duration of illness.  (114) Glutamate has been 
implicated in keratinocyte signaling pathways and is linked to wound healing  
(115).  
 
Aspartate levels in this thesis were initially high, and decreased with time in all 
zones, but the decrease was more blunted in the zones of stasis and coagulation. 
Glutamate levels showed a similar trend, although this did not attain 
significance either for time or probe location.  
 
The data presented here are consistent with similar data on these transmitter 
amino acids in liver  (62). A proposed mechanism for the findings is that initial 
implantation injury results in the release of aspartate and glutamate into the 
extracellular space. The injury quickly stabilizes and uptake mechanisms begin 
to remove the transmitter amino acids from the extracellular space to avoid 
over-stimulation of receptors, and toxicity. Our results showed that the 
downward trend with time was much reduced for both the zones of coagulation 
and stasis. This suggests that the uptake mechanisms have been impaired by the 
burn injury locally, and this could in turn lead to over-stimulation of receptors, 
or toxicity, and a delay or prevention of normal wound healing mechanisms. 
Thus, although normal skin is damaged by probe implantation, endogenous 
uptake mechanisms quickly restore the ‘status quo’. In contrast, these uptake 
mechanisms have been rendered less efficient by the burn, more so in the zone 
of coagulation than in the zone of stasis, so these tissue sites take longer to 
recover from probe implantation and may not recover fully at all.  
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Taurine 
Taurine has osmoregulatory and neuromodulatory roles which have been 
studied in the central nervous system  (116). Its neuromodulatory role protects 
the cell from overstimulation of excitatory amino acids in the context of 
ischaemic injury, and has been linked to glutamate receptor stimulation, and to 
nitric oxide activity  (117). It is known to protect the cell from free radicals, and 
improves in vitro polymorphonuclear cell function in normal and burned 
patients  (118).Its osmoregulatory role has been explored in the brain. Taurine 
levels were found to increase when neuronal and glial cells were placed in a 
hypotonic environment, and prevented further swelling of the cells in vitro  
(117).  
Two patients within this thesis showed rising levels of extracellular taurine 
within the zone of stasis during the study period.These are the two patients with 
the strongest suspicion of a secondary insult, as shown by a rise in LPR and 
glycerol after a theatre episode. Of note was a concomitant rise in 
Citrulline/Arginine ratio in S10 following the theatre episode, indicating 
increase in nitric oxide production. The two patients with raised levels of 
taurine within the first 4 hours of recruitment were both within the group, 
recruited early, in which significant peaks of glycerol were found in the zone of 
coagulation This supports the theory that this early glycerol peak is due to the 
primary injury. 
 
This observational study has revealed that there are significant differences in 
levels of excitatory amino acids, and amino acids involved in the urea pathway 
between different zones of burn when compared to unburned skin in acute burn 
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patients. The response of excitatory amino acids appears to be dampened in 
burned skin. Arginine levels were significantly higher, and Citrulline/Arginine 
ratio significantly lower in the zones of stasis and coagulation, than in the 
unburned skin, indicating that there is a reduction of arginine uptake, and 
synthesis of nitric oxide in the areas of injury. It appears that the thermal injury 
shows different trends from an incisional wound. The protective amino acid, 
Taurine, showed increased levels in the zone of stasis following a possible 
secondary ischaemic event. 
 
 
5.2 Discussion of Microdialysis Technique 
The microdialysis system used was easy to handle, and straightforward to use. 
The probe insertion technique was mastered quickly, and insertion into the 
dermis was shown to be reproducible on ultrasound examination. Both 
volunteers and patients tolerated the insertion procedure well. Retention of the 
probes in the skin for the study period was generally very good, although a few 
probes were lost due to displacement. There were no adverse events. For the 
majority of the time, the probe and pump system produced consistent and 
reproducible results. 
A few abnormal sample volumes were noted (See Table A20 in Appendix C).  
There appeared to be a tendency of the analyzing equipment to give falsely low 
results if the sample volume was insufficient. Once this was recognized, the 
approximate volumes of the sample vials were noted in patients S09 and S10 to 
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allow identification of possible anomalous results. Since the calibration study 
assessing the effect of volume on analysis was inconclusive, these low volume 
results were included in the statistical analysis.  
On several occasions it was noted that the pump output was inappropriately 
high, possibly due to a temporary power failure initiating the pump flush 
sequence. In addition to any effect on the analytical process, a higher flow rate 
will have decreased the relative recovery, leading to a falsely low result for all 
substances within that sample. Episodes where this occurred have been noted in 
Appendix B Table A20.  
Microdialysis samples from a number of probes contained blood, and therefore 
had to be discarded. The maximum pore size of the microdialysis probes was 
20kDa, which is less than the size of haemoglobin (68kDa). This finding may 
have been due to damage of the probe on insertion into the skin. This 
explanation is consistent with information from the manufacturer’s website  
(119). An alternative insertion method, which puts less pressure on the probe, 
may need to be sought to prevent this occurrence.  
Since the microdialysis probe must be placed invasively into the tissue, there is 
potential for a tissue reaction to the probe, which could confound results. This is 
of particular importance in the burn wound, since many of the processes to be 
measured are those relating to inflammation. Additionally, any time for 
equilibration of the probes must be minimal to allow the earliest possible 
reliable sampling in this acutely presenting study group.  
Local anaesthetic was given in the normal volunteers and the unburned and 
zone B areas of the burn patients to make probe insertion less painful. EMLA 
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was used in normal volunteers as it was thought to be more acceptable for this 
group. 1% lignocaine injection was given to the burn patients in the interest of a 
timely probe insertion, and because the occlusive dressing required with EMLA 
would be difficult to use on an area with epidermal loss. The effects of local 
anaesthesia are discussed below, and were not thought to have an effect on 
results. However, a potential confounding factor cannot be ruled out and 
therefore ideally a more detailed study on the comparative effects on EMLA vs 
1% lignocaine would be required. 
Groth  (120) studied the effects of insertion trauma on human skin. She found 
significant increases in skin blood flow, colour and erythema which had 
normalised by 120 minutes. This was confirmed by Anderson  (121) and 
Petersen  (77), who found increases in perfusion lasting 60 minutes and 90-135 
minutes respectively. The former and the latter of these three studies used linear 
probes, with may represent a greater degree of trauma than with the double 
lumen probe. Probe insertion without prior anaesthesia was found to have a 
change in blood flow of a greater magnitude, and lasting for a longer period 
than those inserted with anaesthesia  (122). Skin thickness was increased as a 
result of probe insertion by up to 38% as measured by ultrasound, and did not 
return to normal within 2 hours. The finding of a low echogenic area around the 
probe would suggest oedema formation  (122). However Ault et al found no 
oedema or tissue disruption  (123). After 6 hours a lymphocyte infiltrate has 
been noted in skin  (124) and after eight days a fibrosis was apparent at the 
insertion site in liver  (125). 
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Results in this thesis showed that an equilibration period is necessary for some 
but not all substances. Glucose, Lactate and Pyruvate individually were stable 
from the time of probe insertion. Glycerol required 30 minutes equilibration 
time, and LPR calculation required one hour. This knowledge is important when 
interpreting results from probes inserted into burn patients. There is no need to 
completely disregard all results for 90 minutes as was implied from previous 
studies. However, results need to be interpreted with caution with respect to 
LPR (for the first 60 minutes) and Glycerol (for the first 30 minutes). It is likely 
that the small rise in Glycerol is caused by insertion trauma. Lactate, Pyruvate 
and Glycerol molecules are all smaller than Glucose, and if the difference were 
due to diffusion characteristics, it would be more likely that glucose would 
show the longest equilibration time.  
 
The hypothesis asserts that the changes observed within the burn wound are due 
to the initial burn injury and to the natural progression of the burn proceeding. 
The assumption is that the insertion of the probes had no lasting effect on the 
natural progression. This assumption was based on the findings of Study 1 in 
normal volunteers and on the supporting literature. However such an 
assumption, based on findings in uninjured skin, may not hold true for 
extrapolation to burned skin. The constraints of a clinical study meant that 
recruitment and probe insertion could not be commenced at a uniform time 
following the burn. Based on the findings of Study 1, a decision was made to 
analyse the data based on time post burn rather than time post probe insertion. 
The striking findings of glycerol in the zone of coagulation appear to support 
the validity of this assumption. There were marked peaks only in patients 
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recruited early in the post-burn period which were not present in those recruited 
later. This supports the interpretation that observed changes were attributable to 
the burn and not to the secondary trauma of probe insertion. 
For consistency, the same method was used to interpret the amino acid data. 
However no data were available for amino acids from probe insertion into 
normal volunteers, and the same assumptions that probe insertion causes only 
temporary changes may not be valid. Whereas lactate, pyruvate, glucose and 
glycerol are markers of basic glucose metabolism in the tissues, some of the 
amino acids are a reflection of the neuro-humoral responses in the wound. 
Certain amino acids are much more likely to show changes related to probe 
insertion, and so should be interpreted with caution in this study. This effects of 
the microdialysis probe on different substances and physiological processes is 
highlighted in a study by Stenken & Church  (126). A further study would be 
necessary to ascertain the effect of probe insertion on amino acids in the burn 
wound. 
To allow a calculation of the actual tissue concentration of a substance 
measured within the microdialysate, a recovery coefficient is required. 
Recovery of substances from the tissues using microdialysis can only reach 
100% at a theoretical flow rate of zero. 
In-vivo and in-vitro systems are different and require different methods of 
calibration. An in-vitro system is static. There is no replenishment of substances 
by a capillary supply, therefore dilution occurs as substances are removed in the 
dialysate, but there is no other change in the environment. Direct comparison to 
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a known concentration of a prepared solution, or time-based methods, such as 
no-net-flux can be used to calculate recovery. 
An in vivo system is dynamic. Concentration of substances is constantly 
changing, in response to the local and systemic environment. The microdialysis 
system competes with capillaries for uptake of substances, and changes in blood 
flow affect rates of recovery. Levels of substances are in constant flux and are 
very difficult to control for. True values are almost impossible to attain. Most 
methods of calculating recovery are performed in series, and are based on the 
premise that there is no change in the environment. 
Flow-rate variation  (127), one of the first methods of calibration to be 
published, uses the principle that relative recovery varies with flow rate. At high 
flow rates, recovery is low and it increases with lower flow rates. 100% 
recovery occurs at a flow rate of zero. Therefore a series of flow rates are 
utilised, and the results plotted on a graph. Extrapolation to zero flow gives the 
true value in the tissue. This is described by the equation Cdial = C0(1-e-rA/F), 
where Cdial is the concentration of the compound in the dialysate collected, C0 is 
the concentration in the fluid surrounding the probe, r is the mass transport 
coefficient, A the surface area of the membrane and F is the flow rate. 
Disadvantages of this method include the length of time needed to perform 
these serial tests, particularly when using lower flow rates where collection of 
adequate sample volumes for analysis can be lengthy. Also, extrapolation 
contains an exponential function which may be difficult to determine. It is 
suitable for in-vitro studies only. 
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Method of no-net-flux  (128) utilises the premise that there is only a change in 
the concentration of the perfusate if there is a concentration gradient by which 
the substance in question can diffuse across the membrane. If the concentration 
in the perfusate equals that in the dialysate, then there will be no movement 
across the membrane (i.e. “no net flux”). Varying concentrations of the 
substance in question are added to the perfusate, both higher and lower than the 
assumed concentration in the tissue. Where the concentration in the perfusate is 
lower than that of the tissue, the substance will move into the microdialysis 
system, and the dialysate concentration will increase. Conversely, where the 
concentration in the perfusate is higher than that of the tissue, the substance will 
move out into the surrounding tissue, leaving a lower concentration in the 
dialysate. Concentration of the perfusate (Cperf) is plotted against the difference 
between the concentration of the dialysate and the concentration of the perfusate 
(Cdial – Cperf). On the graph plot, the points are joined with a straight line, and 
where this line crosses zero, the point of no net flux, can be assumed to be the 
actual tissue concentration of the substance. This method is more accurate than 
the flow rate variation method since interpolation rather than extrapolation is 
used. However this method is also time-consuming, and assumes a steady state 
throughout the experimental period. This is most suitable for an in-vitro, or 
steady state in-vivo environment. 
Dynamic no-net-flux (129)  (130) takes advantage of parallel study design in 
perfusing each individual in the study with a different concentration for one unit 
of time, and then pooling the results. While this reduces the time needed for 
calibration, it also assumes all probes, and all individuals will behave in the 
same way, and gives an average calibration for the whole group. Higher 
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numbers of participants are therefore required to overcome this inter-subject or 
inter-probe variability. For certain studies, particularly those where all other 
conditions can be controlled, this method is a useful alternative. However in the 
clinical setting, there is too much inter-patient variability both in individual 
physiological response, and in the disease severity, for this method to be 
feasible. 
Retrodialysis  (131) uses the principle that the passage of a substance across the 
membrane is equal in both directions. A substance of known concentration, and 
which does not already exist in the peri-probe tissue, is added to the perfusion 
solution. Measurement of the remainder in the dialysate allows calculation of 
recovery, as loss of this substance should be equal to recovery of the other 
substances in question. Recovery can thus be calculated using the following 
formula: Recovery (%) = 100 – (Cdial/Cperf x100). A variation of this method is 
the use of an internal standard. This consists of the addition of a standard 
amount of a substance to the perfusion fluid throughout the study period. The 
concentrations both of the remaining calibration standard, and of the substance 
in question can be expressed as a ratio to give recovery for any one sample 
during the entire study period. This method is therefore of particular use in the 
clinical setting as a continuous measure of recovery is then available. The 
proviso for this method is that the substance added to the perfusate does not 
interfere with the biochemical environment being monitored. In the zone of 
stasis, an additional problem may be that due to the postulated impairment of 
capillary function in this zone, the clearance of this substance may be impaired, 
allowing it to build up within this zone. While this would indeed provide useful 
information on the alterations in recovery as a result of this ‘closed’ system, it is 
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impossible to predict the effect of this substance on the very metabolism being 
monitored. 
The Endogenous reference substance method  (69)  (132) has the advantage of 
being less time-consuming, and not requiring steady-state conditions. It relies 
upon the existence of a substance within the tissue to be studied which diffuses 
freely between compartments, and is small enough to enter the microdialysis 
system. This substance should not be affected by the environment which is 
being studied. Several substances have been investigated, but urea has been 
acknowledged to be an ideal candidate, due to its properties of freely diffusing 
within tissue. It has been proposed that its recovery in vivo should be similar to 
its recovery in vitro for this reason  (132). However, this takes into account only 
its properties of equal diffusion through tissues, and not the difference in 
tortuosity between living tissue and liquid media. An experimental study in 
humans by Strindberg supported this argument, showing an in-vivo to in-vitro 
recovery ratio of 0.4, comparable to that of the other substances tested. In this 
study, comparison of plasma and interstitial concentrations was performed, and 
urea was found to be equal in the muscle compartment and the plasma. These 
authors have therefore suggested that true interstitial values can be calculated 
for all substances, based on a plasma reading of urea, and the dialysate 
concentrations of urea and of the other substances in question  (69). In contrast, 
Brunner performed a similar study to assess the validity of the urea endogenous 
reference technique, and found that results for glucose were significantly 
different when calculated by the urea endogenous reference technique and the 
no-net-flux method. He explained this was most likely due to a difference in the 
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ratio between in vivo and in vitro recovery of the two substances, a basic 
supposition of the urea endogenous reference method.  
 
For the in-vitro component of this thesis, direct comparison with a solution of 
known concentration was used. The solution itself was tested before and after 
microdialysis had taken place, and the microdialysate was compared to it. Probe 
recovery overall was high (Appendix B, Tables A6-A9), as would be expected 
with a slow perfusion rate of 0.3µl/min. A single probe measured consistently 
low during the calibration experiments. The remainder of the probes showed 
recovery rates of around 100%. This showed that the results obtained in these 
experiments, for glucose, lactate, pyruvate and glycerol, could be reasonably 
assumed to reflect the actual values in interstitial fluid throughout these 
experiments. Interestingly, the majority showed recovery rates above 100%. 
Reasons for this are not clear, and there is no discussion of this in the literature.  
Dilution of the environment being sampled (in this case the calibration solution) 
can occur during microdialysis sampling in a closed system. This in theory 
could lead to a lower denominator, giving a falsely high % recovery. In this 
study, the calibration solution was measured immediately prior to the start of 
microdialysis, to prevent this error.  
Contamination of a sample from residue in the probe could lead to a falsely high 
result (if the previous probe environment was more concentrated). This would 
give a falsely high % recovery. There is no evidence to suggest contamination 
of samples from residue in the probe had any effect in this study. In the pre-
study calibration (Appendix B, Tables A6-A9, Column C1, 01, 02), a new probe 
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was placed into the calibration solution and microdialysis took place for two 
continuous 30 minute periods. In all cases except NV11, the first result (01) was 
lower than the second (02), showing that any contaminant, from probe 
manufacture or initial flush sequence, was serving to dilute rather than 
concentrate the samples. Indeed at the end of study calibration (13), where in 
some cases the probe had been in the more concentrated environment of the 
volunteer’s skin, results show % recovery values which are almost identical to 
those from the first calibration.  
A sampling error of the analyser overestimating the numerator, and/or 
underestimating the denominator could explain this, however it would be 
expected that this would occur in a random fashion. In this series, not only was 
there a significant majority of the probes reading >100%, but the probes 
themselves showed consistent readings for pre- and post- microdialysis 
calibration, and for the different substances. This points towards a sampling 
equipment related reason. 
Evaporation of water from the calibration fluid during the microdialysis process 
could be another cause. Since the sample of calibration fluid measured in the 
analyser, was taken prior to microdialysis taking place, the measured sample 
may be more dilute than the actual fluid sampled during the microdialysis 
process. If this was the case, it would be expected that the values at the end of 
the experiment (columns C2; % recovery 2) would show a higher value than 
those at the beginning (columns C1; % recovery 1), however this was not the 
case for the majority of results. 
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The probe used in NV02 showed a lower % recovery than the other probes. This 
was consistent at the beginning (% recovery 1) and the end of the study (% 
recovery 2), indicating a malfunction with the probe. It is possible that part of 
the membrane was blocked, giving the effect of a shorter probe, and thus a 
reduced % recovery. 
In summary, all of the results except one are close to 100%, showing that 
recovery with this method is consistently high. It is unclear why the % recovery 
calculated was often >100%. It must be kept in mind that there may be an 
occasional underperforming probe. 
 
The endogenous reference technique seemed to be most appropriate for the in-
vivo studies undertaken in this thesis. At the planning stage of this study, the 
endogenous reference technique using urea was not known to the author. A late 
addition was made to the protocol after the commencement of the study, to 
attempt to gain the information needed to perform these calculations. There 
were a number of limitations to the data thus collected. Instead of protocol-
based collection of timed blood samples and simultaneous microdialysis, blood 
samples drawn during the course of routine care, at varying times, had to be 
used retrospectively, after permission for their use was obtained from the Ethics 
Committee. Accurate data on time of blood collection was not available and had 
to be estimated from the biochemistry laboratory booking system. Length of 
storage before microdialysis occurred was variable. It is therefore impossible to 
comment on the accuracy of this reference technique in this study.  
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In this thesis, urea showed good concordance between zones in the burns 
patients, and therefore shows promise for use as an endogenous substance. Any 
further study should ideally include microdialysis of serum samples 
synchronous with the dermal microdialysis, to allow the endogenous reference 
substance method to be further evaluated. Alternatively, the retrodialysis 
method could be used, which would require further investigation into a suitable 
substance, which would not interfere with local metabolism. 
 
Best attempts were made to maximise recovery in this study to ensure that 
results are as close as possible to real values. It is known that recovery is 
proportional to length of membrane, and to flow rate. The longest membrane 
commercially available was used, together with the lowest practical flow rate, 
0.3µl/min. This is commonly accepted as the optimum flow rate in order to 
balance sampling volumes (and time intervals) with maximum recovery. The in-
vitro methods of calculating recovery in this thesis showed results around 100% 
recovery. With a recovery ratio close to 1.0, the requirement for an accurate 
coefficient decreases.  
 
Thus the endogenous reference technique for calibration using urea in these 
experiments was not possible. This means that absolute values cannot be 
calculated with accuracy. However this does not affect the validity of the 
analysis of patterns of changes with time and across zones. 
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In order to assess the effects of sample volume and storage conditions on the 
results, a set of supporting studies was undertaken in this thesis. Some 
statistically significant differences were identified amongst the results of these 
experiments, although the size of the differences was very small. There was no 
clear trend in samples becoming either more or less concentrated over the study 
period with each particular storage condition or sample volume, nor was there 
any storage condition or sample volume which consistently produced more 
concentrated samples.  
Since Day 1 samples for storage analysis were identical, any differences 
observed could not be attributed to the variability in storage conditions. In the 
case of pyruvate and glycerol there were significant differences at the P<0.05 
level between Day 1 samples. This may have been due to the error range of the 
analytical equipment, or due to a Type 1 statistical error. Each sample took 7 
minutes for full analysis, so the maximum length of time between analyses was 
63 minutes, leaving room for the possibility of machine drift or evaporation of 
samples.  
Differences between days, and thus between batches, introduces the possibility 
of variation due to recalibration of the analyser. If the differences were 
attributable to storage conditions or sample volume alone, it would be expected 
that a trend in the direction of the difference (either becoming more or less 
concentrated) would be observed. This was not the case: the differences 
appeared to be random, supporting the likelihood that the significant differences 
can be attributed to slight variations in the analytical process. 
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A total of eight results lay outside of two standard deviations from the mean. 
For each of lactate, pyruvate, glucose and glycerol, there was a single outlying 
result. Reviewing the results revealed that the outliers were all from different 
sample vials, and different variables. These are likely to be random occurrences. 
Four outliers were found within the urea results. The three below 2 standard 
deviations from the mean were all located within the High Volume samples. 
The one abnormally high result was from the Low Volume samples. On initial 
observation there appears to be a trend here, however the High Volume 
samples, as well as containing the three lowest results, also contained some of 
the highest results, so it does not appear that the low results are entirely due to 
the high sample volume. The Low Volume samples were all within the high 
range but there was no trend with time, so any concentrating effect caused by 
the low volume of the samples is not affected by repeated freeze-thaw cycles. 
Although statistically significant, the size of these differences is very small, and 
the clinical significance of this is doubtful. Further clarity would be gained by 
repeating this study with a larger sample size.  
11 samples would be required for a two-way ANOVA to have at least an 80% 
chance of detecting a difference in means at the 5% level of significance for 
glucose, lactate, pyruvate and urea. Glycerol showed a non-normal distribution 
and would therefore need to by transformed before analysis. 
 
In summary, this thesis has shown that microdialysis of the burn wound 
environment is both possible, and promising. The procedure was well tolerated 
by patients and volunteers, and there were no adverse effects. A normal range 
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for glucose, lactate, pyruvate, glycerol and urea within the dermis was 
calculated from volunteers, a useful baseline for future studies. Significant 
findings within the burn wounds included an initial peak of glycerol in Zone A 
early following burn injury. Low glucose together with high LPR gave evidence 
of peripheral ischaemia in the unburned skin early on, with a normalization over 
time. Significant alterations in physiology from a theatre episode raised the 
possibility of either capillary leak in the injured zones, or cell breakdown in 
response to the surgical or anaesthetic manipulation. High arginine and low 
citrulline/arginine ratio in the burned areas may indicate a failure of nitric oxide 
synthesis in zone A with a reversal of this trend in the unburned skin. This has 
not been previously described in relation to the zones of the burn. Arginase 
activity, which relates to wound healing processes, was also found to be greatest 
in the unburned skin. 
The microdialysis technique itself, and supporting studies have been critiqued, 
and a series of recommendations follows for future work. 
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6 CONCLUSIONS AND FURTHER WORK 
The microdialysis method is a safe and valid technique to monitor metabolism within 
the skin, in normal subjects, and following a burn injury. Probe insertion was 
consistently achieved within the dermal layer of the skin, and was well tolerated by 
patients. It was shown that changes in ambient temperature do not affect microdialysis 
results when using the probes and flow rates selected for this study. The microdialysis 
method is the first time in-vivo measurements of the biochemistry of a burn wound 
have been possible, giving a window into the workings of the wound environment. 
This series of studies represent the first steps in gaining the ability to monitor 
progression of a burn in-vivo. Results have shown differences between the zones of 
the burn wound, and changes in the environment with time following burn. Some 
consistent patterns have been identified, including evidence of primary injury, with a 
high peak of glycerol in patients recruited in the early hours post-burn. Some 
prolonged periods of low glucose and high LPR were observed, consistent with 
hypoperfusion and ischaemia, but in no patient did this lead to a rise in glycerol (an 
indicator of cell death) in any zone. Theatre visits had an effect on the biochemistry of 
these zones, with release of glycerol in zones of stasis and coagulation, however this 
was not preceded by low glucose or high LPR, and may have been due to anaesthetic 
agents. Burn progression is multifactorial, and burns patients are complex. There was 
insufficient evidence from these studies to conclusively link microdialysis changes 
with wound progression, as only one of the patients showed progression over the area 
of the probes. There was no evidence to suggest that any rises in glycerol were caused 
by an ischaemic mechanism.  
 
 233 
Significant results in the amino assays were found to support the previous theories on 
loss of endothelial cell nitric oxide synthesis in the burned areas. The burn wound 
showed behaviour distinctive from that of a surgical wound in that high levels of 
arginine were measured, in contrast to other studies of incised wounds. Low Cit/Arg 
in the burned areas as compared to unburned areas, indicated low nitric oxide 
synthase activity in the injured zones. This is consistent with the burn wound model 
showing endothelial damage beyond the immediate cellular damage, and thus the 
wound being susceptible to further injury, though this further injury was not observed 
within our patient cohort. 
 
These studies have given a valuable insight into the exciting opportunities which the 
microdialysis technique brings to the field of burns. As a series of pilot studies, this 
thesis has identified patterns in the course of the burn wound which would be worthy 
of further research. From the experience of these studies, the following 
recommendations can be made for further research; 
1)  The normal volunteer studies give valuable baseline data for comparison with 
diseased states in future studies. 
2)  Identification of zones of burn, as described by Jackson, was found to be 
difficult in this study, since the method used in the original paper required 
tourniquet control of the area. This was not possible to apply in wounds of the 
trunk. While it is of academic interest to define these areas accurately, it is 
perhaps unnecessary for evaluating burn wound progression. Since in clinical 
practice the burn wound can be seen to progress in depth from a superficial to 
a deep burn, monitoring of an area of burn of superficial or mid-dermal depth 
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on initial examination should be adequate to detect progression. This theory 
was supported by the differences in the biochemistry seen in the three distinct 
areas monitored in the studies in this thesis. However caution should be used 
since there was little evidence of any wound progression in any of the ‘zone of 
stasis’ areas. A better way of defining this zone may be sought, for example 
using confocal microscopy (See Section 1.2.3.4). 
3)  Monitoring of progression of a burn using the microdialysis technique may 
have some intrinsic difficulty. One potential confounding factor is the 
introduction of hydration, via the microdialysis cannula, directly to the area in 
which the mechanism of progression may be linked to profound dehydration. 
An animal study would be ideal to study the question of whether the 
microdialysis technique has a protective effect on the wound, preventing 
progression. This question would need to be answered before a larger study, to 
look at whether burn progression can be predicted, could be commenced. 
4)   Further investigation could be made into the reason for some of the volume 
variations of samples seen in this study. A simple mechanical fault could be 
ruled out by running the pump in an in vitro environment and measuring 
volumes produced each half an hour. The effect of a dehydrated environment, 
on volumes produced, could also be evaluated experimentally. 
5) Analysis calibration studies in this thesis were performed on a small sample 
number (n=3). The resulting statistically significant differences, although 
clinically small, led to some uncertainty in their interpretation. These 
experiments could be repeated with a larger sample number to clarify the 
effects of volume and storage conditions on the analysis.  
 235 
6)   The endogenous reference method for in-situ calibration was not addressed 
adequately in these studies, as the concept was introduced late into the study 
design. The urea endogenous reference method did not produce promising 
results, because the method (comparisons with urea from blood samples drawn 
at varying times and analysed retrospectively) was flawed. We would 
recommend blood samples to be taken as part of the study protocol at pre-
determined times, and the serum microdialysed contemporaneously. This 
would require an additional microdialysis pump and probe. Alternatively a 
different reference method could be used, for example the retrodialysis 
technique (see Introduction 1.3.2.2). 
7)  Interpretation of results in this study was based on the assumption that the 
insertion of the probe had no effect on the tissue being studied. Therefore, 
although probes were inserted at different times post-injury, all results were 
analysed with reference to time post-burn. It is worth noting that if the probe 
insertion itself causes a response in the tissues (i.e. a second injury), the 
method of analysis in this study may have hidden interesting data trends. A 
further study design could address this issue by standardising the time of 
probe insertion in relation to the time of burn. This would certainly be possible 
in an animal model. 
8)   LDI is a widely accepted, validated method for measuring burn wound depth, 
however results were somewhat disappointing in this study. More familiarity 
with the LDI may improve the quality of images, and attention should be paid 
to ensuring appropriate skin temperature of the wound being imaged to avoid 
a globally hypoperfused image seen in at least 2 patients in this study. 
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9) The interesting finding of raised glycerol in zones of coagulation and stasis 
during theatre episodes warrants further investigation. Microdialysis of a 
series of animal or human burn wounds in a standardised scenario, with or 
without the administration of propofol, or of a systemically administered, 
labeled substance would clarify the source of the additional glycerol seen in 
the wound, and ascertain whether further investigation on a secondary insult 
during the theatre episode is warranted. 
10)  Significant differences in Citrulline/Arginine ratios, and in Arginine values 
were seen in burned areas of these patients, but without evidence of wound 
progression. Whilst loss of nitric oxide production itself may not cause 
reperfusion injury, loss of its protective effect, in combination with a large 
secondary insult, may have a permissive effect in allowing wound 
progression. This could be further assessed using a standardized animal model 
for burn wound progression. 
11) The microdialysis technique could be used to monitor other substances in the 
burn wound such as cytokines and Damage Associated Molecular Pattern 
Molecules (DAMPs). This could give insight into cell signaling pathways, and 
the ongoing immune response seen particularly in patients with major burns. 
DAMPs have a broad spectrum of molecular weight from around 6kDa to 
100kDa. Pore size of the probes needs to be 4x the size of the molecules to be 
investigated to allow good recovery, and commercialy available probes have a 
maximum pore size of 100kDa. A custom probe may need to be made in order 
to investigate some of the larger molecules. 
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Appendix A: Ethics Approval and Patient Consent 
Ethics committee approval was given for the study by the Black Country 
Ethics Committee. Ref 05/Q2702/76. See below for copy of approval 
form, and samples of the consent forms and patient information sheets 
prepared for the study. 
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Trial R&D number: RRK 2975 
Patient Identification Number for this trial:___________ 
CONSENT FORM 
 
Investigation of dermal metabolism in burned and unburned skin 
Study 1 – Normal skin 
Name of Researchers: Miss E Breuning, Mr N Moiemen, Dr P Gosling, Dr D Richards 
 
1. I confirm that I have read and understand the information sheet dated ____________  
(version ___________) for the above study. I have had the opportunity to consider the 
information, ask questions and have had these answered satisfactorily. 
2. I understand that my participation is voluntary and that I am free to withdraw at any time 
without giving any reason, without my medical care or legal rights being affected. 
3 I agree to have a sensor inserted into the skin of my forearm for 4 hours. I agree that  
samples of fluid taken from my skin may be used for analysis and stored for further study. 
4. I agree that any photographs or other images taken during this period may be 
 used in future scientific publications. I understand that I will not be identifiable from these 
images. 
5. I understand that relevant sections of any of my medical notes and data collected during 
the study, may be looked at by responsible individuals from the research team, from 
regulatory authorities or from the NHS Trust, where it is relevant to my taking part in this 
research.  I give permission for these individuals to have access to my records.   
6. I agree to my GP being informed of my participation in the study. 
7. I agree to take part in the above study. 
 
_________________________ _____________ ________________________ 
Name of Patient Date Signature 
_________________________ _____________ ________________________ 
Name of Person taking consent Date Signature 
(if different from researcher) 
 
_________________________ __________________________________ 
Researcher   Date  Signature 
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Participant Information Sheet – Study 2 
Study Title: Investigation of dermal metabolism in burned and unburned human skin 
You are being invited to take part in a research study.  Before you decide it is 
important for you to understand why the research is being done and what it will 
involve.  Please take time to read the following information carefully. Talk to others 
about the study if you wish.  
 
• Part 1 tells you the purpose of this study and what will happen to you if you take 
part.   
• Part 2 gives you more detailed information about the conduct of the study.  
 
Ask us if there is anything that is not clear or if you would like more information.  
Take time to decide whether or not you wish to take part. 
 
Part 1 
What is the purpose of the study? 
Background 
Burn injuries present the patient and the medical team with several problems. 
Small burn injuries cause localised problems in the injured area. A burn is an open 
wound which is prone to infection before it heals. Infection can cause the patient to 
become unwell. It also delays healing and makes scars worse. 
Extensive burns behave differently to small burns. In addition to the above problems, 
extensive burns can lead to swelling of the normal tissues as well as the burned skin 
itself.  This process can be life-threatening, but in surviving patients leads to further 
delays in healing, and can increase the area of the scar.  
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We know that patients whose wounds heal quickly are much less likely to suffer 
complications and will leave hospital sooner than those who take longer to heal. 
Research into the processes that occur in burn wounds is vital to our understanding of 
how these wounds heal. This will help us to identify ways in which we can improve 
treatment in order to improve healing, leading to lower infection and improved 
survival rates in large burns, and improvement in the long-term appearance of scars. 
Zones of injury 
A burn wound can be divided into three areas which behave differently. The central 
zone is permanently damaged, but there is a zone surrounding this which can heal or 
can turn into a permanently damaged area depending on various factors. The normal 
skin in small burns is assumed to be unaffected, but in larger burns the normal skin 
changes too. It is important that we study each of these zones of the burn to gain a 
better understanding of what factors improve the chances of healing. 
Microdialysis 
Microdialysis is the name of the process by which we can obtain a sample of fluid 
from the skin. The equipment is composed of a thin probe which contains a type of 
filter, similar to that found in a kidney dialysis machine. This is the part which is 
inserted into your skin. It is put in place using a needle which is then removed. The 
probe is connected by plastic tubing to a small pump which pumps very small 
amounts of sterile fluid through the probe. The fluid is collected in tiny plastic bottles 
(a small droplet every 10 minutes), which are then removed for analysis. 
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Why have I been chosen? 
We need to study twelve patients who have had a burn injury which is less than 15% 
of their body surface area. You have been chosen because you fit into this category, 
and because your burn was sustained within the last 5 hours. 
 
Do I have to take part? 
No. It is up to you to decide whether or not to take part. If you do, you will be given 
this information sheet to keep and be asked to sign a consent form. You are still free 
to withdraw at any time and without giving a reason.  
 
What will happen to me if I take part? 
If you agree to take part, you will have exactly the same treatment for your burn as if 
you did not take part. The only difference is that we will insert three probes into 
different areas of your burn wound to allow us to measure the changes in the skin 
from normal. 
The following sets out what will happen during this period: 
 
1. Local Anaesthetic Injection: A small injection will be given to you in two places 
around your burn. This is local anaesthetic to numb the area. This is the only part of 
the study which is uncomfortable. It means that you won’t feel the probes being put 
in. The centre of your burn doesn’t have any nerve fibres, so it is not necessary to 
have an injection here. 
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2. Cuff Inflation: A blood pressure cuff will be put on your arm or leg above the site 
of your burn. It will be inflated so it is tight for no longer than 3 minutes. This will 
help us to identify the correct areas of the burn in which the probes will be placed. 
3. Insertion of microdialysis probe: A microdialysis probe will be inserted into the 
numbed skin of your burn in three areas. A needle (similar to those used for drips in 
hospital) will be used to put the probe in place. The needle will be removed, but the 
probe remains in the skin. This is connected to a small pump (about the size of a 
mobile phone) which will be started immediately. Fluid is collected in a small plastic 
tube. These tubes will be changed every 30 minutes throughout the study and will be 
labelled for analysis. 
4. Your stay in hospital: Your treatment will continue as normal while you are in 
hospital, except that every 30 minutes we will disconnect the sample from the 
machine and connect a new collecting tube. This should not disturb you. You will 
receive standard dressings on your burn wound. These are the same as you would 
have received if you were not in the study. The equipment will not restrict you from 
moving around.  
5. Removal of probe: After 36 hours, the study will be complete and the probe will 
be removed. No further input will be required from you. If for any reason it becomes 
necessary for you to leave hospital before 36 hours is complete, we will remove the 
probe and stop the study early. 
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N.B. If you feel uncomfortable at any point, please inform one of the nursing staff. 
The study can be stopped at any time. If you change your mind at any point, you are 
free to do so. 
If you have any concerns following the procedure you are most welcome to contact us 
using the details below. 
 
Expenses and payments 
No payment will be made to you for your participation. 
 
What do I have to do? 
You will be admitted to the ward as usual. The Research Doctor will explain the 
procedures to you before doing anything. We would ask you not to interfere with the 
probes or equipment while they are attached to you, since some parts of the 
equipment are quite delicate. If they cause you any discomfort, please speak to a 
member of staff who will deal with the problem. You may walk around with the 
equipment, but please speak to a member of staff if you wish to leave the ward, or if 
you wish to take a shower. 
 
What is the drug, device or procedure that is being tested? 
 
Microdialysis is the name of the process by which we can obtain a sample of fluid 
from the skin. The equipment is composed of a thin probe which contains a type of 
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filter, similar to that found in a kidney dialysis machine. This is the part which is 
inserted into your skin. It is put in place using a needle which is then removed. The 
probe is connected by plastic tubing to a small pump which pumps very low volumes 
of sterile fluid through the probe. The fluid is collected in tiny plastic bottles (a small 
droplet every 30 minutes), which are then removed for analysis. 
 
What are the side effects of any treatment received when taking part? 
You are not being given any medication or treatment during this study. The needle 
placed in your arm is taking samples from your skin using a sterile solution to collect 
it. There is a small potential risk of having an allergy to the materials present in the 
needle, probe or tubing. 
 
What are the other possible disadvantages and risks of taking part? 
The needle, probe, tube and fluid are all sterile, and the skin is cleaned before the 
needle is inserted, however there is a very small risk of getting an infection from 
where the needle is inserted, as would be possible with any scratch. 
The local anaesthetic injection is in routine use in hospitals. It is usually used to numb 
the skin before a minor operation. There is a theoretical risk of allergy. 
The fluid in the pump is a sterile, neutral solution. It does not contain any drugs. 
There are no long-term risks from this study. 
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There is no reason to suspect that any part of this study could harm an unborn child. 
However the results we obtain from your skin could be different if you are pregnant. 
If you know you are pregnant, we will not perform the study on you at this time. If 
you find out later that you were pregnant at the time of the study, there is no need for 
concern, however please contact us so that we can adjust our results if necessary. 
 
What are the possible benefits of taking part? 
There are no direct benefits to you in taking part. We hope that as a result of this 
study, there may be benefits to burns patients in the future. 
 
What happens when the research study stops? 
You will not be required to have any more participation after the day you attend. 
However, if you wish to receive information on how the study is progressing or 
details of any scientific publications, then please inform us and we will send you a 
summary sheet at the end of the study period. 
 
What if there is a problem? 
Any complaint about the way you have been dealt with during the study or any 
possible harm you might suffer will be addressed. The detailed information on this is 
given in Part 2. 
 
 249 
Will my taking part in the study be kept confidential?  
Yes. All the information about your participation in this study will be kept 
confidential.  The details are included in Part 2. 
 
Contact Details: 
Elly Breuning 
Burns Research Fellow 
Tissue Services 
Burns Unit 
Selly Oak Hospital 
Raddlebarn Road 
Birmingham 
B29 6JD 
 
Tel: 0121 627 8718 (office hours) 
Tel: 0121 6271627 ask for Elly Breuning (out-of-hours, emergency only) 
 
This completes Part 1 of the Information Sheet. 
If the information in Part 1 has interested you and you are considering 
participation, please continue to read the additional information in Part 2 before 
making any decision. 
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Part 2 
 
What will happen if I don’t want to carry on with the study? 
You can withdraw from the study at any time. Information and samples we have 
already collected may still be used unless you specifically request that they are not. 
 
What if there is a problem? 
If you have a concern about any aspect of this study, you should ask to speak with the 
researchers who will do their best to answer your questions. If you remain unhappy 
and wish to complain formally, you can do this through the NHS Complaints 
Procedure. Details can be obtained from the hospital. 
 
Harm 
In the event that something does go wrong and you are harmed during the research 
study there are no special compensation arrangements.  If you are harmed and this is 
due to someone’s negligence then you may have grounds for a legal action for 
compensation against University Hospital Birmingham NHS Foundation Trust NHS 
Trust, but you may have to pay your legal costs. The normal National Health Service 
complaints mechanisms will still be available to you.  
 
Will my taking part in this study be kept confidential? 
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When you are enrolled into the trial, you will be given a unique code number. Your 
data will be stored in a booklet identified with this code. Details of your name, 
address and contact details will be kept separately in case we need to contact you for 
any reason. The contact details will be kept securely and only the researchers and the 
hospital Research and Development office will have access.  
All information which is collected about you during the course of the research will be 
kept strictly confidential.  Any information about you which leaves the hospital will 
have your name and address removed so that you cannot be recognised from it. 
Procedures for handling, processing, storage and destruction of their data are 
compliant with the Data Protection Act 1998. 
 
Involvement of the General Practitioner/Family doctor (GP)  
A letter will be sent to your GP to inform them that you are taking part in this study. 
 
What will happen to any samples I give? 
The microdialysis samples taken from you during this study will be stored and tested 
in the laboratories at University Hospital Birmingham and at the University of 
Birmingham. All samples will be stored with an identification code with no direct 
reference to your details. Samples will be kept for up to 10 years following 
completion of the study to allow results to be checked and re-analysed if necessary. 
Samples will then be destroyed. 
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Will any genetic tests be done?   
No genetic tests will be done in this study. 
 
What will happen to the results of the research study? 
Results of the study will be published in a scientific journal. You will not be 
identifiable from these results. 
 
Who is organising and funding the research? 
The study is sponsored by University Hospital Birmingham Foundation NHS Trust. 
Funding is being sought from burns charities and medical research charities. 
 
Who has reviewed the study? 
This study has been reviewed by the Dudley Research Ethics Committee and has been 
given a favourable ethical opinion for conduct in the NHS. 
 
You will be given a copy of this information sheet and a copy of the signed consent 
form to keep. 
 
Thank you for taking the time to read this sheet and considering taking part in 
the study. 
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Appendix B: Raw data for calibration experiments 
Table A1: Raw data for glucose in calibration experiments (mmol/l) 
 Group A B C D E 
 
Storage 
temperature  
Freezer, 
-80oC 
Fridge,  
2-5oC 
Room,  
22oC 
Freezer, -
80oC 
Freezer, -
80oC 
 Volume Medium Medium Medium High Low 
Day Sample      
1 a 6.10 6.67 5.99 6.00 5.79 
 b 5.83 5.80 5.97 6.14 5.97 
 c 6.03 5.77 5.84 5.77 6.07 
2 a 6.25 5.69 5.53 5.54 5.72 
 b 5.85 5.93 5.57 5.65 5.93 
 c 5.77 5.35 5.59 5.42 5.74 
3 a 5.66 5.54 5.54 5.74 5.82 
 b 5.64 5.52 5.42 6.01 6.23 
 c 5.53 5.44 5.40 5.93 6.22 
       
1 Ave (a,b,c) 5.99 6.08 5.93 5.97 5.94 
2 Ave (a,b,c) 5.96 5.66 5.56 5.54 5.80 
3 Ave (a,b,c) 5.61 5.50 5.45 5.89 6.09 
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Table A2: Raw data for lactate in calibration experiments (mmol/l) 
 Group A B C D E 
 
Storage 
temperature 
Freezer, 
-80oC 
Fridge,  
2-5oC 
Room,  
22oC 
Freezer, -
80oC 
Freezer, -
80oC 
 Volume Medium Medium Medium High Low 
Day Sample      
1 a 2.79 2.88 2.84 2.80 3.89 
 b 2.64 2.61 2.70 2.73 2.78 
 c 2.73 2.68 2.66 2.73 2.79 
2 a 2.59 2.52 2.50 2.76 2.72 
 b 2.52 2.70 2.55 2.63 2.56 
 c 2.56 2.59 2.59 2.63 2.65 
3 a 2.70 2.55 2.52 2.63 2.60 
 b 2.75 2.54 2.57 2.67 2.72 
 c 2.70 2.51 2.50 2.64 2.81 
       
1 Ave (a,b,c) 2.72 2.72 2.73 2.75 3.15 
2 Ave (a,b,c) 2.56 2.60 2.55 2.67 2.64 
3 Ave (a,b,c) 2.72 2.53 2.53 2.65 2.71 
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Table A3: Raw data for pyruvate in calibration experiments (µmol/l) 
 
 Group A B C D E 
 
Storage 
temperature  
Freezer, 
-80oC 
Fridge,  
2-5oC 
Room,  
22oC 
Freezer, -
80oC 
Freezer, -
80oC 
 Volume Medium Medium Medium High Low 
Day Sample      
1 a 240 235 248 235 244 
 b 235 228 250 232 252 
 c 225 235 240 232 249 
2 a 238 239 244 259 248 
 b 252 256 237 247 248 
 c 250 236 245 244 253 
3 a 230 233 234 246 238 
 b 222 222 213 241 247 
 c 223 222 216 235 249 
       
1 Ave (a,b,c) 233 233 246 233 248 
2 Ave (a,b,c) 247 244 242 250 250 
3 Ave (a,b,c) 225 226 221 241 245 
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Table A4: Raw data for glycerol in calibration experiments (µmol/l) 
 
 Group A B C D E 
 
Storage 
temperature  
Freezer, 
-80oC 
Fridge,  
2-5oC 
Room,  
22oC 
Freezer, -
80oC 
Freezer, -
80oC 
 Volume Medium Medium Medium High Low 
Day Sample      
1 a 475 471 483 486 493 
 b 452 463 478 489 496 
 c 466 468 480 468 485 
2 a 483 469 469 497 509 
 b 480 462 463 478 484 
 c 495 458 459 474 475 
3 a 458 454 451 480 508 
 b 457 442 442 473 506 
 c 463 458 441 468 517 
       
1 Ave (a,b,c) 464 467 480 481 491 
2 Ave (a,b,c) 486 463 464 483 489 
3 Ave (a,b,c) 459 451 445 474 510 
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Table A5: Raw data for urea in calibration experiments (mmol/l) 
 Group A B C D E 
 
Storage 
temperature  
Freezer, 
-80oC 
Fridge,  
2-5oC 
Room,  
22oC 
Freezer, -
80oC 
Freezer, -
80oC 
 Volume Medium Medium Medium High Low 
Day Sample      
1 a 14.0 13.9 13.8 12.8 14.1 
 b 13.8 14.1 14.2 13.8 14.5 
 c 13.9 14.3 14.0 13.6 14.4 
2 a 13.9 13.8 13.7 14.1 14.4 
 b 13.9 13.6 13.6 14.0 14.7 
 c 14.1 13.7 13.8 14.2 14.9 
3 a 14.2 13.8 13.8 13.0 14.2 
 b 14.7 13.8 13.7 12.5 14.4 
 c 14.3 13.9 13.6 13.8 14.6 
       
1 Ave (a,b,c) 13.9 14.1 14.0 13.4 14.3 
2 Ave (a,b,c) 14.0 13.7 13.7 14.1 14.7 
3 Ave (a,b,c) 14.4 13.8 13.7 13.1 14.4 
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Appendix B: Raw Data for Study 1 
 
Table A6: Glucose results (mmol/l) for calibration fluid (C1, C2) and 
microdialysis of calibration fluid at the start (01,02) and end (12,13) of the study 
 
Volunteer 
number 
C1 01 02 %recovery 1 
(02/C01) 
12 13 C2 % recovery 2 
(13/C02) 
NV02 5.48 1.83 3.42 62% 5.97 3.22 5.82 55% 
NV03 5.83 3.87 6.12 105% 7.30 6.00 5.63 107% 
NV04 5.91 4.08 6.37 108% 6.64 6.26 6.07 103% 
NV05 6 0.90 7.15 119% 6.40 6.76 5.70 119% 
NV06 5.59 2.12   4.87 5.22 5.59 93% 
NV07 5.76 3.54 5.40 94%   5.24  
NV08 5.44 3.35 5.52 101% 4.83 5.69 5.50 104% 
NV09 5.66 4.78 6.51 115% 5.49 6.02 5.86 103% 
NV10 5.32 4.12 5.55 104% 6.17 5.50 5.49 100% 
NV11 6.00 6.02 5.96 99%   5.67  
 259 
Table A7: Lactate results (mmol/l) for calibration fluid (C1, C2) and 
microdialysis of calibration fluid at the start (01,02) and end (12,13) of the study 
 
Volunteer 
number 
C1 01 02 %recovery 1 
(02/C01) 
12 13 C2 %recovery 2 
(13/C02) 
NV02 2.41 1.02 1.78 74% 2.67 2.48 2.61 95% 
NV03 2.76 2.01 2.80 102% 3.20 3.04 2.58 118% 
NV04 2.73 2.13 3.07 113% 3.15 2.90 2.84 102% 
NV05 2.75 0.49 3.44 125% 3.64 3.01 2.76 109% 
NV06 2.77 1.10   4.43 3.37 2.62 128% 
NV07 2.23 1.55 2.22 100%   2.10  
NV08 2.19 1.45 2.21 101% 2.63 2.16 2.14 101% 
NV09 2.09 2.20 2.90 139% 2.60 2.58 2.48 104% 
NV10 2.35 2.09 2.43 103% 3.02 2.88 2.33 124% 
NV11 2.32 2.39 2.35 101%   2.25  
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Table A8: Pyruvate results (µmol/l) for calibration fluid (C1, C2) and 
microdialysis of calibration fluid at the start (01,02) and end (12,13) of the study 
 
Volunteer 
number 
C1 01 02 %recovery 1 
(02/C01) 
12 13 C2 %recovery 2 
(13/C02) 
NV02 226 102 167 74% 202 234 245 96% 
NV03 258 178 268 104% 250 275 246 119% 
NV04 259 198 288 112% 234 286 260 110% 
NV05 259 42 333 129% 258 289 258 112% 
NV06 257 104   272 304 242 126% 
NV07 245 141 222 91%   225  
NV08 232 154 242 105% 230 239 227 105% 
NV09 228 199 274 120% 222 249 232 108% 
NV10 230 183 240 104% 222 243 228 106% 
NV11 238 252 245 103%   230  
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Table A9: Glycerol results (µmol/l) for calibration fluid (C1, C2) and 
microdialysis of calibration fluid at the start (01,02) and end (12,13) of the study 
 
Volunteer 
number 
C1 01 02 %recovery 1 
(02/C01) 
12 13 C2 %recovery 2 
(13/C02) 
NV02 481 200 319 66% 252 495 524 94% 
NV03 511 328 511 100% 318 534 460 116% 
NV04 499 376 541 109% 382 736 513 144% 
NV05 540 93 662 123% 354 599 548 109% 
NV06 497 225   330 609 480 127% 
NV07 485 333 449 93%   457  
NV08 465 300 485 104% 280 484 456 106% 
NV09 452 388 538 119% 700 750 462 163% 
NV10 459 366 464 101% 408 706 456 155% 
NV11 499 532 517 103%   490  
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Table A10: Glucose results (mmol/l) for the equilibration period (03, 04, 05) and 
study period 1 (06,07) 
 
Volunteer 
number 
03 04 05 06 07 
NV02 5.97 5.96 6.30 7.33 6.41 
NV03 6.17 6.43 6.18 5.98 6.42 
NV04  *  * 1.27 2.77 6.07 
NV05 *0.01 7.19 6.20 6.52 5.71 
NV06 6.12 4.26 3.33 3.16 4.35 
NV07 5.37 *0.02 1.79 2.59 5.40 
NV08 4.77 4.41 5.52 5.97 5.02 
NV09 8.33 8.23 7.43 7.47 6.04 
NV10 5.81 7.25 6.15 5.53 5.70 
NV11 * * 2.41 5.14 5.82 
* Anomalous result, and below detection limit of analyser. Due to an air bubble in the 
microdialysis system, the collecting vial is underfilled, and there is insufficient 
sample for accurate analysis.  
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Table A11: Lactate results (mmol/l) for the equilibration period (03, 04, 05) and 
study period 1 (06,07) 
 
Volunteer 
number 
03 04 05 06 07 
NV02 2.19 1.48 1.82 3.00 3.14 
NV03 2.33 1.65 1.71 2.08 2.84 
NV04  *  * 0.38 0.92 1.91 
NV05 *0.02 3.09 2.48 2.73 3.60 
NV06 2.76 2.95 4.02 4.58 5.03 
NV07 2.30  * 0.67 1.06 1.28 
NV08 1.55 1.02 1.59 2.39 2.65 
NV09 2.24 1.84 1.98 2.45 2.64 
NV10 2.02 2.35 3.29 3.51 3.49 
NV11 * * 1.44 2.22 3.52 
 
* Anomalous result, and below detection limit of analyser. Due to an air bubble in the 
microdialysis system, the collecting vial is underfilled, and there is insufficient 
sample for accurate analysis.  
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Table A12: Pyruvate results (µmol/l) for the equilibration period (03, 04, 05) and 
study period 1 (06,07) 
 
Volunteer 
number 
03 04 05 06 07 
NV02 206 147 168 239 215 
NV03 185 160 148 173 213 
NV04  *  * 31 59 112 
NV05  * 275 176 180 220 
NV06 248 184 226 254 326 
NV07 238  * 58 91 57 
NV08 172 101 150 203 199 
NV09 215 209 234 278 268 
NV10 200 217 267 248 218 
NV11 * * 84 158 217 
* Anomalous result, and below detection limit of analyser. Due to an air bubble in the 
microdialysis system, the collecting vial is underfilled, and there is insufficient 
sample for accurate analysis.  
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Table A13: Glycerol results (µmol/l) for the equilibration period (03, 04, 05) and 
study period 1 (06,07) 
 
Volunteer 
number 
03 04 05 06 07 
NV02 275 36 25 22 27 
NV03 191 66 87 113 138 
NV04  *  * 86 219 397 
NV05  * 299 48 54 57 
NV06 409 93 146 156 124 
NV07 197  * 23 11 4 
NV08 240 44 62 67 70 
NV09 194 73 74 84 94 
NV10 278 39 39 38 39 
NV11 * * 48 30 37 
* Anomalous result, and below detection limit of analyser. Due to an air bubble in the 
microdialysis system, the collecting vial is underfilled, and there is insufficient 
sample for accurate analysis.  
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Table A14: Lactate/Pyruvate ratio (LPR) calculations for the equilibration 
period (03, 04, 05) and study period 1 (06,07). Missing values where source data 
for either lactate or pyruvate was erroneous or missing 
 
Volunteer 
number 
03 04 05 06 07 
NV02 12.6 10.3 11.5 12.0 13.4 
NV03  *  * 12.2 15.5 17.0 
NV04  * 11.2 14.1 15.2 16.4 
NV05 11.1 16.1 17.8 18.0 15.4 
NV06 9.7 * 11.5 11.7 22.5 
NV07 9.0 10.1 10.6 11.7 13.3 
NV08 10.4 8.8 8.5 8.8 9.9 
NV09 10.1 10.8 12.3 14.2 16.0 
NV10 * * 17.1 14.1 16.2 
NV11 12.6 10.3 11.5 12.0 13.4 
 
* Anomalous results in lactate and pyruvate data, preventing calculation of LPR  
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Table A15: Glucose results (mmol/l) for the study period 1(06,07) and study 
period 2 (08,09) and study period 3 (10,11) 
 
Volunteer 
number 
06 07 08 09 10 11 
 
NV02 7.33 6.41 5.34 5.80 5.67 6.09 
NV03 5.98 6.42 7.02 *0.01 6.42 6.87 
NV04 2.77 6.07 8.12 8.66 9.10 8.42 
NV05 6.52 5.71 5.84 5.23 7.10 5.97 
NV06 3.16 4.35 6.54 6.14 4.87 5.22 
NV07 2.59 5.40 5.78 6.18 6.10 4.94 
NV08 5.97 5.02 1.20 4.82 4.19 3.97 
NV09 7.47 6.04 5.44 6.57 5.83 5.81 
NV10 5.53 5.70 4.96 4.37 4.69 6.28 
NV11 5.14 5.82 *0.42 5.84 4.86 5.25 
* Anomalous result. Due to an air bubble in the microdialysis system, the collecting 
vial is underfilled, and there is insufficient sample for accurate analysis.  
 
 
 
 268 
Table A16: Lactate results (mmol/l) for the study period 1(06,07) and study 
period 2 (08,09) and study period 3 (10,11) 
 
Volunteer 
number 
06 07 08 09 10 11 
 
NV02 3.00 3.14 3.36 3.34 3.28 2.99 
NV03 2.08 2.84 3.31  * 3.64 3.66 
NV04 0.92 1.91 2.17 2.82 3.37 3.8 
NV05 2.73 3.60 4.19 3.88 *0.79 4.45 
NV06 4.58 5.03 6.12 5.77 5.53 6.11 
NV07 1.06 1.28 2.17 2.29 1.77 1.33 
NV08 2.39 2.65 *0.67 3.10 3.24 3.14 
NV09 2.45 2.64 2.44 2.55 2.02 2.75 
NV10 3.51 3.49 3.27 2.58 2.25 2.53 
NV11 2.22 3.52 *0.32 3.95 3.45 2.87 
* Anomalous result, and below detection limit of analyser. Due to an air bubble in the 
microdialysis system, the collecting vial is underfilled, and there is insufficient 
sample for accurate analysis.  
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Table A17: Pyruvate results (µmol/l) for the study period 1(06,07) and study 
period 2 (08,09) and study period 3 (10,11) 
Volunteer 
number 
06 07 08 09 10 11 
 
NV02 239 215 207 191 163 146 
NV03 173 213 243  * 246 236 
NV04 59 112 122 165 178 166 
NV05 180 220 229 204 *13 255 
NV06 254 326 406 331 266 265 
NV07 91 57 165 167 146 122 
NV08 203 199 *2 211 225 203 
NV09 278 268 239 236 197 206 
NV10 248 218 187 136 120 168 
NV11 158 217 *16 223 212 180 
 
* Anomalous result, and below detection limit of analyser. Due to an air bubble in the 
microdialysis system, the collecting vial is underfilled, and there is insufficient 
sample for accurate analysis.  
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Table A18: Glycerol results (µmol/l) for the study period 1(06,07) and study 
period 2 (08,09) and study period 3 (10,11) 
 
Volunteer 
number 
06 07 08 09 10 11 
 
NV02 22 27 38 29 30 31 
NV03 113 138 140  * 95 87 
NV04 219 397 299 160 118 139 
NV05 54 57 *6 60 *5 62 
NV06 156 124 136 126 110 120 
NV07 11 4 14 14 13 17 
NV08 67 70  * 80 74 95 
NV09 84 94 95 101 102 113 
NV10 38 39 45 39 41 45 
NV11 30 37 *3 29 48 46 
 
* Anomalous result, and below detection limit of analyser. Due to an air bubble in the 
microdialysis system, the collecting vial is underfilled, and there is insufficient 
sample for accurate analysis.  
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Table A19: Lactate/Pyruvate ratio (LPR) calculations for the study period 1 
(06,07), study period 2 (08,09) and study period 3 (10,11). Missing values where 
source data for either lactate or pyruvate was erroneous or missing 
 
Volunteer 
number 
06 07 08 09 10 11 
 
NV02 12.5 14.6 16.2 17.5 20.1 20.5 
NV03 12.0 13.4 13.6 * 14.8 15.5 
NV04 15.5 17.0 17.9 17.1 18.9 22.9 
NV05 15.2 16.4 18.3 19.0 *63.1 17.5 
NV06 18.0 15.4 15.1 17.4 20.8 23.1 
NV07 11.7 22.5 13.2 13.7 12.2 10.9 
NV08 11.7 13.3 * 14.7 14.4 15.5 
NV09 8.8 9.9 10.2 10.8 10.3 13.4 
NV10 14.2 16.0 17.5 19.0 18.7 15.0 
NV11 14.1 16.2 *20.4 17.7 16.3 15.9 
* Anomalous results in lactate and pyruvate data, preventing accurate calculation 
of LPR 
 272 
Appendix C: Raw data for Study 2 
 
TABLE A20: Missing Results, and labeling errors. Reasons for missing data are 
noted, together with the original value attributed to that data point, where applicable. 
‘Empty sample’ refers to the finding of no microdialysate within the sample vial at 
the end of the sampling period. These samples were not put through the analyser. 
‘Blood in sample’ refers to a sample contaminated with blood, presumed to be due to 
damage to the membrane during insertion. These samples were not put through the 
analyser to avoid potential damage to the analyzing equipment, and because the 
results were assumed to be invalidated by the presence of metabolically active cells 
within the sample. 
Patient 
Time 
post-
burn 
(h) 
Sample 
number 
Substance 
not 
analysed 
Original 
Value 
Reason for  
missing result 
S01 10 A01 Glu,L,P,Gly n/a Empty sample 
S01 10.5 A02 Glu,L,P,Gly n/a Empty sample 
S01 11 A03 Glu,L,P,Gly n/a Empty sample 
S01 11.5 A04 Glu,L,P,Gly n/a Empty sample 
S01 12 A05 Glu,L,P,Gly n/a Empty sample 
S01 12.5 A06 Glu,L,P,Gly n/a Empty sample 
S01 13 A07 Glu,L,P,Gly n/a Empty sample 
S01 18 B17 Glu,L,P,Gly n/a Empty sample 
S01 10 C01 Glu,L,P,Gly n/a Empty sample 
S01 10.5 C02 L 0.008 Empty sample 
   Glu,P,Gly n/a  
S01 11 C03 L 0.009 Empty sample 
   Glu,P,Gly n/a  
S01 11.5 C04 Glu,L,P,Gly n/a Empty sample 
S01 12.0 C05 Glu,L,P,Gly n/a Empty sample 
S01 28.0 C37 Glu,L,P,Gly n/a Empty sample 
S02 
  
B47 
 Glu.L.P.Gly  
Mislabeled as 10:15.  
Should be 09:45 
S02 16.0 C19 Glu,L,P,Gly n/a Empty vial 
S03 7.5 A01 Glu.L.P.Gly n/a Blood in sample 
 8 A02 Glu.L.P.Gly n/a Blood in sample 
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 8.5 A03 Glu.L.P.Gly n/a Blood in sample 
 9 A04 Glu.L.P.Gly n/a Blood in sample 
 9.5 A05 Glu.L.P.Gly n/a Blood in sample 
 10 A06 Glu.L.P.Gly n/a Blood in sample 
  A55-59  Glu,L,P,Gly  
Mislabelled as 27/1/7.  
Shd be 28/1/7 
 7.5 C01 Glu,L,P,Gly n/a Blood in sample 
 8 C02 Glu,L,P,Gly n/a Blood in sample 
 8.5 C03 Glu,L,P,Gly n/a Blood in sample 
 9 C04 Glu,L,P,Gly n/a Blood in sample 
 9.5 C05 Glu,L,P,Gly n/a Blood in sample 
 10 C06 Glu,L,P,Gly n/a Blood in sample 
 10.5 C07 Glu,L,P,Gly n/a Blood in sample 
 11 C08 Glu,L,P,Gly n/a Blood in sample 
 11.5 C09 Glu,L,P,Gly n/a Blood in sample 
 12 C10 Glu,L,P,Gly n/a Blood in sample 
 12.5 C11 Glu,L,P,Gly n/a Blood in sample 
 13 C12 Glu,L,P,Gly n/a Blood in sample 
 13.5 C13 Glu,L,P,Gly n/a Blood in sample 
 14 C14 Glu,L,P,Gly n/a Blood in sample 
 14.5 C15 Glu,L,P,Gly n/a Blood in sample 
 15 C16 Glu,L,P,Gly n/a Blood in sample 
 19 C24 Glu,L,P,Gly n/a Empty sample 
 19.5 C25 Glu,L,P,Gly n/a Empty sample 
 20 C26 Glu,L,P,Gly n/a Empty sample 
 20.5 C27 Glu,L,P,Gly n/a Empty sample 
 
22.5-
36.5 
 
C31-59 
 
 
Glu,L,P,Gly n/a 
Probe pulled out and  
replaced. 
All further vials empty 
S04 23.5 B30 Glu,L,P,Gly n/a missing sample point   
S05 
 
32.5 
 
A53 
 Glu,L,P,Gly 
n/a 
 
Mislabeled as 14/4/7. 
Shd be 5/4/7 
 32.5  
B53 
 Glu,L,P,Gly 
n/a 
 
Mislabeled as13/4/7  
Shd be 5/4/7 
 6.5 C01 Glu,L,P,Gly n/a Blood in sample 
 7 C02 Glu,L,P,Gly n/a Blood in sample 
 7.5 C03 Glu,L,P,Gly n/a Blood in sample 
 8 C04 Glu,L,P,Gly n/a Blood in sample 
 21.5 C31 Glu,L,P,Gly n/a Blood in sample 
 22 C32 Glu,L,P,Gly n/a Blood in sample 
 22.5 C33 Glu,L,P,Gly n/a Blood in sample 
 23 C34 Glu,L,P,Gly n/a Blood in sample 
 23.5 C35 Glu,L,P,Gly n/a Blood in sample 
 24 C36 Glu,L,P,Gly n/a Blood in sample 
 24.5 C37 Glu,L,P,Gly n/a Blood in sample 
 25 C38 Glu,L,P,Gly n/a Blood in sample 
 25.5 C39 Glu,L,P,Gly n/a Blood in sample 
 26 C40 Glu,L,P,Gly n/a Blood in sample 
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 28  
C44 
 Gly 
n/a 
 
Insufficient sample for  
Gly analysis 
 30.5 C49 Glu,L,P,Gly n/a Blood in sample 
 31  
C50 
 Glu,L,P,Gly 
n/a 
 
Mislabeled as 15/4/7. 
Shd be 5/4/7 
 31.5 C51 Glu,L,P,Gly n/a Blood in sample 
 32 C52 Glu,L,P,Gly n/a Blood in sample 
 32.5 C53 Glu,L,P,Gly n/a Blood in sample 
 33 C54 Glu,L,P,Gly n/a Blood in sample 
      
S06 34 A44 Glu,L,P,Gly n/a Insufficient for analysis 
 34.5 A45 Glu,L,P,Gly n/a Empty sample 
 35 A46 Glu,L,P,Gly n/a Empty sample 
 35.5 A47 Glu,L,P,Gly n/a Empty sample 
 36 A48 Glu,L,P,Gly n/a Empty sample 
 29 C34 Glu,L,P,Gly n/a Empty sample 
 29.5 C35 Glu,L,P,Gly n/a Empty sample 
 30 C36 Glu,L,P,Gly n/a Empty sample 
  C37 Glu,L,P,Gly  Mislabelled as 08:00 Shd be 06:00 
 31 C38 Glu,L,P,Gly n/a Empty sample 
 31.5 C39 Glu,L,P,Gly n/a Empty sample 
 32 C40 Glu,L,P,Gly n/a Empty sample 
 32.5 C41 Glu,L,P,Gly n/a Empty sample 
 33 C42 Glu,L,P,Gly n/a Empty sample 
  C43 Glu,L,P,Gly  Mislabelled as 14:00  Shd be 09:00 
 34 C44 Glu,L,P,Gly n/a Empty sample 
  C45 Glu,L,P,Gly  Mislabelled as 16:00 Shd be 10:00 
 35 C46 Glu,L,P,Gly n/a Empty sample 
 35.5 C47 Glu,L,P,Gly n/a Empty sample 
 36 C48 Glu,L,P,Gly n/a Empty sample 
  B59 Glu,L,P,Gly n/a No sample 
  C1-59 Glu,L,P,Gly n/a 
Blood in initial sample 
Then all remaining C’s 
empty 
 15.5 C17 L n/a ?Insufficient for analysis 
 16 C18 L n/a ?Insufficient for analysis 
 16.5 C19 L n/a ?Insufficient for analysis 
S07 17 C20 Glc,L n/a ?Insufficient for analysis 
 17.5 C21 Glu,L,P n/a ?Insufficient for analysis 
S08 18-36 C22-57 Glu,L,P,Gly n/a 
Study concluded early 
due to  
excision of burn in 
theatre 
S09 
 
15.0 
 
A16a 
 Glu,L,P,Gly - 
Sample point missed,  
but numbering continues 
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  B16a Glu,L,P,Gly - Sample point missed,  but numbering continues 
  C16a Glu,L,P,Gly - Sample point missed,  but numbering continues 
  C24-30 Glu,L,P,Gly  
Tubing cut whilst 
removing 
 dressings in theatre. 
 Probe replaced at C30 
S10 21.5 A25 Glu,L,P,Gly n/a Empty sample 
 29.5  
A41 
 Glu 
12.16453
4 
 
Exchanged with C vial. 
Values reversed 
   L 4  
   P 338.613  
   Gly 116.666  
  A43-48 Glu,L,P,Gly n/a Empty sample 
      
  A53-55 L n/a No lactate result ?why 
  B01 Glu,L,P,Gly n/a Empty sample 
      
      
      
      
  B43-48 Glu,L,P,Gly  Empty samples 
  B50 Glu,L,P,Gly n/a Empty sample 
 20.5 C23 Glu,L,P,Gly n/a Empty sample 
 21.5 C25 Glu,L,P,Gly n/a Empty sample 
 29.5 C41 Glu 4.442825 
C and A samples noted 
to be in wrong trays. 
Numbers exchanged 
   L 3.909  
   P 193.059  
   Gly 93.713  
  C43-48 Glu,L,P,Gly n/a Empty samples 
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TABLE A21: Anomalous Results. Reasons for anomaly are noted, together with the 
original value.  
Patient Time post-
burn (h) 
Sampl
e 
numb
er 
Analy
te 
Original 
Value 
Changes 
made 
Reason for  
inaccurate result 
S01 25.0 A31 Glu 2.318 None v minimal sample 
   L 0.202   
   P 41.708   
   Gly 20.703   
   U 3.574   
S01 25.5 A32 Glu 0.997 None v minimal sample 
   L 0.344   
   P 34.056   
   Gly 23.855   
   U n/a   
S01 26.0 A33 Glu 0.786 None v minimal sample 
   L 0.343   
   P 30.949   
   Gly 20.805   
   U 0.528  Under detection limit 
S01 26.5 A34 Glu 0.850 None v minimal sample 
   L 0.321   
   P 19.784   
   Gly 11.185   
   U 0.272  Under detection limit 
S01 17.5 B16 Glu 1.995 None v minimal sample 
   L 0.812   
   P 51.565   
   Gly 15.911   
   U n/a   
S05 20.5 C29 Gly 7.533  Under detection limit 
   U 3.949   
 21 C30 Gly 7.540  Under detection limit 
   U n/a   
 27 C42 Gly 2.407  Under detection limit 
   U n/a   
 27.5 C43 Gly 3.667  Under detection limit 
   U n/a   
 28.5 C45 Gly 9.105  Under detection limit 
   U n/a   
 30 C48 Gly 8.429  Under detection limit 
   U 3.347   
S06 29.0 A34 Glu 0.035  V minimal sample 
   L 0.064   
   P n/a   
   Gly 3.727   
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   U n/a   
 33 A42 Glu 0.034 None V minimal sample 
   L .040   
   P n/a   
   Gly 65.038   
   U n/a   
 30 C37 Glu 4.830 30h Wrongly attributed to 31h post burn 
       
  C43 Glu 6.353 33h Wrongly attributed to 37h 
  C45 Glu 1.394 34h Wrongly attributed to 39h 
S09 8.0 A03 Glu 0.873  minimal sample 
   L 0.212   
   P 24.445   
   Gly 54.998   
   U n/a   
 9.0 A05 Glu 1.753  virtually empty   
   L 0.442   
   P 16.232   
   Gly 5.440  Under detection limit 
   U n/a   
 10.0 A07 Glucose 
2.342  minimal sample 
   L 0.927   
   P 45.683   
   Gly 46.530   
   U n/a   
 12.0 A11 P 54.591  Minimal sample 
   Gly 33.760   
   U 1.244   
 13.0 A13 P 76.352  Minimal sample 
   Gly 51.302   
   U n/a   
 14.0 A15 Glu 2.549  v minimal sample 
   L 0.359   
   P 66.539   
   Gly 23.128   
   U n/a   
 14.5 A16 Glu 1.861  minimal sample 
   L 1.113   
   P 81.118   
   Gly 53.428   
   U n/a   
 15.0 
A16a 
Glu,L,
P,Gly,
U 
- 
 
Sample point missed,  
but numbering 
continues 
 16.0 A18 Glu 0.632  V minimal sample 
   L 0.652   
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   P 45.913   
   Gly 15.140   
   U n/a   
 16.5 A19 P 75.428  Minimal sample 
   Gly 18.976   
   U n/a   
 17.0 A20 L,P,G
ly 
  Minimal samples,  but results left 
   U n/a   
 17.5 A21 L,P,Gly 
  Minimal samples,  
   U n/a  but results left 
 8.0 B03 Glu 1.065  V minimal sample 
   L 0.319   
   P 15.827   
   Gly 13.671   
   U n/a   
 15.0 
B16a 
Glu,L,
P,Gly 
- 
 
Sample point missed,  
but numbering 
continues 
 16.0 B18 L 1.857  V minimal sample 
   P 36.436   
   Gly 18.156   
   Urea n/a   
 23.5 B33 P 47.131  Low sample 
   Gly 27.155   
   U n/a   
 28.0 B42 L 0.732  ?Air bubble on lact analysis 
 15.0 
C16a 
Glu,L,
P,Gly 
- 
 
Sample point missed,  
but numbering 
continues 
S10 14.0 A10 L 1.704  Minimal sample 
   P 31.071   
   Gly 79.256   
   U 1.636   
 29.5 A41 Glu 12.165 4.443 A&C Sample vials swapped 
   L 4.000 3.909 (LPR 11.811 = 20.249) 
   P 338.600 193.100  
   Gly 116.700 93.710  
   U 6.053 6.808  
 33.5-> A49, 
A51-
55 
Glu,L,
P,Gly,
U 
 
 
Very full  
(no changes made to 
results) 
 35.5-> A53-
55 
L n/a  No lactate result ?why 
 14.0 B10 Glu 1.356  V minimal sample 
   L 2.169   
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   P 17.576   
   Gly 27.288   
   U 11.030   
 14.5 
B11 
Glu,L,
P,Gly, 
U 
 
 
Minimal sample  
(no changes made to 
results) 
 15.0 
B12 
Glu 1.503 
unchanged 
V minimal sample 
(no changes made to 
L,P,Gly) 
   U n/a   
 26.5 B35 L,Gly   Low vol sample (?gly and p affected) 
   U n/a   
 28.5 B39 Glu 0.136  v minimal sample 
   L 2.703   
   P 106.697   
   Gly 42.010   
   U n/a   
 33.5 B49 Glu 1.685  Very full therefore dilute 
   L 2.546  ? pump malfunction 
   P 102.832   
   Gly 32.976   
   U 3.836   
 14.0 C10 L 2.664  Low volume sample 
   P 69.297   
   Gly 98.976   
   U n/a   
 17.5 C17 Glu 3.126 None v full sample:  
   L 1.504  likely pump malfunction 
   P 154.371   
   Gly 74.059   
   U 5.200   
 28.5 C39 P 20.248  Minimal sample 
   Gly 39.797   
   U n/a   
 29.5 C41 Glu 4.443 12.165 C and A samples in wrong trays. 
   L 3.909 4.000  
   P 193.059 338.600  
   Gly 93.713 116.700  
   U 6.808 6.053  
 
 
 
 280 
REFERENCES 
1.  History of treatment of burns. In: Herndon DN, editors. Total Burn Care. 
Galveston, USA: Saunders; 2006. p. 1-6. 
2. BULL JP, FISHER AJ. A study of mortality in a burns unit: A revised estimate. 
Ann Surg 1954, Mar;139(3):269-74. 
3. Bull JP. Revised analysis of mortality due to burns. The Lancet 
1971;298(7734):1133-4. 
4. Herndon DN, Gore D, Cole M, Desai MH, Linares H, Abston S, et al. Determinants 
of mortality in pediatric patients with greater than 70% full-thickness total body 
surface area thermal injury treated by early total excision and grafting. J Trauma 
1987, Feb;27(2):208-12. 
5.  Bessey P. Wound care. In: Total Burn Care. Galveston, USA: Saunders. 
6. Deitch EA, Wheelahan TM, Rose MP, Clothier J, Cotter J. Hypertrophic burn 
scars: Analysis of variables. J Trauma 1983, Oct;23(10):895-8. 
7. JACKSON DM. [The diagnosis of the depth of burning]. Br J Surg 1953, 
May;40(164):588-96. 
8. Singer AJ, Berruti L, Thode HC, McClain SA. Standardized burn model using a 
multiparametric histologic analysis of burn depth. Acad Emerg Med 2000, Jan;7(1):1-
6. 
9. deCamara DL, Raine TJ, London MD, Robson MC, Heggers JP. Progression of 
thermal injury: A morphologic study. Plast Reconstr Surg 1982, Mar;69(3):491-9. 
 281 
10. Watts AM, Tyler MP, Perry ME, Roberts AH, McGrouther DA. Burn depth and 
its histological measurement. Burns 2001, Mar;27(2):154-60. 
11. Nanney LB, Wenczak BA, Lynch JB. Progressive burn injury documented with 
vimentin immunostaining. J Burn Care Rehabil 1996;17(3):191-8. 
12. Tyler MPH, Watts AMI, Perry ME, Roberts AHN, McGrouther DA. Dermal 
cellular inflammation in burns. An insight into the function of dermal microvascular 
anatomy. Burns 2001;27(5):433-8. 
13. Boykin JV, Eriksson E, Pittman RN. In vivo microcirculation of a scald burn and 
the progression of postburn dermal ischemia. Plast Reconstr Surg 1980, 
Aug;66(2):191-8. 
14. Ganong W. A review of medical physiology. 17th ed.  Appleton & Lange; 1995. 
15. Choi M, Rabb H, Arnaout MA, Ehrlich HP. Preventing the infiltration of 
leukocytes by monoclonal antibody blocks the development of progressive ischemia 
in rat burns. Plast Reconstr Surg 1995;96(5):1177. 
16. Zawacki BE. Reversal of capillary stasis and prevention of necrosis in burns. Ann 
Surg 1974, Jul;180(1):98-102. 
17. SEVITT S. Early and delayed oedema and increase in capillary permeability after 
burns of the skin. J Pathol Bacteriol 1958, Jan;75(1):27-37. 
18. Gravante G, Palmieri MB, Esposito G, Delogu D, Santeusanio G, Filingeri V, 
Montone A. Apoptotic cells are present in ischemic zones of deep partial-thickness 
burns. J Burn Care Res 2006;27(5):688-93. 
 282 
19. Knabl JS, Bauer W, Andel H, Schwendenwein I, Dado PF, Mittlböck M, et al. 
Progression of burn wound depth by systemical application of a vasoconstrictor: An 
experimental study with a new rabbit model. Burns 1999, Dec;25(8):715-21. 
20. Horton JW. Free radicals and lipid peroxidation mediated injury in burn trauma: 
The role of antioxidant therapy. Toxicology 2003, Jul 15;189(1-2):75-88. 
21. Horton JW. Free radicals and lipid peroxidation mediated injury in burn trauma: 
The role of antioxidant therapy. Toxicology 2003;189(1/2):75-88. 
22. Latha B, Babu M. The involvement of free radicals in burn injury: A review. 
Burns 2001, Jun;27(4):309-17. 
23. Kaufman T, Neuman RA, Weinberg A. Is postburn dermal ischaemia enhanced by 
oxygen free radicals? Burns 1989, Oct;15(5):291-4. 
24. S Noble HG, Robson MC, Krizek TJ. Dermal ischemia in the burn wound. Journal 
of Surgical Research 1977;23(2):117-25. 
25. Saliba MJ, Dempsey WC, Kruggel JL. Large burns in humans. Treatment with 
heparin. JAMA 1973, Jul 16;225(3):261-9. 
26. Baskaran H, Toner M, Yarmush ML, Berthiaume F. Poloxamer-188 improves 
capillary blood flow and tissue viability in a cutaneous burn wound. J Surg Res 2001, 
Nov;101(1):56-61. 
27. Robson MC, Kucan JO, Paik KI, Eriksson E. Prevention of dermal ischemia after 
thermal injury. Arch Surg 1978, May;113(5):621-5. 
 283 
28. Mileski W, Borgstrom D, Lightfoot E, Rothlein R, Faanes R, Lipsky P, Baxter C. 
Inhibition of leukocyte-endothelial adherence following thermal injury. J Surg Res 
1992, Apr;52(4):334-9. 
29. Tarnow P, Jönsson A, Rimbäck G, Cassuto J. Increased dermal perfusion after 
skin burn injury by d-myo-inositol-1,2,6-trisphosphate. Burns 1996, Aug;22(5):363-8. 
30. Lund T, Reed RK. Alpha-Trinositol inhibits edema generation and albumin 
extravasation in thermally injured skin. J Trauma 1994, Jun;36(6):761-5. 
31. Giles N, Rea S, Beer T, Wood FM, Fear MW. A peptide inhibitor of c-jun 
promotes wound healing in a mouse full-thickness burn model. Wound Repair Regen 
2008;16(1):58-64. 
32. Morellini NM, Giles NL, Rea S, Adcroft KF, Falder S, King CE, et al. Exogenous 
metallothionein-iia promotes accelerated healing after a burn wound. Wound Repair 
Regen 2008;16(5):682-90. 
33. Del Beccaro EJ, Heggers JP, Robson MC. Preventing the prostaglandin effect on 
dermal ischemia in the burn wound. Surg Forum 1978;29:603-5. 
34. Heggers JP, Robson MC, Zachary LS. Thromboxane inhibitors for the prevention 
of progressive dermal ischemia due to the thermal injury. J Burn Care Rehabil 
1985;6(6):466-8. 
35. Kurose I, Wolf R, Grisham MB, Granger DN. Modulation of 
ischemia/reperfusion-induced microvascular dysfunction by nitric oxide. Circ Res 
1994, Mar;74(3):376-82. 
 284 
36. Kubes P, Suzuki M, Granger DN. Nitric oxide: An endogenous modulator of 
leukocyte adhesion. Proc Natl Acad Sci U S A 1991, Jun 1;88(11):4651-5. 
37. Ma XL, Weyrich AS, Lefer DJ, Lefer AM. Diminished basal nitric oxide release 
after myocardial ischemia and reperfusion promotes neutrophil adherence to coronary 
endothelium. Circ Res 1993, Feb;72(2):403-12. 
38. Lovett JE, Fink BF, Bernard A, Ochoa J. Analysis of nitric oxide activity in 
prevention of reperfusion injury. Ann Plast Surg 2001, Mar;46(3):269-73; discussion 
273-4. 
39. Luo G, Peng D, Zheng J, Chen X, Wu J, Elster E, Tadaki D. The role of NO in 
macrophage dysfunction at early stage after burn injury. Burns 2005, Mar;31(2):138-
44. 
40. Tokyay R, Zeigler ST, Kramer GC, Rogers CS, Heggers JP, Traber DL, Herndon 
DN. Effects of hypertonic saline dextran resuscitation on oxygen delivery, oxygen 
consumption, and lipid peroxidation after burn injury. J Trauma 1992, Jun;32(6):704-
12; discussion 712-3. 
41. Germonpré P, Reper P, Vanderkelen A. Hyperbaric oxygen therapy and piracetam 
decrease the early extension of deep partial-thickness burns. Burns 1996, 
Sep;22(6):468-73. 
42. Kopal C, Deveci M, Oztürk S, Sengezer M. Effects of topical glutathione 
treatment in rat ischemic wound model. Ann Plast Surg 2007, Apr;58(4):449-55. 
43. Kloppenberg FW, Beerthuizen GI, ten Duis HJ. Perfusion of burn wounds 
assessed by laser doppler imaging is related to burn depth and healing time. Burns 
2001, Jun;27(4):359-63. 
 285 
44. McGill DJ, Sørensen K, MacKay IR, Taggart I, Watson SB. Assessment of burn 
depth: A prospective, blinded comparison of laser doppler imaging and 
videomicroscopy. Burns 2007, Nov;33(7):833-42. 
45. Riordan CL, McDonough M, Davidson JM, Corley R, Perlov C, Barton R, et al. 
Noncontact laser doppler imaging in burn depth analysis of the extremities. J Burn 
Care Rehabil 2003;24(4):177-86. 
46. Hoeksema H, Van de Sijpe K, Tondu T, Hamdi M, Van Landuyt K, Blondeel P, 
Monstrey S. Accuracy of early burn depth assessment by laser doppler imaging on 
different days post burn. Burns 2009, Feb;35(1):36-45. 
47. Vo LT, Papworth GD, Delaney PM, Barkla DH, King RG. A study of vascular 
response to thermal injury on hairless mice by fibre optic confocal imaging, laser 
doppler flowmetry and conventional histology. Burns 1998, Jun;24(4):319-24. 
48. Ungerstedt U, Pycock C. Functional correlates of dopamine neurotransmission. 
Bull Schweiz Akad Med Wiss 1974, Jul;30(1-3):44-55. 
49. Rooyackers O. Microdialysis to investigate tissue amino acid kinetics. Curr Opin 
Clin Nutr Metab Care 2005, Jan;8(1):77-82. 
50. Brunner M, Müller M. Microdialysis: An in vivo approach for measuring drug 
delivery in oncology. European Journal of Clinical Pharmacology 2002;58(4):227-34. 
51. Bradford HF. Glutamate, GABA and epilepsy. Prog Neurobiol 1995;47(6):477-
511. 
 286 
52. Krogstad AL, Jansson PA, Gisslén P, Lönnroth P. Microdialysis methodology for 
the measurement of dermal interstitial fluid in humans. Br J Dermatol 1996, 
Jun;134(6):1005-12. 
53. Silva MA, Richards DA, Bramhall SR, Adams DH, Mirza DF, Murphy N. A 
study of the metabolites of ischemia-reperfusion injury and selected amino acids in 
the liver using microdialysis during transplantation. Transplantation 2005, Apr 
15;79(7):828-35. 
54. Dabrosin C. Microdialysis—an in vivo technique for studies of growth factors in 
breast cancer. Front Biosci 2005;10:1329-35. 
55. Ungerstedt U, Rostami E. Microdialysis in neurointensive care. Curr Pharm Des 
2004;10(18):2145-52. 
56. Edsander-Nord A, Röjdmark J, Wickman M. Metabolism in pedicled and free 
TRAM flaps: A comparison using the microdialysis technique. Plast Reconstr Surg 
2002, Feb;109(2):664-73. 
57. Nielsen HT, Gutberg N, Birke-Sorensen H. Monitoring of intraoral free flaps with 
microdialysis. Br J Oral Maxillofac Surg 2011, Oct;49(7):521-6. 
58. Papp A, Härmä M, Harvima R, Lahtinen T, Uusaro A, Alhava E. Microdialysis 
for detection of dynamic changes in tissue histamine levels in experimental thermal 
injury. Burns 2005, Jun;31(4):476-81. 
59. Samuelsson A, Steinvall I, Sjöberg F. Microdialysis shows metabolic effects in 
skin during fluid resuscitation in burn-injured patients. Crit Care 2006;10(6):R172. 
 287 
60. Plock N, Kloft C. Microdialysis--theoretical background and recent 
implementation in applied life-sciences. European Journal of Pharmaceutical 
Sciences: Official Journal of the European Federation for Pharmaceutical Sciences 
2005;25(1):1. 
61. Chaurasia CS. In vivo microdialysis sampling: Theory and applications. Biomed 
Chromatogr 1999, Aug;13(5):317-32. 
62. Richards DA, Silva MA, Murphy N, Wigmore SJ, Mirza DF. Extracellular amino 
acid levels in the human liver during transplantation: A microdialysis study from 
donor to recipient. Amino Acids 2007, Sep;33(3):429-37. 
63. Baumeister FA, Rolinski B, Busch R, Emmrich P. Glucose monitoring with long-
term subcutaneous microdialysis in neonates. Pediatrics 2001, Nov;108(5):1187-92. 
64. Khramov AN, Stenken JA. Enhanced microdialysis extraction efficiency of 
ibuprofen in vitro by facilitated transport with β-cyclodextrin. Anal Chem 1999, Apr 
1;71(7):1257-64. 
65. Sun L, Stenken JA. Improving microdialysis extraction efficiency of lipophilic 
eicosanoids. J Pharm Biomed Anal 2003, Dec 4;33(5):1059-71. 
66. Plock N, Buerger C, Kloft C. Successful management of discovered ph 
dependence in vancomycin recovery studies: Novel HPLC method for microdialysis 
and plasma samples. Biomed Chromatogr 2005, Apr;19(3):237-44. 
67. Höistad M, Chen KC, Nicholson C, Fuxe K, Kehr J. Quantitative dual-probe 
microdialysis: Evaluation of [3H]mannitol diffusion in agar and rat striatum. J 
Neurochem 2002, Apr;81(1):80-93. 
 288 
68. Nicholson C, Syková E. Extracellular space structure revealed by diffusion 
analysis. Trends Neurosci 1998, May;21(5):207-15. 
69. Strindberg L, Lönnroth P. Validation of an endogenous reference technique for 
the calibration of microdialysis catheters. Scand J Clin Lab Invest 2000, 
May;60(3):205-11. 
70. Petersen LJ, Poulsen LK, Søndergaard J, Skov PS. The use of cutaneous 
microdialysis to measure substance p-induced histamine release in intact human skin 
in vivo. J Allergy Clin Immunol 1994, Oct;94(4):773-83. 
71. Petersen LJ, Nielsen HJ, Skov PS. Codeine-induced histamine release in intact 
human skin monitored by skin microdialysis technique: Comparison of intradermal 
injections with an atraumatic intraprobe drug delivery system. Clin Exp Allergy 1995, 
Nov;25(11):1045-52. 
72. Petersen LJ, Skov PS, Bindslev-Jensen C, Søndergaard J. Histamine release in 
immediate-type hypersensitivity reactions in intact human skin measured by 
microdialysis. A preliminary study. Allergy 1992, Dec;47(6):635-7. 
73. Schmelz M, Luz O, Averbeck B, Bickel A. Plasma extravasation and 
neuropeptide release in human skin as measured by intradermal microdialysis. 
Neurosci Lett 1997, Jul 18;230(2):117-20. 
74. Schmelz M, Petersen LJ. Neurogenic inflammation in human and rodent skin. 
News Physiol Sci 2001, Feb;16:33-7. 
75. Clough GF, Church MK. Vascular responses in the skin: An accessible model of 
inflammation. News Physiol Sci 2002, Aug;17:170-4. 
 289 
76. Jansson PA, Krogstad AL, Lönnroth P. Microdialysis measurements in skin: 
Evidence for significant lactate release in healthy humans. Am J Physiol 1996, 
Jul;271(1 Pt 1):E138-42. 
77. Petersen LJ, Kristensen JK, Bülow J. Microdialysis of the interstitial water space 
in human skin in vivo: Quantitative measurement of cutaneous glucose 
concentrations. J Invest Dermatol 1992, Sep;99(3):357-60. 
78. Petersen LJ. Interstitial lactate levels in human skin at rest and during an oral 
glucose load: A microdialysis study. Clin Physiol 1999, May;19(3):246-50. 
79. de Boer J, Plijter-Groendijk H, Visser KR, Mook GA, Korf J. Continuous 
monitoring of lactate during exercise in humans using subcutaneous and 
transcutaneous microdialysis. Eur J Appl Physiol Occup Physiol 1994;69(4):281-6. 
80. Lee YS, Yang JH, Choi JC, Eun HC. Age-dependent change of uric acid level in 
the dermis using cutaneous microdialysis. Gerontology 2005;51(4):231-3. 
81. Papp A, Kiraly K, Härmä M, Lahtinen T, Uusaro A, Alhava E. The progression of 
burn depth in experimental burns: A histological and methodological study. Burns 
2004, Nov;30(7):684-90. 
82. Machens HG, Pabst A, Dreyer M, Gliemroth J, Görg S, Bahlmann L, et al. C3a 
levels and occurrence of subdermal vascular thrombosis are age-related in deep 
second-degree burn wounds. Surgery 2006, Apr;139(4):550-5. 
83. Tisdall MM, Smith M. Cerebral microdialysis: Research technique or clinical tool. 
Br J Anaesth 2006, Jul;97(1):18-25. 
 290 
84. Waelgaard L, Thorgersen EB, Line PD, Foss A, Mollnes TE, Tønnessen TI. 
Microdialysis monitoring of liver grafts by metabolic parameters, cytokine 
production, and complement activation. Transplantation 2008, Oct 27;86(8):1096-
103. 
85. Haugaa H, Thorgersen EB, Pharo A, Boberg KM, Foss A, Line PD, et al. 
Inflammatory markers sampled by microdialysis catheters distinguish rejection from 
ischemia in liver grafts. Liver Transpl 2012, Jul 5. 
86. Hamrin K, Rosdahl H, Ungerstedt U, Henriksson J. Microdialysis in human 
skeletal muscle: Effects of adding a colloid to the perfusate. J Appl Physiol 2002, 
Jan;92(1):385-93. 
87. Lanier ST, McClain SA, Lin F, Singer AJ, Clark RA. Spatiotemporal progression 
of cell death in the zone of ischemia surrounding burns. Wound Repair Regen 
2011;19(5):622-32. 
88. Fluhr JW, Darlenski R, Surber C. Glycerol and the skin: Holistic approach to its 
origin and functions. Br J Dermatol 2008, Jul;159(1):23-34. 
89. Large V, Reynisdottir S, Eleborg L, van Harmelen V, Strömmer L, Arner P. 
Lipolysis in human fat cells obtained under local and general anesthesia. Int J Obes 
Relat Metab Disord 1997, Jan;21(1):78-82. 
90. Rawlingson A. Nitric oxide, inflammation and acute burn injury. Burns 2003, 
Nov;29(7):631-40. 
91. Inoue H, Ando K, Wakisaka N, Matsuzaki K, Aihara M, Kumagai N. Effects of 
nitric oxide synthase inhibitors on vascular hyperpermeability with thermal injury in 
mice. Nitric Oxide 2001, Aug;5(4):334-42. 
 291 
92. Yonehara N, Yoshimura M. Interaction between nitric oxide and substance P on 
heat-induced inflammation in rat paw. Neurosci Res 2000, Jan;36(1):35-43. 
93. Lindblom L, Cassuto J, Yregård L, Mattsson U, Tarnow P, Sinclair R. Importance 
of nitric oxide in the regulation of burn oedema, proteinuria and urine output. Burns 
2000, Feb;26(1):13-7. 
94. Paulsen SM, Wurster SH, Nanney LB. Expression of inducible nitric oxide 
synthase in human burn wounds. Wound Repair Regen 1998;6(2):142-8. 
95. Schäffer MR, Tantry U, van Wesep RA, Barbul A. Nitric oxide metabolism in 
wounds. J Surg Res 1997, Jul 15;71(1):25-31. 
96. Witte MB, Thornton FJ, Tantry U, Barbul A. L-Arginine supplementation 
enhances diabetic wound healing: Involvement of the nitric oxide synthase and 
arginase pathways. Metabolism 2002, Oct;51(10):1269-73. 
97. Devés R, Boyd CA. Transporters for cationic amino acids in animal cells: 
Discovery, structure, and function. Physiol Rev 1998, Apr;78(2):487-545. 
98. Van Winkle LJ. Endogenous amino acid transport systems and expression of 
mammalian amino acid transport proteins in xenopusoocytes. Biochimica Et 
Biophysica Acta (BBA)/Reviews on Biomembranes 1993;1154(2):157-72. 
99. Kilberg MS, Stevens BR, Novak DA. Recent advances in mammalian amino acid 
transport. Annu Rev Nutr 1993;13:137-65. 
100. Stevens BR, Kakuda DK, Yu K, Waters M, Vo CB, Raizada MK. Induced nitric 
oxide synthesis is dependent on induced alternatively spliced CAT-2 encoding l-
arginine transport in brain astrocytes. J Biol Chem 1996, Sep 27;271(39):24017-22. 
 292 
101. Gill DJ, Low BC, Grigor MR. Interleukin-1 beta and tumor necrosis factor-alpha 
stimulate the cat-2 gene of the l-arginine transporter in cultured vascular smooth 
muscle cells. J Biol Chem 1996, May 10;271(19):11280-3. 
102. Cendan JC, Topping DL, Pruitt J, Snowdy S, Copeland III EM, Lind DS. 
Inflammatory mediators stimulate arginine transport and arginine-derived nitric oxide 
production in a murine breast cancer cell line. Journal of Surgical Research 
1996;60(2):284-8. 
103. Schmidlin A, Wiesinger H. Stimulation of arginine transport and nitric oxide 
production by lipopolysaccharide is mediated by different signaling pathways in 
astrocytes. J Neurochem 1995, Aug;65(2):590-4. 
104. Durante W, Liao L, Schafer AI. Differential regulation of l-arginine transport 
and inducible NOS in cultured vascular smooth muscle cells. Am J Physiol 1995, 
Mar;268(3 Pt 2):H1158-64. 
105. Bogle RG, Baydoun AR, Pearson JD, Moncada S, Mann GE. L-arginine 
transport is increased in macrophages generating nitric oxide. Biochem J 1992, May 
15;284 ( Pt 1):15-8. 
106. Simmons WW, Closs EI, Cunningham JM, Smith TW, Kelly RA. Cytokines and 
insulin induce cationic amino acid transporter (CAT) expression in cardiac myocytes. 
Regulation of l-arginine transport and no production by CAT-1, CAT-2A, and CAT-
2B. J Biol Chem 1996, May 17;271(20):11694-702. 
107. Witte MB, Barbul A, Schick MA, Vogt N, Becker HD. Upregulation of arginase 
expression in wound-derived fibroblasts. J Surg Res 2002, Jun 1;105(1):35-42. 
 293 
108. Schwacha MG, Nickel E, Daniel T. Burn injury-induced alterations in wound 
inflammation and healing are associated with suppressed hypoxia inducible factor-
1alpha expression. Mol Med 2008;14(9-10):628-33. 
109. Debats IB, Wolfs TG, Gotoh T, Cleutjens JP, Peutz-Kootstra CJ, van der Hulst 
RR. Role of arginine in superficial wound healing in man. Nitric Oxide 2009;21(3-
4):175-83. 
110. Holowatz LA, Kenney WL. Up-regulation of arginase activity contributes to 
attenuated reflex cutaneous vasodilatation in hypertensive humans. J Physiol 2007, 
Jun 1;581(Pt 2):863-72. 
111. Cahusac P, Senok SS. Metabotropic glutamate receptor antagonists selectively 
enhance responses of slowly adapting type I mechanoreceptors. Synapse 
2006;59(4):235-42. 
112. Cahusac PM, Senok SS, Hitchcock IS, Genever PG, Baumann KI. Are 
unconventional NMDA receptors involved in slowly adapting type I mechanoreceptor 
responses? Neuroscience 2005;133(3):763-73. 
113. Fagan BM, Cahusac PMB. Evidence for glutamate receptor mediated 
transmission at mechanoreceptors in the skin. Neuroreport 2001;12(2):341-7. 
114. Ono S, Yamauchi M. Glutamate and aspartate are decreased in the skin in 
amyotrophic lateral sclerosis. Acta Neurol Scand 1992, Nov;86(5):481-4. 
115. Genever PG, Maxfield SJ, Kennovin GD, Maltman J, Bowgen CJ, Raxworthy 
MJ, Skerry TM. Evidence for a novel glutamate-mediated signaling pathway in 
keratinocytes. J Invest Dermatol 1999, Mar;112(3):337-42. 
 294 
116. Saransaari P, Oja SS. Taurine and neural cell damage. Amino Acids 2000;19(3-
4):509-26. 
117. Oja SS, Saransaari P. Modulation of taurine release by glutamate receptors and 
nitric oxide. Prog Neurobiol 2000, Nov;62(4):407-25. 
118. Farriol M, Venereo Y, Rosselló J, Gomez P, Palao R, Orta X, Segovia-Silvestre 
T. Effects of taurine on polymorphonuclear phagocytosis activity in burned patients. 
Amino Acids 2002;23(4):441-5. 
119. www.Mdialysis.com/faq_clinical 
120. Groth L, Serup J. Cutaneous microdialysis in man: Effects of needle insertion 
trauma and anaesthesia on skin perfusion, erythema and skin thickness. Acta Derm 
Venereol 1998, Jan;78(1):5-9. 
121. Anderson C, Andersson T, Wårdell K. Changes in skin circulation after insertion 
of a microdialysis probe visualized by laser doppler perfusion imaging. J Invest 
Dermatol 1994, May;102(5):807-11. 
122. Groth L. Cutaneous microdialysis. Methodology and validation. Acta Derm 
Venereol Suppl (Stockh) 1996;197:1-61. 
123. Ault JM, Riley CM, Meltzer NM, Lunte CE. Dermal microdialysis sampling in 
vivo. Pharm Res 1994, Nov;11(11):1631-9. 
124. Mathy FX, Denet AR, Vroman B, Clarys P, Barel A, Verbeeck RK, Préat V. In 
vivo tolerance assessment of skin after insertion of subcutaneous and cutaneous 
microdialysis probes in the rat. Skin Pharmacol Appl Skin Physiol 2003;16(1):18-27. 
 295 
125. Davies MI, Lunte CE. Microdialysis sampling for hepatic metabolism studies. 
Impact of microdialysis probe design and implantation technique on liver tissue. Drug 
Metab Dispos 1995, Oct;23(10):1072-9. 
126. Stenken JA, Church MK, Gill CA, Clough GF. How minimally invasive is 
microdialysis sampling? A cautionary note for cytokine collection in human skin and 
other clinical studies. AAPS J 2010, Mar;12(1):73-8. 
127. Jacobson I, Sandberg M, Hamberger A. Mass transfer in brain dialysis devices--a 
new method for the estimation of extracellular amino acids concentration. J Neurosci 
Methods 1985;15(3):263-8. 
128. Lönnroth P, Jansson PA, Smith U. A microdialysis method allowing 
characterization of intercellular water space in humans. Am J Physiol 1987, 
Aug;253(2 Pt 1):E228-31. 
129. Stahl M, Bouw R, Jackson A, Pay V. Human microdialysis. Curr Pharm 
Biotechnol 2002, Jun;3(2):165-78. 
130. Olson RJ, Justice Jr JB. Quantitative microdialysis under transient conditions. 
Anal Chem 1993;65(8):1017-22. 
131. Ståhle L, Arner P, Ungerstedt U. Drug distribution studies with microdialysis. 
III: Extracellular concentration of caffeine in adipose tissue in man. Life Sci 
1991;49(24):1853-8. 
132. Brunner M, Joukhadar C, Schmid R, Erovic B, Eichler HG, Müller M. 
Validation of urea as an endogenous reference compound for the in vivo calibration of 
microdialysis probes. Life Sci 2000, Jul 14;67(8):977-84.
 296 
 
Plate 1: Photographs and LDI Images for Patient S01. Above left: Photograph of burn before 
probe insertion with 5cm standard line marked.  Above right: Photograph of burn at end of 
study period with 5cm standard line marked, and probes A and B still in situ. Below left: LDI 
before probe insertion. Below right: LDI at end of study period.
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Plate 2: Photographs and LDI Images for Patient S02. Above left: Photograph of burn before 
probe insertion with site for probe B marked with a dotted line.  Above right: Photograph of 
burn at end of study period with site of probe B marked with dotted line. Below left: LDI before 
probe insertion. Below right: LDI at end of study period. 
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Plate 3: Photographs and LDI Images for Patient S03. Above left: Photograph of burn before 
probe insertion. Above right: Photograph of burn at end of study period with probe A (centre of 
wound) and probe B, loser left side of wound still In situ. Below left: LDI before probe insertion. 
Below right: LDI at end of study period. 
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Plate 4: Photographs and LDI Images for Patient S04. Above left: Photograph of burn before 
probe insertion with standard 5cm line and site for probe B marked with a dotted line.  Above 
right: Photograph of burn at end of study period with standard 5cm line, and site of probe B 
marked with dotted line. Below left: LDI before probe insertion. Below right: LDI at end of study 
period. 
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Plate 5: Photographs and LDI Images for Patient S05. Above left: Photograph of burn before 
probe insertion with standard 5cm line (far left), and site for probe B and A marked at edge and 
centre of wound respectively.  Above right: Photograph of burn at end of study period with 
standard 5cm line, and site for probe B marked with dotted line. Below left: LDI before probe 
insertion. Below right: LDI at end of study period. 
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Plate 6: Photographs and LDI Images for Patient S06 Above left: Photograph of burn before 
probe insertion with standard 5cm line, site for probe B marked with dotted line, and probe A 
between two dots in centre of wound.  Above right: Photograph of burn at end of study period 
with site of probe B marked with dotted line. Below left: LDI before probe insertion. Below right: 
LDI at end of study period. 
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Plate 7: Photographs and LDI Images for Patient S07 Above left: Photograph of burn before 
probe insertion with standard 5cm line,  site for probe B marked with dotted line, and probe A 
between two dots in centre of wound.  Above right: Photograph of burn at end of study period 
with site of probe B marked with dotted line. Below left: LDI before probe insertion. Below right: 
LDI at end of study period. 
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Plate 8: Photograph and LDI Image for Patient S08. Above: Photograph of burn before probe 
insertion. Below: LDI before probe insertion. No photograph/LDI image at end of study period 
as this patient did not complete the study. 
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Plate 9: Photographs and LDI Images for Patient S09. Above left: Photograph of burn before 
probe insertion with standard 5cm line, and site for probe B marked with dotted line.  Above 
right: Photograph of burn at end of study period with standard 5cm line, and site for probe B 
marked with dotted line. Below left: LDI before probe insertion. Below right: LDI at end of study 
period. 
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Plate 10: Photographs and LDI Images for Patient S10. Above left: Photograph of burn before 
probe insertion with standard 5cm line, and site for probe B marked with dotted line.  Above 
right: Photograph of burn at end of study period with standard 5cm line, and site for probe B 
marked with dotted line. Probe A can be seen still in situ. Below left: LDI before probe insertion. 
Below right: LDI at end of study period. 
 
 
